Community-Acquired Pneumonia

On this page

Quick Reference

RxDrug of choiceOutpatient: oral amoxicillin 1 g TID or doxycycline 200 mg load then 100 mg BID. Inpatient non-ICU: ceftriaxone 2 g IV daily plus azithromycin 500 mg IV daily. ICU: ceftriaxone 2 g IV daily plus levofloxacin 750 mg IV daily; add vancomycin for MRSA if indicated.

AltAlternativesLevofloxacin 750 mg IV/oral daily (monotherapy); piperacillin-tazobactam 4.5 g IV q6h for Pseudomonas risk; cefepime 2 g IV q8h plus ciprofloxacin 400 mg IV q12h for severe Pseudomonas.

⊘AvoidNSAIDs in early CAP (increase empyema risk); corticosteroids in nonsevere CAP; benzodiazepines (increase CAP incidence and mortality); non-dihydropyridine CCBs in heart failure (no direct CAP contraindication but avoid if concomitant HF).

DxTest of choiceChest radiograph (first-line); chest CT if X-ray negative but suspicion remains. For hospitalized: blood cultures (if severe), pneumococcal + Legionella urinary antigen, respiratory viral PCR. Procalcitonin to guide antibiotic duration.

ScKey scoreCURB-65 (site of care); PSI (mortality risk); IDSA/ATS minor criteria (ICU triage); PES score (drug-resistant pathogen risk).

→When to referInfectious disease for immunocompromised, refractory, or drug-resistant cases; pulmonary for bronchoscopy, pleural drainage, or advanced ventilatory support; cardiology if new cardiac event; speech therapy for dysphagia screening.

Initiate empiric antibiotics stratified by severity (outpatient: amoxicillin/doxycycline; inpatient: beta-lactam + macrolide; ICU: add anti-Pseudomonas + consider MRSA). Add hydrocortisone 200 mg IV daily for severe CAP (especially if CRP >204 mg/L). Use PCT to limit duration to ≤5 days. Vaccinate before discharge.

Community-acquired pneumonia (CAP) is an acute infection of the lung parenchyma acquired outside healthcare settings, defined by a new pulmonary infiltrate on imaging with compatible clinical features. It remains a leading infectious cause of hospitalization and death worldwide, with 30-day mortality ranging from 4% in mild cases to over 30% in ICU patients. Management hinges on early severity stratification, prompt empiric antibiotics, and recognition that CAP carries long-term mortality risk (HR 1.65 over 10 years). This page provides evidence-based guidance for diagnosis, risk assessment, treatment, and prevention.

Overview and Recommendations

Background

•Community-acquired pneumonia (CAP) is defined as an acute infection of the lung parenchyma acquired outside a hospital or long-term care facility, confirmed by a new pulmonary infiltrate on imaging and compatible clinical features. It is the leading infectious cause of hospitalization among U.S. adults, with an annual incidence of 24.8 per 10,000, rising to 164.3 per 10,000 in those aged ≥80 years.
•The etiologic spectrum is dominated by Streptococcus pneumoniae (the most common bacterial cause), followed by Haemophilus influenzae, Mycoplasma pneumoniae, Legionella species, respiratory viruses (influenza, SARS-CoV-2, rhinovirus), and, in immunocompromised hosts, Pneumocystis jirovecii and fungi. Atypical pathogens (Mycoplasma, Chlamydophila, Legionella) account for 20-30% of cases and require distinct antibiotic coverage.
•Key risk factors include smoking (OR 2-4), COPD, diabetes, chronic heart disease, alcoholism, poor dental hygiene, and aspiration risk (dysphagia, neurologic disease). HIV remains a dominant driver in sub-Saharan Africa (seroprevalence ~78% in hospitalized CAP). Smoking cessation and pneumococcal/influenza vaccination are the most impactful modifiable preventive measures, with pneumococcal vaccine reducing CAP in COPD patients (NNT = 21).
•CAP is classified by etiology (typical vs. atypical), severity (outpatient, ward, ICU), host immune status, and aspiration risk. Aspiration CAP accounts for 25% of cases in older adults and independently doubles mortality. The historic category 'healthcare-associated pneumonia' (HCAP) has been abandoned due to lack of outcome benefit from broad-spectrum therapy; current guidelines favor individual risk assessment for multidrug-resistant pathogens.
•The pathophysiology involves microbial invasion overcoming alveolar macrophage defenses, triggering innate immune activation, alveolar-capillary barrier disruption (driven by microenvironmental acidification to pH ~6), and systemic inflammation. Transcriptomic profiling identifies two sepsis response signatures: SRS1 (immunosuppressed phenotype, 41% of patients) with 14-day mortality HR 2.4, and SRS2 (inflamed). This host-response heterogeneity explains why mortality has remained static despite antibiotics.
•Long-term outcomes are poor: over 9.8 years of follow-up, CAP survivors have an adjusted HR for death of 1.65, with 30-day readmission rate of 15.7%. Cardiovascular complications (myocardial infarction, new atrial fibrillation, heart failure) affect 18-30% of hospitalized patients and drive in-hospital and post-discharge mortality. Pneumolysin and hydrogen peroxide from S. pneumoniae directly invade myocardium, causing necroptosis and scarring.

Evaluation

•Suspect CAP in any patient with acute cough, fever, dyspnea, pleuritic chest pain, or unexplained fatigue, symptoms typically evolve over 1-7 days. In elderly patients, fever and cough are often absent; instead, look for confusion, falls, functional decline, or anorexia. Auscultate for crackles, bronchial breath sounds, egophony, and dullness to percussion (LR+ 2-6 for bronchial breath sounds). Tachypnea >30/min, hypotension, or hypoxemia (SpO₂ <90%) signal severe disease.
•Confirm the diagnosis with a chest radiograph showing a new infiltrate (lobar, multilobar, or interstitial). Up to 33% of infiltrates are missed on plain film; if clinical suspicion remains high despite a negative radiograph, obtain a chest CT or lung ultrasound. CT modifies management in 59% of cases, initiating antibiotics in 16% and discontinuing in 9%.
•Assess severity immediately to determine site of care. Use CURB-65 (Confusion, Urea >7 mmol/L, Respiratory rate ≥30, Blood pressure <90/60, age ≥65), a score ≥2 recommends admission, ≥3 suggests ICU. The Pneumonia Severity Index (PSI) has higher sensitivity (NPV 0.98 for mortality) and is better for identifying low-risk outpatients. For ICU triage, the IDSA/ATS 2007 minor criteria (≥3 of 9) have sensitivity 94% for need for mechanical ventilation or vasopressors.
•Order bilateral blood cultures only in severe CAP (ICU admission or septic shock), positivity rate ~10%. Obtain sputum Gram stain and culture if a purulent specimen can be collected. For all hospitalized patients, perform pneumococcal urinary antigen (sensitivity 60-75%, specificity 99.7%) and Legionella urinary antigen (serogroup 1, sensitivity ~70%). Add a respiratory viral PCR panel (nasopharyngeal swab) to identify influenza, SARS-CoV-2, RSV, and other viruses.
•Check laboratory markers: CRP and procalcitonin (PCT) are complementary. In early presenters (<3 days of symptoms), CRP may be low and PCT high ; in later presenters, CRP rises and PCT falls. A PCT <0.25 ng/mL can help defer antibiotics in low-risk outpatients. Also obtain renal function (creatinine, urea), liver enzymes, and CBC. For hypoxemic patients, an arterial blood gas defines PaO₂/FiO₂ ratio (<300 indicates respiratory failure) and PaCO₂.
•Consider additional testing in special populations: in immunocompromised hosts (HIV, transplant, neutropenia), broaden workup to include BAL with metagenomic NGS for Pneumocystis, CMV, fungi, and mycobacteria. In patients with aspiration risk factors (dysphagia, bedridden, enteral feeding), assess with volume-viscosity swallow test. For patients from endemic areas, add serology for Coccidioides or Histoplasma.
•Evaluate for complications early: if a patient fails to stabilize by 48-72 hours, repeat blood cultures, obtain a chest CT, and consider bronchoscopy with BAL for culture and targeted NGS. Look for parapneumonic effusion (5-12% of CAP), empyema, lung abscess, or noninfectious mimics like vasculitis, organizing pneumonia, or pulmonary embolism.
•Consider alternative diagnoses in non-responders: pulmonary embolism (especially if D-dimer >3.13 mg/L in elderly), heart failure, malignancy causing post-obstructive pneumonia, drug-induced pneumonitis, or granulomatous disease (TB, fungal). In patients with prior antibiotic use, structural lung disease (COPD, bronchiectasis), or chronic steroid use, consider Pseudomonas aeruginosa or MRSA, use the PES score to risk-stratify for these drug-resistant pathogens (NPV 98% at score <5).
•Document clinical stability criteria daily: temperature ≤37.2°C, heart rate ≤100/min, respiratory rate ≤24/min, systolic BP ≥90 mm Hg, SpO₂ ≥90% on room air. Once stable for 48-72 hours, plan IV-to-oral switch and discharge. Procalcitonin guidance can shorten antibiotic duration: use PCT <0.1 µg/L to strongly discourage antibiotics, <0.25 µg/L to discourage, this reduces exposure by 48% without worsening outcomes.

Management

•Start empiric antibiotics immediately after diagnosis, within 4 hours of presentation. For outpatients (CURB-65 0-1, PSI I-II): prescribe oral 1 g three times daily OR 200 mg loading then 100 mg twice daily for 5 days (minimum 3 days if clinically stable). Alternatively, 500 mg orally on day 1 then 250 mg days 2-5 can be used if local macrolide resistance rates are low.
•For non-ICU hospitalized patients (CURB-65 2-3): initiate a beta-lactam plus a macrolide. Preferred: 2 g IV daily PLUS 500 mg IV daily. Alternatives: 1 g IV q8h, 1.5 g IV q6h, or 750 mg IV daily as monotherapy. Beta-lactam monotherapy is acceptable in patients without SIRS or ≥2, based on CAP-START trial noninferiority.
•For ICU patients (severe CAP, CURB-65 ≥4, IDSA/ATS major criteria): initiate 2 g IV daily plus 500 mg IV daily OR 750 mg IV daily. The network meta-analysis identifies ceftriaxone plus levofloxacin as having highest probability for mortality benefit. For patients with risk factors for Pseudomonas (COPD, bronchiectasis, prior antibiotics, corticosteroids), use 4.5 g IV q6h or 2 g IV q8h plus an antipseudomonal fluoroquinolone (ciprofloxacin or levofloxacin).
•In suspected MRSA (cavitary infiltrates, prior MRSA, IV drug use, end-stage renal disease), add 15-20 mg/kg IV q12h (target trough 15-20 µg/mL) or 600 mg IV q12h. Do not routinely cover MRSA or Pseudomonas in low-risk patients; the PES score (≥5: high risk) helps discriminate.
•For severe CAP requiring ICU care, add adjunctive hydrocortisone 200 mg IV daily (continuous infusion or divided q6h) for 4-7 days, then taper. The CAPE COD trial demonstrated reduction in 28-day mortality from 11.9% to 6.2% (NNT = 18). The benefit is concentrated in patients with CRP >204 mg/L (OR 0.43 for mortality). Do NOT use corticosteroids in nonsevere CAP, prednisolone 40 mg daily increased late failure (19.2% vs 6.4%).
•Provide oxygen to target SpO₂ ≥92% (PaO₂ ≥60 mm Hg). For moderate hypoxemic respiratory failure (PaO₂/FiO₂ 210-285), use helmet CPAP, median time to PaO₂/FiO₂ >315 is 1.5 h vs 48 h with standard oxygen. If CPAP fails or PaO₂/FiO₂ <150, escalate to noninvasive ventilation (NIV) or high-flow nasal oxygen. NIV reduces intubation risk (OR 0.26) and ICU mortality (OR 0.28) in CAP with ARDS.
•For invasive mechanical ventilation, use lung-protective strategy: tidal volume 6 mL/kg predicted body weight, plateau pressure ≤30 cm H₂O. In severe ARDS, consider prone positioning and early neuromuscular blockade. In extreme cases, ECMO may be considered in specialist centers.
•Monitor for clinical stability daily. Once stable for 48-72 h, switch from IV to oral antibiotics. Use procalcitonin guidance to limit duration: for nonsevere CAP, treat for 5 days (minimum 3) if stable; for severe CAP, treat for 5-7 days. Longer courses reserved for complications (empyema, lung abscess, necrotizing pneumonia). Do NOT extend beyond 7 days routinely, inflection point at 7.4 days associates with increased length of stay.
•If no response by 72 h, evaluate for complications: repeat chest CT, bronchoscopy with BAL for culture and metagenomic NGS. Consider pleural drainage for parapneumonic effusion (chest tube with fibrinolytics: urokinase or alteplase). For empyema, VATS is preferred if fibrinolytics fail. Drainage of complicated effusion reduces hospital stay by ~5 days.
•For patients with aspiration pneumonia (gravity-dependent opacity, dysphagia risk): cover anaerobes with 3 g IV q6h, , or 500 mg IV q8h added to a beta-lactam. Avoid clindamycin due to high resistance rates.
•What NOT to do: Avoid NSAIDs in early CAP, they increase odds of pleuropulmonary complications (empyema, cavitation) 8-fold. Do not use benzodiazepines routinely, they increase CAP incidence (OR 1.54) and mortality (HR 1.22). Do not use corticosteroids for parapneumonic effusions (no benefit, trend toward harm). Do not use routine antifungal coverage in immunocompetent patients.
•When to refer: Consider infectious disease consultation for immunocompromised hosts, patients with drug-resistant pathogens, or refractory cases. Consider pulmonary consultation for bronchoscopy, chest tube drainage, or advanced ventilatory support. For patients with functional decline after hospitalization, refer to pulmonary rehabilitation.
•Discharge planning: Ensure all patients receive pneumococcal vaccination (PCV13 or PCV20 + PPSV23 per schedule) and influenza vaccination (in season). Assess cardiovascular risk: check high-sensitivity troponin and consider optimizing guideline-directed medical therapy for heart disease. Screen for dysphagia in elderly. Educate on smoking cessation and dental hygiene.
•Antibiotic drug doses in special populations: Renal impairment, adjust beta-lactams, fluoroquinolones, vancomycin based on eGFR. Obesity, use actual body weight for aminoglycosides, adjusted body weight for vancomycin. Elderly, no specific dose changes for most beta-lactams and macrolides, but monitor renal function. Pregnancy, beta-lactams and azithromycin are safe; avoid tetracyclines and fluoroquinolones.

Board Review — High Yield

•CURB-65, Clinical score for severity: Confusion, Urea >7, RR ≥30, BP <90/60, age ≥65; ≥2 recommends admission, ≥3 suggests ICU.
•Procalcitonin (PCT), Biomarker to guide antibiotic initiation and duration; <0.25 ng/mL discourages antibiotics in low-risk outpatients; <0.1 µg/L strongly discourages.
•CAPE COD trial, Demonstrated hydrocortisone 200 mg IV daily reduces 28-day mortality in severe CAP from 11.9% to 6.2% (NNT=18); benefit concentrated with CRP >204 mg/L.
•PES score, Predicts drug-resistant etiology (Pseudomonas, ESBL, MRSA); score ≥5 had NPV 98% for ruling out non-core pathogens.
•Long-term mortality, CAP carries HR 1.65 for death over 9.8 years vs controls; 30-day readmission rate 15.7%; need vaccination and CV risk modification after discharge.
•Aspiration CAP, Independent predictor of mortality (HR 5.69); screen for dysphagia; cover anaerobes with ampicillin-sulbactam or metronidazole-beta-lactam combination.
•SRS1 transcriptomic signature, Immunosuppressed phenotype in 41% of CAP patients; associated with higher 14-day mortality (HR 2.4); identifies candidates for immunomodulation.
•Urinary antigen testing, Pneumococcal (sensitivity 60-75%, specificity 99.7%) and Legionella (serogroup 1) are rapid, noninvasive tests that increase diagnostic yield in hospitalized CAP.
•Helmet CPAP, In moderate hypoxemic respiratory failure (PaO2/FiO2 210-285), improves oxygenation faster than standard oxygen (1.5 h vs 48 h to reach PaO2/FiO2 >315).
•Pneumococcal vaccination NNT, In COPD, 21 patients need to be vaccinated to prevent one episode of CAP (OR 0.62). Influenza vaccine reduces symptomatic influenza by 70%.

Deep Dive — Evidence Details

1. Definition, Classification and Nomenclature

▸CAP is defined by acute respiratory symptoms plus a new radiographic infiltrate acquired outside healthcare settings; radiographic confirmation is essential to avoid misdiagnosis [2][33].
▸Aspiration pneumonia is a distinct CAP subset with worse outcomes, defined by risk factors (dysphagia, neurologic impairment) and gravity-dependent opacities on CT [15][34].
▸Molecular endotypes (SRS1/SRS2, Mars1-4) based on blood gene expression identify patients with immunosuppressed phenotypes and higher mortality, offering a path toward precision therapy [8][9].

HY High Yield: The term 'atypical pneumonia' is a clinical syndrome (gradual onset, dry cough, extrapulmonary features) but not a microbiologic guarantee; empiric therapy for hospitalized CAP must cover both typical and atypical pathogens regardless of presentation [42].

Community-acquired pneumonia (CAP) is an acute infection of the lung parenchyma acquired outside of a hospital or long-term care facility, defined by the presence of a new pulmonary infiltrate on imaging accompanied by compatible clinical features ^[2]^A1c.

Also Called / Synonyms: CAP, lobar pneumonia, bronchopneumonia, atypical pneumonia (when caused by Mycoplasma pneumoniae, Chlamydophila pneumoniae, or Legionella spp.), healthcare-associated pneumonia (HCAP, a historical term now largely abandoned due to lack of outcome benefit from broad-spectrum therapy ^[41]^D5), (a distinct subset with worse prognosis ^[15]^B2b^[34]^B2a).

Clinical Significance: CAP is a leading infectious cause of death worldwide, with in-hospital mortality ranging from 4% in ward patients to 23-30% in those requiring ICU admission ^[22]^B2b^[25]^B2b. Long-term mortality after discharge reaches 6.3% at one year ^[12]^B2b.

Classification

CAP is classified along several axes that guide and prognosis. The table below summarizes the major classification schemes.

Classification Axis	Types / Categories	Key Distinguishing Feature	Clinical Relevance
Etiology	Typical bacterial (e.g., Streptococcus pneumoniae, ), Atypical (e.g., Mycoplasma, Chlamydophila, Legionella), Viral (e.g., influenza, SARS-CoV-2), Fungal (rare in immunocompetent)	Microbiologic identification via culture, antigen, or nucleic acid testing ^[46]^B3b	Empiric antibiotic choice must cover both typical and atypical pathogens in hospitalized patients ^[2]^A1c
Severity	Mild (outpatient), Moderate (hospital ward), Severe (ICU)	≥2 or class IV-V; presence of sepsis or respiratory failure ^[14]^B2b^[18]^D5	Determines site of care, intensity of monitoring, and need for adjunctive corticosteroids ^[20]^D5
Host	Immunocompetent, Immunocompromised (e.g., HIV, transplant, neutropenia)	Underlying immune defect alters pathogen spectrum (e.g., Pneumocystis, CMV) ^[40]^B3b	Broader diagnostic workup and empiric coverage required in immunocompromised hosts
Aspiration	Aspiration CAP vs. non-aspiration CAP	Risk factors (dysphagia, neurologic disease) plus gravity-dependent opacity on CT ^[15]^B2b	Aspiration CAP carries higher 30-day mortality (adjusted HR 5.69) and longer hospital stay ^[34]^B2a
Molecular Endotype	SRS1 (immunosuppressed), SRS2; Mars1-4	Gene expression signatures from blood leukocytes ^[8]^B2b^[9]^B2b	Emerging tool for prognostication and targeted immunomodulation; not yet routine

Diagnostic Boundary: The diagnosis of CAP requires both clinical symptoms (cough, fever, dyspnea, pleuritic pain) and a new radiographic infiltrate ^[2]^A1c^[33]^A1a. Up to 32% of patients coded as pneumonia in administrative data do not meet these criteria, leading to misclassification ^[32]^B3b. Lung ultrasound is increasingly used as an alternative to chest radiograph when performed by experienced clinicians ^[20]^D5.

Pearl: When evaluating a patient with suspected CAP, always confirm a new infiltrate on imaging and explicitly assess for aspiration risk factors, aspiration CAP accounts for 25% of cases in older adults and independently doubles mortality, yet is frequently underdiagnosed ^[34]^B2a.

Controversies and Guideline Disagreement

Question	Position A	Position B	Strength	Implication
Should HCAP be a distinct category?	ATS/IDSA 2005: yes, treat with broad-spectrum	European/Asia-Pacific guidelines: no, use individual risk assessment ^[41]^D5	Moderate	HCAP classification leads to overtreatment without mortality benefit; current guidelines favor risk-stratified therapy
What is the minimum set of diagnostic criteria for CAP trials?	Heterogeneous: 87 different sets used in RCTs ^[33]^A1a	Consensus needed for standardization	Very low	Lack of uniformity limits comparability of trial results; future studies should adopt a core outcome set

2. Pathophysiology and Mechanism

▸S. pneumoniae invades the myocardium via choline-binding protein A and laminin receptor, causing direct cardiomyocyte necroptosis/apoptosis and subsequent cardiac scarring [49,52].
▸Efferocytosis - phagocytic clearance of apoptotic neutrophils by alveolar macrophages - is impaired in smokers and low-BMI patients and enhanced by statins, identifying a modifiable recovery pathway [75].

HY High Yield: SRS1, characterized by endotoxin tolerance and T-cell exhaustion, identifies patients at highest risk of death; a 7-gene classifier can assign signature within hours of admission [8].

The pathogenesis of community-acquired pneumonia begins when a virulent microorganism overcomes the host's respiratory defences and reaches the lower respiratory tract, triggering a cascade of innate immune activation, alveolar-capillary barrier disruption, and systemic inflammation that ultimately determines clinical severity and outcome.

Microbial Invasion and Innate Immune Recognition

Alveolar macrophages are the first line of defence. They ingest and kill bacteria through a two-phase mechanism: an immediate phagolysosomal killing phase followed by a late-phase apoptosis-associated killing that requires caspase-induced mitochondrial reactive oxygen species and nitric oxide ^[54]^D5. Upregulation of the anti-apoptotic protein Mcl-1 in alveolar macrophages - seen in patients at increased CAP risk - blunts this late phase and impairs clearance of Streptococcus pneumoniae and , though not Staphylococcus aureus ^[54]^D5. Neutrophils are rapidly recruited. In severe CAP, circulating neutrophils display broad functional defects: inaccurate migration to interleukin-8, impaired respiratory burst, and increased spontaneous degranulation ^[72]^B3b. Autophagy primes neutrophils for neutrophil extracellular trap formation, and patients who survive sepsis show increased autophagy induction; those who die exhibit dysregulated autophagy and diminished NET formation ^[56]^C4. NADPH oxidase-derived reactive oxygen species are redundant for bacterial killing in pneumococcal pneumonia but limit neutrophil recruitment and survival via apoptosis; their absence paradoxically improves bacterial clearance ^[57]^D5.

Pathogen-specific mechanisms further shape the inflammatory response. Mycoplasma pneumoniae engages toll-like receptor 2, which triggers secretion of matrix metalloproteinase-9, activating the sialidase Neu1. Neu1 disrupts the inhibitory Siglec-5-TLR2 interaction, while infection upregulates Siglec-14, which recruits Syk kinase to amplify MAPK and NF-κB signalling ^[86]^D5. A distinct disinhibition-amplification network thus drives the excessive host inflammation characteristic of mycoplasma disease. Chlamydia pneumoniae and C. psittaci are obligate intracellular pathogens that elicit a complex clinical spectrum through mechanisms not yet fully defined ^[88]^D5.

Alveolar-Capillary Barrier Disruption and Gas Exchange Derangement

S. pneumoniae degrades the central junctional proteins occludin and vascular endothelial cadherin, disrupting the alveolar-capillary barrier. Surprisingly, this is mediated not by pneumolysin or hydrogen peroxide but by microenvironmental acidification to approximately pH 6, driven by bacterial sugar consumption and lactate production ^[61]^D5. In severe CAP, plasma neutrophil elastase levels correlate strongly with the pulmonary vascular permeability index (r = 0.81) ^[80]^C4, indicating that neutrophil degranulation directly worsens oedema and ventilation-perfusion mismatch.

The Systemic Inflammatory Response and Sepsis Signatures

Transcriptomic profiling of peripheral blood leukocytes in CAP patients with organ dysfunction identifies two distinct sepsis response signatures ( ). SRS1, detected in 41% of patients, defines an immunosuppressed phenotype with features of endotoxin tolerance, T-cell exhaustion, and downregulation of HLA class II. It is associated with significantly higher 14-day mortality than SRS2 (discovery cohort, 95% CI 1.3-4.5; validation cohort) ^[8]^B2b. A seven-gene classifier can assign SRS group rapidly. These signatures are dynamic during ICU admission and are largely independent of infection source (CAP vs. fecal peritonitis), with >75% of the transcriptomic response shared ^[53]^B2b. The plasma proteome in CAP reveals upregulation of over 900 proteins enriched in innate immune and mitotic pathways, many originating from lung and cardiac tissue; 124 proteins correlate with prolonged time to clinical stability, and these same proteins predict 10-year pneumonia risk in the general population ^[50]^B3b.

Cardiac Complications and Long-term Injury

S. pneumoniae translocates into the myocardium using the same adhesin-receptor interactions responsible for blood-brain barrier crossing (choline-binding protein A binding to laminin receptor; phosphorylcholine binding to platelet-activating factor receptor) ^[49]^D5. Within the heart, pneumococci form non-purulent microscopic lesions and cause cardiomyocyte death via pneumolysin and hydrogen peroxide. In a nonhuman primate model, this induces necroptosis and apoptosis, followed by cardiac scar formation after antibiotic rescue ^[52]^C4. Nox2-derived oxidative stress is upregulated during CAP; higher soluble Nox2 levels are independently associated with new-onset within 24-72 h of admission (9.5% of patients), and those remaining in AF have persistently elevated Nox2 levels ^[74]^B2b. Platelet activation, mediated by both host inflammatory cytokines and direct bacterial effects, promotes thrombosis and acute coronary events ^[63]^D5^[58]^D5. These mechanisms likely explain the increased risk of adverse cardiac events during and after CAP.

Resolution and Host Factors Modulating Outcome

Recovery from CAP requires efferocytosis - phagocytic clearance of apoptotic neutrophils by alveolar macrophages. This process is impaired in smokers and in patients with low body mass index, and is enhanced by prior statin use ^[75]^B2b. Persistent pulmonary inflammatory foci, visualised by ¹⁸FDG-PET/CT, remain in 68% of CAP survivors after clinical resolution, with glycolytic activity significantly higher than in matched controls (tPGA 80.0 vs. -19.4) ^[65]^B2b. This ongoing lung inflammation provides a plausible mechanism for the increased long-term cardiovascular, cognitive, and mortality risks seen in CAP survivors. Pre-existing diabetes does not alter the immediate immune response but increases mortality (adjusted HR 1.3, 95% CI 1.03-1.65) through exacerbation of underlying cardiovascular and kidney disease ^[76]^B2b.

Pearl: The two distinct sepsis response signatures identified by transcriptomic profiling, SRS1 (immunosuppressed, -2.8 for 14-day mortality) and SRS2 (inflamed), highlight that CAP mortality is driven more by host immune response heterogeneity than by pathogen factors alone; the 7-gene classifier can assign signature within hours of admission, enabling potential targeted immunomodulation ^[8]^B2b.

3. Epidemiology, Etiology and Risk Factors

▸Annual CAP incidence is 24.8 per 10,000 in U.S. adults and 15.7 per 10,000 in U.S. children, with highest rates in the elderly and infants.
▸Smoking, chronic respiratory/cardiovascular disease, HIV, and poor functional status are the strongest risk factors; occupational exposures contribute 10% of CAP in working-age adults.
▸Long-term mortality after CAP remains elevated (aHR 1.65) for nearly a decade, driven by cardiovascular events and comorbidity decompensation.

HY High Yield: Smoking cessation and vaccination (pneumococcal and influenza) are the most effective preventive strategies; occupational history should be routine in working-age adults with CAP.

The immune dysregulation and pathogen-host interactions described above translate into a substantial global burden that varies markedly by age, geography, and underlying risk profile.

Incidence and Prevalence

Community-acquired pneumonia (CAP) is the leading infectious cause of hospitalization and death among adults in the United States. The annual incidence of CAP requiring hospitalization among U.S. adults is 24.8 cases per 10,000 (95% CI 23.5-26.1), with rates rising sharply with age: 63.0 per 10,000 among those aged 65-79 years and 164.3 per 10,000 among those aged ≥80 years ^[135]^B2b. Among U.S. children, the annual incidence is 15.7 per 10,000 (95% CI 14.9-16.5), with the highest rate in children <2 years of age (62.2 per 10,000) ^[136]^B2b. In Europe, overall annual incidence ranges from 1.07 to 1.2 per 1000 person-years, increasing to 14 per 1000 person-years in adults aged ≥65 years ^[140]^D5^[141]^D5. Incidence is higher in men than in women ^[140]^D5.

In low- and middle-income countries (LMICs), data are sparse. A systematic review of CAP patients admitted to ICUs in middle-income countries reported a pooled mortality of 37% (95% CI 31-42), rising to 61% among those requiring mechanical ventilation ^[147]^B2a. In Malawi, 30-day mortality among hospitalized adults was 14.6%, with HIV seroprevalence of 78.4% ^[115]^B2b.

Temporal Trends

Despite advances in antimicrobial therapy and vaccination, CAP mortality has changed little over the past four decades ^[51]^D5. Long-term outcomes after an episode of CAP are worse than in the general population: over a median follow-up of 9.8 years, patients with CAP had an adjusted hazard ratio for death of 1.65 compared with matched controls ^[113]^B2b. Readmission rates after CAP hospitalization are increasing; in England, 15.7% of survivors were readmitted within 30 days, with pneumonia the most common reason (39.6%) and a readmission mortality of 15.9% ^[142]^B3b.

Risk Factors

Multiple modifiable and non-modifiable factors increase the risk of CAP and its severity. The table below summarizes key risk factors with their effect sizes.

Risk Factor	Odds Ratio / Relative Risk	Evidence Level
Smoking	OR ~2.0-4.0	Moderate ^[140]^D5^[138]^D5
Alcohol abuse	OR ~2.0-3.0	Moderate ^[140]^D5
Underweight (BMI <18.5)	OR ~1.5-2.0	Low ^[140]^D5
Regular contact with children	OR ~1.5-2.0	Low ^[140]^D5
Poor dental hygiene	OR ~1.5	Low ^[140]^D5
Asthma	OR ~2.0-3.0	Moderate ^[138]^D5
Diabetes mellitus	OR ~1.5-2.0	Moderate ^[138]^D5
Chronic heart disease	OR ~2.0-3.0	Moderate ^[138]^D5^[140]^D5
Cerebrovascular disease	OR ~2.0-4.0	Moderate ^[140]^D5
Dementia / dysphagia	OR ~2.0-4.0	Moderate ^[140]^D5^[129]^B2c
HIV infection	OR ~2.0-4.0	High ^[140]^D5^[115]^B2b
Chronic renal or liver disease	OR ~2.0-4.0	Moderate ^[140]^D5
Nursing home residence	OR ~2.0-3.0	Moderate ^[131]^D5^[129]^B2c
Occupational exposure (e.g., silica, healthcare)	PAF 10% for CAP in working-age adults	Moderate ^[111]^A1c
Aspiration risk factors (male, bedridden, enteral feeding)	OR ~2.0-4.0	Moderate ^[129]^B2c
	RR 0.43 (95% CI 0.24-0.75) for pneumococcal pneumonia	High ^[92]^B2a
Influenza vaccination	RR 0.30 (95% CI 0.22-0.40) for symptomatic influenza	High ^[92]^B2a

Smoking is one of the strongest modifiable risk factors, increasing the risk of pneumococcal disease two- to fourfold ^[138]^D5. Chronic respiratory disease ( , asthma) and chronic heart disease each double the risk ^[140]^D5. HIV infection remains a dominant driver in sub-Saharan Africa, where it is present in nearly 80% of hospitalized CAP patients ^[115]^B2b. Occupational exposures contribute an estimated population attributable fraction of 10% for CAP in working-age adults ^[111]^A1c. Influenza independently predisposes to invasive pulmonary aspergillosis ^[101]^B3b. Poor functional status ( ≥3) is a powerful predictor of 30-day mortality, independent of age and severity scores ^[162]^B2b.

Seasonal Variation

CAP occurs year-round, but winter accounts for about 34% of cases ^[158]^B2b. Streptococcus pneumoniae peaks in winter (21% vs. 13% in autumn), influenza viruses in autumn and winter (5-6% vs. 1% in summer), and Legionella pneumophila in summer and autumn (4% vs. 1% in winter) ^[158]^B2b. Polymicrobial pneumonia also shows seasonal variation, most frequent in winter (7%) ^[158]^B2b.

Special Considerations

Post-infection timing: The elevated risk of death after CAP persists for at least 1 year, driven by cardiovascular events and decompensation of comorbidities ^[113]^B2b^[58]^D5. Myocardial injury occurs in 85% of patients with severe CAP ^[117]^B3b. Vaccine-preventable burden: Pneumococcal vaccination reduces CAP in COPD patients (OR 0.62; NNT 21) ^[153]^A1a. Influenza vaccination reduces symptomatic influenza by 70% ^[92]^B2a. Nursing home residents often present atypically; S. pneumoniae remains the most common pathogen, but multidrug-resistant organisms are uncommon ^[131]^D5. Solid organ transplant recipients have poor predictive performance of standard severity scores ^[175]^B2b. Children have a high viral burden (57.4% viral detection), with rhinovirus, RSV, and bocavirus most common ^[108]^C4. Sickle cell disease patients are at high risk, but no randomized trials guide antibiotic choice ^[152]^B2a.

Pearl: Smoking cessation and pneumococcal/influenza vaccination are the most impactful modifiable interventions to reduce CAP risk; the occupational attributable fraction of 10% underscores the need to inquire about workplace exposures in working-age adults.

4. Clinical Presentation

▸Classic symptoms (fever, productive cough, dyspnoea) are absent in up to 30% of elderly patients, who may present with confusion or falls.
▸Certain pathogens produce distinctive clinical syndromes (e.g., bird exposure in psittacosis, haemoptysis in PVL-positive S. aureus) that guide empiric therapy.
▸Vital sign abnormalities (tachypnoea >30/min, hypotension, hypoxemia) are the most reliable predictors of severe disease and need for ICU admission.

HY High Yield: In elderly patients, the absence of fever or cough does not rule out CAP; altered mental status or functional decline may be the only clue.

The clinical presentation of CAP reflects the host inflammatory response to microbial invasion of the lower respiratory tract, with symptom severity and pattern shaped by pathogen virulence, host age, and comorbidities. The classic syndrome, acute fever, productive cough, dyspnoea, and pleuritic chest pain, is seen in only a subset of patients; many present with non‑specific or atypical features that delay diagnosis.

Presenting Symptoms

Symptoms typically evolve over 1 to 7 days before presentation ^[184]^B2b. Fever (≥38°C) is present in 80-90% of immunocompetent adults but may be absent in older patients ^[195]^B2b. Cough is nearly universal (91.8% in paediatric CAP ^[223]^B2b), initially dry then productive of purulent sputum. Dyspnoea ranges from mild exertional breathlessness to severe respiratory distress. Pleuritic chest pain suggests parapneumonic effusion or empyema. Constitutional symptoms, fatigue, myalgia, anorexia, are common and may dominate in the elderly ^[32]^B3b.

Physical Examination Findings

Vital sign abnormalities are the most reliable objective findings. Tachypnoea (respiratory rate >20 breaths/min) is present in 50-70% of hospitalized patients; a rate >30 breaths/min is a marker of severe pneumonia ^[186]^B2b. Tachycardia, hypotension, and hypoxemia (SpO₂ <90% or PaO₂ <60 mmHg) indicate severe disease. Chest auscultation reveals crackles (fine inspiratory) over the affected lobe, bronchial breath sounds, egophony, and increased tactile fremitus. Dullness to percussion suggests consolidation or effusion. The absence of focal signs does not exclude pneumonia, especially in early or atypical presentations ^[199]^B2b.

Table: Performance of Selected Clinical Signs for Diagnosing CAP

Sign	Sensitivity (%)	Specificity (%)	LR+	LR-	Source
Fever >38°C	60-80	50-70	1.5-2.5	0.4-0.6	^[195]^B2b
Crackles on auscultation	70-85	40-60	1.5-2.0	0.3-0.5	^[199]^B2b
Tachypnoea >20/min	50-70	60-80	1.8-2.8	0.4-0.6	^[186]^B2b
Dullness to percussion	20-30	85-95	2.0-4.0	0.8-0.9	^[199]^B2b
Bronchial breath sounds	15-25	90-98	3.0-6.0	0.8-0.9	^[199]^B2b

Phenotypic Variants

Certain pathogens produce distinctive clinical syndromes:

Mycoplasma pneumoniae: insidious onset, prominent cough, headache, sore throat; often with extrapulmonary manifestations (rash, mucositis, haemolytic anaemia) ^[222]^B2a. The Japanese Respiratory Society criteria (age <60, no/minor comorbidities, persistent cough, limited auscultatory findings, WBC <10,000/μL) have sensitivity 77%, specificity 93% for atypical pneumonia ^[42]^B3b.
Chlamydia psittaci: history of bird exposure (87.8% of cases ^[214]^B2b), high fever, severe headache, and rapid progression to respiratory failure; chest CT shows consolidation with ground‑glass opacities and pleural effusion ^[214]^B2b.
Staphylococcus aureus (especially PVL‑positive): fulminant onset with haemoptysis, necrotizing pneumonia, and rapid progression to ARDS; mortality in older patients is 47% ^[121]^B2b.
Acinetobacter baumannii: community‑acquired form is a distinct syndrome with bacteremia (31.6%), ARDS (84.2%), DIC (57.9%), and median survival of only 8 days ^[66]^B3b.
: risk factors include , bronchiectasis, prior antibiotic use, and corticosteroid therapy; 30‑day mortality is 28% in definitive cases ^[167]^B2b.

Red Flags

Features requiring immediate action include: altered mental status, systolic BP <90 mmHg, respiratory rate >30 breaths/min, SpO₂ <90% despite supplemental oxygen, and multilobar involvement on imaging. These predict early deterioration (need for mechanical ventilation or vasopressors within 72 h) ^[201]^B2b. The ATS/IDSA 2007 minor criteria (≥3 of 9) identify patients at risk for ICU admission with high sensitivity (94%) but low positive predictive value ^[201]^B2b.

Atypical Presentations

In elderly patients (≥65 years), fever and cough are often absent; instead, confusion, falls, functional decline, or anorexia may be the sole presenting features ^[32]^B3b^[131]^D5. In nursing‑home residents, pneumonia frequently presents with non‑specific symptoms, leading to diagnostic delay and worse outcomes ^[131]^D5. Immunocompromised patients (e.g., HIV with CD4 <200/μL) are more likely to have Pneumocystis jirovecii pneumonia, characterized by subacute onset, dry cough, hypoxemia, and elevated LDH (≥598 U/L) ^[193]^B2b. Children with HMPV pneumonia present with fever (98%), cough (97.6%), and wheezing (56.5%); wheezing and co‑infection with Mycoplasma predict severe disease ^[213]^B2b.

Pearl: In elderly patients, the absence of fever or cough does not rule out CAP; altered mental status or functional decline may be the only clue, and a low threshold for chest imaging is warranted.

5. Diagnosis and Workup (Pulmonary Function, Bronchoscopy and Imaging Anchored)

▸Chest radiograph remains the first-line confirmatory test, but CT identifies infiltrates in one-third of patients with negative radiographs and changes management in nearly 60%.
▸Pneumococcal urinary antigen is highly specific (99.7%) and increases pathogen identification by nearly 40%; targeted NGS from BALF offers superior clinical consistency for severe or refractory cases.
▸Blood cultures and respiratory PCR should be targeted to hospitalized or severe CAP; bronchoscopy is reserved for immunocompromised hosts, treatment failure, or suspected noninfectious mimics.

HY High Yield: Pneumococcal urinary antigen specificity is 99.7%, a positive result in a patient with compatible illness essentially confirms S. pneumoniae as the cause, allowing narrowing of empiric therapy to β-lactam monotherapy [259].

The clinical features described in the preceding section raise suspicion for community-acquired pneumonia (CAP); confirmation requires radiographic evidence of an acute pulmonary infiltrate supported by microbiologic and laboratory studies. The diagnostic approach balances test performance, patient severity, and resource availability, guided by the 2019 ATS/IDSA and 2026 updated guidelines ^[2]^A1c^[1]^A1c^[20]^D5.

Imaging - The Initial Anchor

A chest radiograph remains the first-line test to confirm parenchymal involvement. A discrete infiltrate (lobar, multilobar, or interstitial) establishes the diagnosis. However, chest radiograph misses up to 33% of infiltrates: in one prospective study of 319 patients with suspected CAP, CT revealed an infiltrate in 40 of 120 patients (33%) with a negative radiograph, and excluded CAP in 56 of 188 patients (30%) with a positive one ^[4]^B2b. Early multidetector chest CT modified diagnosis and in 58.6% (95% CI 53.2-64.0), leading to antibiotic initiation in 16% and discontinuation in 9% ^[4]^B2b. CT is not routine for all patients but is indicated when the diagnosis is uncertain, complications (empyema, abscess) are suspected, or the patient fails to improve. Dominant HRCT patterns include consolidation, ground-glass opacity, and centrilobular nodules; specific patterns may hint at atypical pathogens (e.g., tree-in-bud for Mycoplasma or viral) ^[251]^C4. The 2025 ATS guideline also supports lung ultrasound for diagnosis when performed by experienced clinicians, especially in emergency and critical care settings ^[20]^D5^[240]^B2b.

Laboratory Biomarkers

Biomarkers support diagnosis and severity assessment but are not diagnostic alone. C-reactive protein (CRP) and procalcitonin (PCT) levels vary with time from symptom onset: in early presenters (<3 days), CRP is lower and PCT higher; in later presenters (≥3 days), CRP rises by 36-38% and PCT falls by 40-56% ^[184]^B2b. In patients with emphysema, median CRP and PCT are significantly lower (CRP 116 vs. 254 mg/L), potentially masking infection ^[263]^C4. A PCT threshold <0.25 ng/mL can help defer in low-risk outpatients with low clinical suspicion.

Microbiologic Testing

Causative pathogen identification guides targeted therapy and is particularly important in moderate-to-severe CAP.

Test	Sensitivity	Specificity	Key Indication
Blood culture	~10% positivity in hospitalized CAP ^[236]^B2b	High	Severe CAP, ICU admission, prior antibiotic failure
Sputum Gram stain + culture	Variable (quality-dependent)	~80% when adequate specimen	Hospitalized patients with productive cough
Pneumococcal urinary antigen	60-75% ^[228]^B2a^[259]^B2b	99.7% ^[259]^B2b	All hospitalized CAP (rapid, noninvasive)
Legionella urinary antigen	~70% for serogroup 1	>99%	Severe CAP, ICU, travel/cluster history
Multiplex PCR (nasopharyngeal swab)	80-95% for viruses/atypicals ^[229]^B3b^[247]^B2b	High	Immunocompromised, ICU, epidemiologic context
Targeted NGS (BALF)	83% clinical consistency ^[211]^B2b	82% ^[211]^B2b	Severe/refractory CAP, suspected rare pathogens

Blood cultures are positive in approximately 10% of hospitalized CAP and are recommended for patients with severe disease (ICU admission, septic shock) ^[236]^B2b. Independent predictors of bacteremia include pleuritic pain, CRP ≥21.6 mg/dL, and ICU admission ^[236]^B2b. Urinary antigen testing for pneumococcus dramatically increases identification of pneumococcal CAP, by 39% in one study, and may allow streamlining to β-lactam monotherapy when positive, given its near-perfect specificity ^[238]^B2b^[259]^B2b. The test is more likely positive in patients with higher severity (low blood pressure, tachypnea, hypoxemia) and less likely if prior antibiotics were given ^[259]^B2b. Tracheal aspirate culture in intubated patients identifies a pathogen in 56% and provides the sole positive result in 39% of cases ^[46]^B3b. Targeted next-generation sequencing (tNGS) from bronchoalveolar lavage fluid (BALF) shows superior clinical consistency (83% vs. 38% for conventional tests) and detects resistance genes ^[211]^B2b. In resource-limited settings, outsourcing BALF-tNGS to a central lab can still yield a rapid diagnosis ^[267]^C4.

Diagnostic Bronchoscopy

Flexible bronchoscopy with bronchoalveolar lavage is reserved for patients who fail to stabilize, are immunocompromised, or have suspected noninfectious mimics. BAL with quantitative cultures has a diagnostic yield of up to 70% when routine tests are negative ^[130]^D5. In solid organ transplant recipients with CAP, bronchoscopy within 24 hours significantly increased the odds of establishing an etiology ^[243]^B2b. Transbronchial biopsy and EBUS-TBNA are rarely needed for typical CAP but may be indicated for suspected granulomatous disease (e.g., tuberculosis, fungal) or malignancy causing post-obstructive pneumonia ^[268]^C4. Therapeutic bronchoscopy is addressed in Section 9.

Arterial Blood Gas

ABG is essential for assessing gas exchange: a PaO₂/FiO₂ ratio <300 defines hypoxemic respiratory failure and upgrades severity ^[186]^B2b. Hypercapnia (PaCO₂ >45 mmHg) signals ventilatory failure, often in patients with underlying . ABG also guides decisions for admission, oxygen therapy, and noninvasive ventilation.

Spirometry and lung volumes are not indicated during the acute phase of CAP. They may be performed 4-6 weeks after resolution to evaluate residual restrictive defects (reduced FVC, TLC) or persistent obstructive physiology, particularly in patients with COPD. DLCO is not routinely measured.

Diagnostic Algorithm

Step 1: Clinical suspicion (cough, fever, dyspnea, focal signs) → Obtain chest radiograph. If infiltrate present, diagnosis confirmed. If radiograph negative but clinical suspicion high, consider chest CT or lung ultrasound. Step 2: Assess severity (see Section 6) to determine site of care (outpatient, ward, ICU). Step 3: In hospitalized patients, obtain blood cultures (×2), sputum culture (if purulent), pneumococcal and Legionella urinary antigen, and respiratory viral PCR. In severe or ICU CAP, add legionella culture on BAL or sputum and consider tNGS if initial tests are negative. Step 4: If no response at 48-72 hours, repeat blood cultures, chest CT, and proceed to bronchoscopy with BAL ± tNGS. Step 5: For immunocompromised patients or those with structural lung disease, consider bronchoscopy earlier with BAL for fungal, mycobacterial, and viral studies.

Controversies and Guideline Disagreement

Question	Position A	Position B	Strength	Implication
Role of routine blood cultures	ATS/IDSA 2019: recommend only for severe CAP ^[2]^A1c	NICE 2014: limited role in nonsevere CAP ^[249]^D5	Moderate	Blood cultures should not be obtained in low-risk outpatients but are essential in ICU patients.
Use of procalcitonin to guide antibiotic initiation	2025 ATS update: consider in low-risk outpatients ^[20]^D5	ESCMID/ERS: not routinely recommended ^[119]^A1c	Weak	PCT can support de-escalation but should not replace clinical judgment.

Pearl: In early presenters (<3 days of symptoms), CRP may be misleadingly low and PCT may be high, do not rule out CAP based on a single biomarker level; use the combination of a negative radiograph and a very low PCT (<0.1 ng/mL) to safely withhold antibiotics ^[184]^B2b^[20]^D5.

6. Severity, Staging and Risk Stratification

▸PSI has highest sensitivity for mortality (NPV ~0.98), best for identifying low-risk patients for outpatient care; CURB-65 is simpler and more specific but less sensitive.
▸Adding biomarkers (PCT, TnT-hs, CRP) to clinical scores improves discrimination for ICU admission and death; a CRP threshold >204 mg/L identifies patients likely to benefit from corticosteroids.
▸Emerging tools (PES score, machine-learning models, molecular endotypes) offer further refinement but require external validation before routine clinical adoption.

HY High Yield: PSI is the best tool to rule out severe disease (NPV 0.98); CURB-65 is simpler for rapid triage but misses some low-risk patients. Never use a score alone, always incorporate clinical judgment.

Dx Diagnostic Essentials: For suspected drug-resistant CAP, calculate the PES score: a score <5 has a 98% NPV for excluding pathogens requiring non-core empirical therapy [279].

The transition from diagnosis to begins with a single critical question: can this patient be treated safely at home, or does severity warrant hospitalization, even intensive care? Several validated risk stratification tools answer that question by estimating short-term mortality, each with distinct strengths and limitations.

Clinical Severity Scores: and

The Pneumonia Severity Index (PSI) and CURB-65 (confusion, urea, respiratory rate, blood pressure, age ≥65) remain the most widely studied. A meta-analysis of 23 studies (22 753 patients, average mortality 7.4%) reported that PSI class IV/V had the highest sensitivity for mortality (negative predictive value [NPV] 0.98) but the lowest specificity (positive predictive value [PPV] 0.14); CRB-65 (score ≥2) was the most specific (PPV 0.28) but least sensitive (NPV 0.94) ^[104]^B2a. The diagnostic odds ratios for mortality were 10.77 for PSI, 6.40 for CURB-65, 5.97 for CRB-65, and 5.75 for CURB ^[104]^B2a. In a nationwide Dutch study of 50 984 patients, CURB-65 hospitals had significantly lower 30-day mortality (8.6% vs. 9.7%; adjusted OR 0.89, 95% CI 0.83‑0.96) compared with PSI hospitals ^[176]^B2b. For identifying low-risk patients suited to outpatient management, PSI is superior; the CURB-65 family is simpler and performs adequately for rapid triage ^[93]^A1a^[126]^D5.

Score	Diagnostic Odds Ratio (95% CI)	Sensitivity	Specificity	NPV	PPV
PSI (class IV/V)	10.77 (NR)	Highest	Lowest	0.98	0.14
CURB-65 (≥3)	6.40 (NR)	Intermediate	Intermediate	0.97	0.21
CRB-65 (≥2)	5.97 (NR)	Lowest	Highest	0.94	0.28
CURB (≥2)	5.75 (NR)	Intermediate	Intermediate	0.96	0.19
NR = not reported in meta-analysis; values from ^[104]^B2a.

Augmenting Scores with Biomarkers

Adding biomarkers improves predictive accuracy. In the CAPNETZ cohort (n = 800), the combination of CRB-65, troponin T (TnT-hs), and procalcitonin yielded an AUC of 0.77 (95% CI 0.72‑0.82) vs. CRB-65 alone AUC 0.67 (95% CI 0.64‑0.73) for death or ICU admission within 28 days ^[170]^B2b. Elevated procalcitonin is a strong independent risk factor for death (RR 4.38, 95% CI 2.98‑6.43) ^[107]^B2a. Angiopoietin-2 serum levels improve the prognostic accuracy of CURB-65 for 28-day survival, ICU care, and length of stay ^[114]^B2b. Most recently, a data-driven meta-analysis identified a CRP threshold of 204 mg/L as the key effect modifier for corticosteroid benefit (30-day mortality OR 0.43 in predicted-benefit group; pinteraction=0.026) ^[97]^A1a.

Identifying Severe CAP and Drug-Resistant Pathogens

For defining severe CAP requiring ICU admission, the IDSA/ATS 2007 minor criteria (≥3 of 9 criteria), , and NEWS2 perform best; in a validation cohort of solid organ transplant recipients, these scores achieved AUCs of 0.67‑0.72, emphasizing the need for transplant-specific tools ^[175]^B2b. The PES score ( , extended-spectrum β-lactamase-producing Enterobacteriaceae, methicillin-resistant Staphylococcus aureus ) predicts drug-resistant etiology: AUC 0.81 in a derivation cohort (n = 1024) and 0.73 in an ICU cohort (n = 299); at a cutoff ≥5, NPV was 98%, suggesting that a low PES score can safely rule out non-core pathogens ^[279]^B2b. Functional status matters: ≥3 carries an adjusted OR of 5.70 (95% CI 3.82‑8.50) for 30-day mortality and significantly improves CRB-65 reclassification ^[162]^B2b.

Emerging Tools: Machine Learning, Immune Endotypes, and Long-Term Risk

Machine-learning models such as SeF-ML (a causal probabilistic network) achieve AUCs of 0.801‑0.826 for 30-day mortality, similar to PSI but superior to CURB-65 and ^[128]^B2b. Molecular endotyping further refines prognosis: the Mars1 endotype in sepsis carries a 28-day mortality of 39% (HR 1.86 vs. all others) ^[9]^B2b, and the SRS1 transcriptomic signature identifies an immunosuppressed phenotype with a 14-day mortality HR of 2.4 ^[8]^B2b. A parsimonious three-biomarker model (procalcitonin, sTREM-1, IL-6) predicts immune dysregulation stage with 91.2% accuracy ^[5]^B2b. For long-term risk, the Long-term Pneumonia Mortality Index (L-PMI), incorporating age, smoking, nursing-home residence, Charlson index, CURB-65, mechanical ventilation, and in-hospital cardiovascular events, predicts 1-year mortality with an AUC of 0.82 (derivation) and 0.75‑0.78 in external validation ^[12]^B2b.

Proper risk stratification directly informs the initial antibiotic choice and level of monitoring, topics taken up in the following section.

Pearl: Emerging tools (PES score, machine-learning models, molecular endotypes) offer further refinement but require external validation before routine clinical adoption.

Performance of Severity Scores for Mortality Prediction

Score	Diagnostic Odds Ratio	Sensitivity	Specificity	NPV	PPV
PSI (class IV/V)	10.77	Highest	Lowest	0.98	0.14
CURB-65 (≥3)	6.40	Intermediate	Intermediate	0.97	0.21
CRB-65 (≥2)	5.97	Lowest	Highest	0.94	0.28
CURB (≥2)	5.75	Intermediate	Intermediate	0.96	0.19
Values from meta-analysis of 23 studies (n=22,753); 95% CIs not reported ^[104]^B2a.

7. Acute Management and Exacerbation Rescue

▸Empiric antibiotic choice depends on severity: beta-lactam monotherapy for non-ICU, beta-lactam plus macrolide for ICU; add clarithromycin if SIRS/SOFA≥2 and PCT≥0.25 ng/mL.
▸Adjunctive hydrocortisone (200 mg/day) reduces mortality in severe CAP (NNT=18) but is contraindicated in nonsevere CAP.
▸Procalcitonin-guided therapy safely reduces antibiotic duration; target 5 days (minimum 3) for nonsevere CAP.

Rx Drug of Choice: For severe CAP: **ceftriaxone 2 g IV daily plus azithromycin 500 mg IV daily** plus **hydrocortisone 50 mg IV every 6 hours** (200 mg/day) for 4-7 days then taper [94,103].

! Warning: Do NOT use corticosteroids in nonsevere CAP (PSI I-III, CURB-65 0-2). The 2025 ATS guidelines recommend against this practice due to lack of benefit and potential harm (increased late failure, hyperglycemia) [20,269].

Once severity is classified (Section 6), proceeds as a time-critical pathway. The 2025 ATS guidelines emphasize early risk-stratified intervention ^[20]^D5.

Step 1: Disposition and Antibiotic Initiation

Outpatient ( I-II, 0-1): Oral 1 g three times daily or 200 mg loading then 100 mg twice daily for 5 days (minimum 3 days if clinically stable) ^[20]^D5.
ICU (severe CAP, PSI V, CURB-65 ≥3, or any IDSA/ATS major criterion): Initiate 2 g IV daily plus 500 mg IV daily or 750 mg IV daily. The network meta-analysis identifies ceftriaxone plus levofloxacin as having the highest probability of best mortality benefit ^[103]^A1a.

Step 2: Adjunctive Corticosteroids

Indication: Severe CAP (ICU admission, need for mechanical ventilation or vasopressors). The CAPE COD trial demonstrated that 200 mg IV daily (4-7 days then taper) reduced 28-day mortality from 11.9% to 6.2% (absolute difference -5.6 percentage points; P=0.006; NNT=18) ^[94]^A1b. The SONIA trial in Kenya confirmed benefit with oral low-dose glucocorticoids (HR 0.84, 95% CI 0.73-0.97) ^[95]^A1b.
Patient selection: An IPD meta-analysis found that benefit is concentrated in patients with CRP >204 mg/L (OR 0.43, 95% CI 0.25-0.76; Pinteraction=0.026) ^[97]^A1a. The 2025 ATS guidelines recommend corticosteroids for severe CAP and recommend against their use in nonsevere CAP ^[20]^D5.

Step 3: Oxygen and Ventilatory Support

Target: SpO₂ ≥92% (or PaO₂ ≥60 mm Hg). For moderate hypoxemic respiratory failure (PaO₂/FiO₂ 210-285), rapidly improves oxygenation: median time to PaO₂/FiO₂ >315 was 1.5 h vs 48 h with standard oxygen (P<0.001) ^[285]^A1b.
Escalation: If CPAP fails or PaO₂/FiO₂ <150, proceed to (NIV) or . NIV reduces intubation risk (OR 0.26, 95% CI 0.11-0.61) and ICU mortality (OR 0.28, 95% CI 0.09-0.88) in CAP with ARDS ^[154]^A1a.
Invasive ventilation: Use lung-protective ventilation (tidal volume 6 mL/kg predicted body weight, plateau pressure ≤30 cm H₂O) ^[200]^C4.

Step 4: Monitoring and De-escalation

Procalcitonin guidance: Use PCT to shorten antibiotic duration. In hospitalized patients, PCT <0.25 µg/L discourages ; PCT <0.1 µg/L strongly discourages. This reduced antibiotic exposure by 48% (RR 0.52, 95% CI 0.48-0.55) without worsening outcomes ^[270]^A1b. In outpatients, PCT guidance reduced duration from 7 to 5 days ^[291]^A1b.
Clinical stability: Defined as temperature ≤37.2°C, heart rate ≤100/min, respiratory rate ≤24/min, systolic BP ≥90 mm Hg, SpO₂ ≥90% on room air. Once stable for 48-72 h, switch from IV to oral antibiotics and plan discharge.
Duration: For nonsevere CAP, 5 days (minimum 3) is sufficient if clinically stable ^[20]^D5. For severe CAP, 5-7 days is recommended; longer courses are reserved for complications (empyema, ).

Step 5: Treatment Failure and Rescue

Definition: Lack of clinical stability by 72 h or deterioration. Evaluate for complications: parapneumonic effusion (consider drainage; corticosteroids showed no benefit in STOPPE trial ^[178]^A1b), empyema, lung abscess, or resistant pathogens.
Escalation: Broaden antibiotics (e.g., add for MRSA, for Pseudomonas) and obtain bronchoscopy with BAL for culture and mNGS. In severe CAP, mNGS combined with conventional tests reduced time to clinical improvement from 13 to 10 days (difference -2.0 days, 95% CI -3.0 to 0.0) ^[283]^A1b.
Consider noninfectious mimics: Vasculitis (e.g., granulomatosis with polyangiitis), organizing pneumonia, pulmonary embolism.

Controversies and Guideline Disagreement

Question	Position A	Position B	Strength	Implication
Corticosteroids in nonsevere CAP	2025 ATS, recommend against ^[20]^D5	Cochrane review, no mortality benefit (RR 0.95, 95% CI 0.45-2.00) ^[36]^A1a	Strong (guideline vs meta-analysis)	Do not use corticosteroids in nonsevere CAP.
Beta-lactam monotherapy vs combination	CAP-START, beta-lactam monotherapy noninferior for 90-day mortality ^[96]^A1b	ACCESS, improves early response in selected patients ^[48]^A1b	Moderate (different populations)	For non-ICU patients without SIRS, monotherapy is acceptable; for those with SIRS/ ≥2, consider adding macrolide.
Antibiotic duration <5 days	2025 ATS, minimum 3 days for nonsevere if stable ^[20]^D5	Traditional guidelines, 5-7 days	Moderate (new vs old)	Shorter courses are safe and reduce resistance.

Pearl: For severe CAP requiring ICU care, initiate a beta-lactam plus macrolide and adjunctive hydrocortisone 200 mg/day (especially if CRP >204 mg/L); use PCT guidance to limit antibiotic duration to 5 days in responders, and escalate to helmet CPAP or NIV early for hypoxemic respiratory failure.

Empiric Antibiotic Regimens for CAP by Severity

Severity	Regimen	Dose	Duration	Key Evidence
Outpatient (PSI I-II)	Amoxicillin or doxycycline	1 g PO TID or 200 mg load then 100 mg PO BID	5 days (min 3)	2025 ATS ^[20]^D5
Non-ICU ward (PSI III-IV)	Ceftriaxone ± clarithromycin	Ceftriaxone 2 g IV daily; clarithromycin 500 mg PO BID	5-7 days	CAP-START ^[96]^A1b; ACCESS ^[48]^A1b
ICU (severe CAP)	Ceftriaxone + azithromycin or levofloxacin	Ceftriaxone 2 g IV daily + azithromycin 500 mg IV daily or levofloxacin 750 mg IV daily	5-7 days	Network meta-analysis ^[103]^A1a

Corticosteroid Dosing for Severe CAP

Drug	Dose	Duration	Taper	Key Monitoring
Hydrocortisone	50 mg IV every 6 h (200 mg/day)	4-7 days	Taper over 4-7 days	Blood glucose, infection surveillance
Dexamethasone (alternative)	4 mg IV twice daily	48 h	None	Hyperglycemia (15.6% vs 7.1%) ^[178]^A1b

8. Long-term and Definitive Management

▸Procalcitonin-guided antibiotic duration reduces treatment from 12 to 5 days without compromising outcomes.
▸Guideline-concordant antibiotic therapy is associated with a 47% reduction in 1-year cardiovascular mortality (HR 0.53).
▸Pneumococcal and influenza vaccination should be administered during or immediately after CAP to reduce recurrence and long-term mortality.

Rx Drug of Choice: For hospitalized patients with severe CAP (SOFA ≥2, systemic inflammation, PCT ≥0.25 ng/mL), add oral clarithromycin 500 mg twice daily for 7 days to β-lactam therapy to improve early clinical and inflammatory response [48].

! Warning: Do NOT prescribe NSAIDs in the early phase of CAP: they are associated with an 8-fold increased odds of pleuropulmonary complications (OR 8.1, 95% CI 2.3-28) [332].

Once clinical stability is achieved, typically within 48-72 hours of starting appropriate , the focus shifts to completing a definitive course of therapy, safely transitioning to outpatient care, and mitigating the elevated long-term risks that persist after an episode of community-acquired pneumonia (CAP).

Step 1: Defining the Antibiotic Course and Duration

Shortening antibiotic exposure without compromising outcomes is a central goal. Procalcitonin (PCT)-guided algorithms safely reduce total antibiotic duration. In a randomized trial of 302 hospitalized adults with CAP, PCT guidance (antibiotics strongly discouraged if PCT < 0.1 µg/L, discouraged if <0.25 µg/L) reduced median treatment from 12 to 5 days (relative risk 0.52, 95% CI 0.48-0.55; NNT for reduced exposure not calculable) with comparable clinical success (83% in both groups) ^[270]^A1b. Similar results were obtained in low-risk outpatients, where PCT guidance cut duration from 7 to 5 days (RR 0.55, 95% CI 0.51-0.60) ^[291]^A1b.

For patients admitted to non-ICU wards, the CAP-START trial showed that a strategy of preferred empirical treatment with beta-lactam monotherapy was noninferior to beta-lactam-macrolide combination or fluoroquinolone monotherapy regarding 90-day mortality (difference 1.9 percentage points, 90% CI -0.6 to 4.4) ^[96]^A1b. However, in patients with more severe disease, systemic inflammatory response,  ≥2, and PCT ≥0.25 ng/mL, addition of oral 500 mg twice daily for 7 days improved early clinical and inflammatory response (68% vs 38% achieving the composite primary endpoint; P < 0.001) and reduced progression to respiratory failure, an effect mediated by attenuation of the IL-1 pathway and enhanced monocyte cytokine production ^[48]^A1b^[303]^A1b.

Early transition from intravenous to oral antibiotics reduces hospital stay. In children, oral was equivalent to intravenous benzyl penicillin (median time to fever resolution 1.3 days in both groups) ^[181]^A1b^[282]^A1b. In older adults with frailty, an ongoing trial tests lascufloxacin switch therapy against continued intravenous /sulbactam ^[143]^D5. For CAP patients on general wards, median time to starting oral therapy was 3 days with fluoroquinolone strategies and 4 days with beta-lactam strategies ^[96]^A1b.

Step 2: Discharge Planning and Long-Term Risk Assessment

CAP is not a self-limited illness. Long-term mortality remains elevated for years after hospitalization. In a large Canadian cohort (N = 6,078 with CAP, matched to 29,402 controls), the adjusted hazard ratio for death over a median 9.8 years was 1.65, corresponding to an absolute risk difference of 30 deaths per 1,000 patient-years ^[113]^B2b. Even after accounting for comorbidities, hospitalization for CAP independently predicted reduced survival (HR 1.4, 95% CI 1.2-1.5) ^[62]^B2b.

Risk stratification at discharge should incorporate cardiac biomarkers. Elevated high-sensitivity cardiac troponin T (≥14 ng/L) was present in 45% of hospitalized patients and was independently associated with 30-day mortality (OR 21.9) and long-term mortality (OR 10.7 over 4.1 years) ^[10]^B2b. The Long-term Pneumonia Mortality Index (L-PMI), which includes age, smoking, nursing home residence, Charlson Comorbidity Index, , need for mechanical ventilation, and in-hospital cardiovascular events, predicts 1-year mortality with areas under the curve of 0.75-0.82 in validation cohorts ^[12]^B2b. In older patients, performance status ≥2, albumin ≤2.5 g/dL, and dementia identify those with very high 180-day mortality (score AUC 0.85) ^[258]^B2b.

Vaccination is the cornerstone of secondary prevention. The CAPITA trial demonstrated 45.6% efficacy (95.2% CI 21.8-62.5) of 13-valent pneumococcal conjugate vaccine against vaccine-type CAP in adults ≥65 years over a mean 3.97 years ^[286]^A1b. In patients aged <65 years, 23-valent polysaccharide vaccine showed 76% efficacy (95% CI 20-93) against pneumococcal/unknown CAP ^[288]^A1b. Influenza vaccination during season is associated with reduced CAP severity (OR for CURB ≥1 = 0.76) and improved 6-month survival (HR 0.63) ^[327]^B2b.

Step 3: Cardiovascular Risk Modification

The inflammatory and thrombotic milieu of CAP transiently increases the risk of myocardial infarction and stroke. Guideline-concordant antibiotic therapy was associated with an almost 50% reduction in 1-year cardiovascular death (HR 0.53, 95% CI 0.34-0.80; NNT not calculable from reported data) ^[330]^B2b. Elevated natriuretic peptides (NT-proBNP, MR-proANP) on admission predict both short- and long-term mortality, with prognostic accuracy comparable to the Pneumonia Severity Index ^[322]^B2b^[333]^B2b^[336]^B2b. Biomarker-guided intensification of cardiovascular prevention after discharge merits further study but is not yet standard.

Adjunctive therapies beyond antibiotics remain experimental. High-dose (80 mg daily for 7 days) improved neutrophil function and Sequential Organ Failure Assessment scores in older adults with CAP and sepsis, and in a post-hoc analysis improved hospitalization-free survival; a definitive trial is needed ^[280]^A1b. Corticosteroids should not be used routinely for non-severe CAP: prednisolone 40 mg daily increased late clinical failure (19.2% vs 6.4%, P = 0.04) and provided no benefit in clinical cure at day 7 or 30 ^[269]^A1b. In severe CAP requiring ICU admission, 200 mg daily reduced 28-day mortality from 11.9% to 6.2% (absolute difference -5.6 percentage points, 95% CI -9.6 to -1.7; NNT = 18) ^[94]^A1b; in resource-limited settings, a pragmatic trial of low-dose oral glucocorticoids for 10 days also reduced 30-day mortality (22.6% vs 26.0%; HR 0.84, 95% CI 0.73-0.97; NNT = 29) ^[95]^A1b.

What NOT to Do

Avoid NSAIDs in early CAP: exposure is associated with an 8-fold increased odds of pleuropulmonary complications (empyema, cavitation) (OR 8.1, 95% CI 2.3-28) ^[332]^B2b.
Do not routinely prescribe benzodiazepines in patients at risk of CAP: they increase both the incidence (OR 1.54, 95% CI 1.42-1.67) and mortality (HR 1.22, 95% CI 1.06-1.39) of CAP ^[230]^B3b.
Do not use adjunctive corticosteroids for parapneumonic effusions: the STOPPE pilot trial found no benefit of 4 mg twice daily for 48 hours, with a trend toward longer time to normalization of vital signs ^[178]^A1b.

Controversies and Guideline Disagreement

Question	Position A	Position B	Strength	Implication for practice
Routine macrolide combination vs β-lactam alone for hospitalized CAP	IDSA/ATS guidelines recommend a β-lactam plus macrolide as preferred option for inpatients	CAP-START trial showed beta-lactam monotherapy noninferior for 90-day mortality in non-ICU patients ^[96]^A1b	Moderate (Class II vs I evidence; population differences in disease severity)	Consider macrolide combination for patients with SIRS, SOFA ≥2, or high PCT; beta-lactam alone is reasonable for low-severity non-ICU patients
PCV vs PPSV23 for adults ≥65 years	ACIP recommends PCV13 for all adults ≥65 based on CAPITA trial ^[286]^A1b	NICE uses a more selective approach for PCV13, citing population-level herd immunity from pediatric vaccination	Mild (different policy contexts; both recommend )	Ensure all eligible patients receive either PCV13 or PPSV23 (and in some countries both); local guidelines determine the schedule

Pearl: Antibiotic duration can be safely shortened using procalcitonin guidance (median 5 vs 12 days; NNT for reduced exposure not calculable), and all patients discharged after CAP should be vaccinated and assessed for elevated cardiovascular risk, even without prior heart disease, because long-term mortality remains high (HR 1.65 vs matched controls) ^[113]^B2b^[270]^A1b.

Evidence for Reduced Antibiotic Duration and Early Oral Switch

Strategy	Population	Duration vs control	Key result	Evidence level
Procalcitonin guidance ^[270]^A1b	Hospitalized CAP (N=302)	Median 5 vs 12 days	RR 0.52 for total antibiotic exposure; similar success 83%	1b
Procalcitonin guidance ^[291]^A1b	Low-risk outpatients (N=156)	Median 5 vs 7 days	RR 0.55; all survived to 4 weeks	1b
Oral amoxicillin vs IV penicillin ^[181]^A1b	Hospitalized children (N=246)	Equivalent 7-day course	Median time to fever resolution 1.3 days both groups	1b
Lascufloxacin switch therapy ^[143]^D5	Older adults with frailty (protocol)	IV step-down to oral	Ongoing trial (non-inferiority design)	5

Key Long-Term Risk Prediction Tools and Biomarkers

Tool / biomarker	Outcome predicted	AUC / odds ratio	Reference
High-sensitivity troponin T ≥28 ng/L	30-day and long-term mortality	OR 21.9 (short-term), 10.7 (long-term)	^[10]^B2b
Long-term Pneumonia Mortality Index (L-PMI)	1-year mortality	AUC 0.75-0.82	^[12]^B2b
MR-proADM	28- and 180-day mortality	AUC 0.85 (28-day), 0.78 (180-day)	^[322]^B2b
Performance status ≥2, albumin ≤2.5 g/dL, dementia	180-day mortality after pneumonia in older adults	AUC 0.85	^[258]^B2b
NT-proBNP	Short- and long-term mortality	AUC comparable to PSI (0.73-0.75)	^[333]^B2b

History and Evolution of Treatment

▸Beta-lactam monotherapy is noninferior to beta-lactam-macrolide combination for non-ICU inpatients (CAP-START trial) [96].
▸Corticosteroids reduce mortality in severe CAP (CAPE COD NNT=18, SONIA HR 0.84) but are not indicated in nonsevere disease [94,95,20].
▸Procalcitonin guidance and respiratory virus testing enable safe antibiotic de-escalation, reducing duration from >10 days to 5 days or fewer [270,306].

HY High Yield: The CAPE COD trial's NNT of 18 for 28‑day mortality with hydrocortisone in severe CAP is one of the largest effect sizes observed in modern critical care [94].

The treatment of community-acquired pneumonia has evolved through successive paradigm shifts, each grounded in landmark clinical trials that challenged entrenched practices and reshaped guidelines.

The Antibiotic Era: From Empirical Coverage to Precision

Empiric therapy in the 1990s relied on macrolides, , or fluoroquinolones for outpatients, with beta-lactam-macrolide combinations recommended for inpatients ^[339]^A1c. The 1995 sparfloxacin trial demonstrated equivalence to -clavulanic acid and erythromycin ^[343]^A1b, and oral was as effective as standard oral therapy ^[345]^A1b. A pivotal shift came with the CAP-START trial (2015), which showed that beta-lactam monotherapy was noninferior to beta-lactam-macrolide combination or fluoroquinolone monotherapy for non-ICU inpatients (90-day mortality 9.0% vs 11.1% and 8.8%, respectively) ^[96]^A1b. This finding challenged the dogma that atypical coverage was mandatory in all hospitalized patients. Observational studies had suggested a mortality benefit with macrolide-containing regimens, but propensity-matched analyses found no difference after accounting for confounders ^[179]^B2b. The ACCESS trial (2024) later demonstrated that added to beta-lactam improved early clinical response at 72 hours in patients with systemic inflammation, suggesting a host-modulatory effect beyond antibacterial activity ^[48]^A1b^[303]^A1b. Oral amoxicillin was shown equivalent to intravenous penicillin in hospitalized children ^[181]^A1b^[282]^A1b.

The Corticosteroid Controversy: Three Decades of Evidence

Corticosteroids have undergone the most dramatic reversal in CAP. An early trial by Confalonieri et al. (2004) in severe CAP showed that infusion (200‑mg bolus + 10 mg/h for 7 days) improved oxygenation, reduced septic shock, and lowered mortality (p = 0.009) ^[341]^A1b. However, Snijders et al. (2010) found that prednisolone 40 mg daily for 7 days in unselected hospitalized patients did not improve clinical cure and increased late failure (19.2% vs 6.4%, p = 0.04) ^[269]^A1b. The CAPE COD trial (2023) resolved the uncertainty in severe CAP: hydrocortisone 200 mg daily, tapered over 8-14 days, reduced 28‑day mortality from 11.9% to 6.2% (absolute difference -5.6 percentage points, P = 0.006); NNT = 18 to prevent one death ^[94]^A1b. This benefit was confirmed in the SONIA trial (2025) from Kenya (HR 0.84; 95% CI 0.73-0.97) ^[95]^A1b and in the APROCCHSS subgroup of CAP septic shock (OR 0.60; 95% CI 0.43-0.83) ^[91]^A1b. In parapneumonic effusions, 4 mg twice daily for 48 hours showed no benefit ^[178]^A1b. The 2025 ATS guideline now recommends corticosteroids for severe CAP and against their use in nonsevere pneumonia ^[20]^D5.

Duration, De‑escalation, and Biomarker‑Guided Care

Antibiotic duration was historically 7-21 days. Procalcitonin (PCT) guidance revolutionized this: Christ‑Crain et al. (2006) showed that PCT <0.25 µg/L discouraged , reducing median duration from 12 to 5 days without worsening outcomes ^[270]^A1b. This was replicated in outpatients ^[291]^A1b. The 2025 ATS guideline recommends <5 days (minimum 3) for nonsevere CAP once clinical stability is achieved, and ≥5 days for severe CAP ^[20]^D5. Respiratory virus testing and PCT combined enable safe antibiotic discontinuation: a pragmatic trial using a templated note interpreting low PCT or positive viral PCR as low probability of bacterial pneumonia reduced in‑hospital antibiotic days by 4.1 (7.5 vs 11.6, P = 0.006) ^[306]^A1b. Metagenomic NGS of BAL fluid in severe CAP reduced time to clinical improvement from 13 to 10 days ^[283]^A1b.

Adjunctive and Supportive Therapies

Several adjunctive strategies have been tested and abandoned. Tifacogin (recombinant tissue factor pathway inhibitor) showed biologic activity but no mortality benefit in severe CAP ^[89]^A1b. High‑dose (80 mg) improved neutrophil function and hospitalization‑free survival in a pilot study but awaits confirmatory trials ^[280]^A1b^[281]^C4. Early mobilization (sitting out of bed or ambulating ≥20 min within 24 hours) reduced length of stay by 1.1 days ^[346]^A1b. Photobiomodulation reduced hospital stay (9.3 vs 7.3 days) in a small trial ^[70]^A1b, but this is not yet standard.

Pearl: The history of CAP treatment teaches that large, well‑designed RCTs can overturn deeply held beliefs, corticosteroids in severe CAP, beta‑lactam monotherapy for non‑ICU patients, and 5‑day antibiotic courses are now evidence‑based standards that once were considered heretical.

9. Respiratory Support, Procedures & Interventional Pulmonology (Specialty-Distinctive)

▸Bronchoscopy with BAL within 24 hours increases diagnostic yield in immunocompromised patients with CAP.
▸Chest tube with fibrinolytics is as effective as VATS for pediatric empyema, with a cost advantage.
▸Long-term oxygen therapy may be required after severe CAP, and NIV can support high-risk patients during bronchoscopy.

HY High Yield: In immunocompromised patients with CAP, early bronchoscopy with BAL and metagenomics can increase diagnostic yield from 35% to 58% [360].

Building on the historical evolution of treatment, the pulmonologist's procedural armamentarium now offers targeted interventions for complicated pneumonia, particularly when standard therapy fails or complications arise.

Bronchoscopy: Diagnostic and Therapeutic Roles

Bronchoscopy with bronchoalveolar lavage (BAL) serves a dual role in CAP: establishing an etiology when initial workup is negative and, in selected cases, providing therapeutic benefit. In immunocompromised patients, such as solid organ transplant recipients, bronchoscopy within the first 24 hours significantly increases the odds of identifying a pathogen ^[243]^B2b. Among kidney transplant recipients, bronchoscopy was performed in 52.7% of CAP episodes, with a diagnostic yield of 44.8% ^[361]^B2b. The addition of clinical metagenomics to conventional testing on BAL fluid raises the diagnostic yield from 35% to 58%, primarily by detecting bacterial causes ^[360]^B2b. In children with severe adenovirus pneumonia, the need for bronchoscopy was strongly associated with disease severity ^[363]^B2b. Bedside fiberoptic bronchoscopy can also assist with sputum clearance, as demonstrated in a case of Chlamydia psittaci pneumonia ^[364]^C4. For patients who cannot tolerate bronchoscopy, sputum targeted next-generation sequencing (tNGS) offers comparable diagnostic accuracy to BALF tNGS at lower cost ^[368]^B2b.

Pleural Drainage for Parapneumonic Effusion and Empyema

Complicated parapneumonic effusion (CPE) and empyema require drainage. In children, a network meta-analysis of 11 RCTs (590 patients) found that chest tube with fibrinolytics, video-assisted thoracoscopic surgery ( ), and thoracotomy all reduced hospital length of stay compared with chest tube alone, with mean differences of 5.05 days, 5.86 days, and 6.33 days, respectively ^[99]^A1a. No substantial differences in LOS were observed among these three interventions, and fibrinolytics had cost advantages over VATS ^[99]^A1a. Short- and long-term morbidity and mortality were very low regardless of modality ^[99]^A1a. The IDSA/PIDS 2026 guideline recommends consideration of chest tube size and the choice between pleural drainage with fibrinolysis versus surgical debridement based on patient factors ^[358]^A1c^[359]^A1c. In adults, predictors of prolonged hospital stay in CPE include fever (aOR 3.42), lower PaO2 (aOR 4.89), lower hemoglobin (aOR 4.90), increased blood neutrophil fraction (aOR 3.83), identification of microbes in pleural fluid (aOR 4.14), and ineffective pleural drainage (aOR 3.28) ^[362]^B2b.

Long-Term Oxygen and Ventilatory Support

A subset of patients with severe CAP develop persistent hypoxemia requiring long-term oxygen therapy. In a case of rapidly progressive hypoxemic respiratory failure, the patient was discharged on 2 L supplemental oxygen after a prolonged course complicated by ECMO ^[292]^C4. Noninvasive ventilation (NIV) may be used during bronchoscopy in high-risk patients to avoid endotracheal intubation ^[233]^D5. In end-stage symptomatic patients, NIV can relieve dyspnea, though it should not replace intubation in progressive ARDS ^[233]^D5.

Pulmonary Rehabilitation

Recovery from CAP involves resolution of inflammation through efferocytosis, which is impaired in smokers and those with low body mass index ^[75]^B2b. Statin use was associated with increased efferocytosis, suggesting a potential role for pharmacologic enhancement of recovery ^[75]^B2b. While formal pulmonary rehabilitation programs are not specifically studied in CAP, the principles of exercise training and respiratory muscle strengthening apply to patients with prolonged recovery.

Pearl: In patients with complicated parapneumonic effusion, chest tube with fibrinolytics offers equivalent efficacy to VATS at lower cost, making it a preferred first-line intervention ^[99]^A1a.

10. Complications

▸Cardiovascular events occur in up to 30% of hospitalized CAP and are associated with 3-4-fold higher mortality; acute myocardial infarction carries 43% in-hospital mortality.
▸Invasive pulmonary aspergillosis complicates 19% of severe influenza CAP with 51% 90-day mortality; early diagnostic vigilance is critical.
▸Functional impairment, fatigue, dyspnoea, gait slowing, persists in the majority of survivors despite radiographic resolution, necessitating structured rehabilitation.

! Warning: Cardiovascular complications are the leading driver of mortality in hospitalised CAP. Perform ECG and troponin at admission and early echocardiography in patients with hypotension, arrhythmia, or pre-existing heart disease [373][385].

HY High Yield: Invasive aspergillosis complicates nearly 1 in 5 severe influenza CAP patients in the ICU, consider bronchoalveolar lavage galactomannan and early antifungal therapy [101].

Even after the initial respiratory stabilisation detailed in the preceding section, the clinical trajectory of CAP is frequently punctuated by pulmonary and systemic complications that independently drive morbidity and mortality. Up to 30% of hospitalised patients develop cardiovascular complications including new or worsening heart failure, arrhythmias, acute myocardial infarction (AMI), or stroke ^[377]^D5. In a large SARS-CoV-2 CAP cohort, CV events occurred in 18% and carried a mortality of 45% vs 13% without such events ^[373]^B2b. AMI specifically occurred in 2.3% of patients with CAP, with in-hospital mortality of 43% (adjusted OR 3.57) ^[385]^B2b. Pathogen-driven myocardial invasion, demonstrated by detection of Streptococcus pneumoniae within the myocardium in a non-human primate model, induces cardiomyocyte necroptosis and apoptosis followed by cardiac scarring, providing a mechanistic basis for these events ^[52]^C4.

Respiratory failure remains the most common pulmonary complication. ARDS develops in a subset, and non-invasive ventilation reduces ICU mortality compared with standard oxygen (OR 0.28) ^[154]^A1a. Parapneumonic effusion occurs in 5-12% of cases; prior use of inhaled corticosteroids is associated with a lower incidence (OR 0.40) ^[232]^B2b. In children, chest tube drainage with fibrinolytics shortens hospital stay by a mean 5.05 days compared with chest tube alone ^[99]^A1a. Pneumothorax is rare, and fluoroquinolone use as a class does not increase its risk; alone was associated with a doubled hazard (HR 2.26) ^[84]^B2b.

Invasive pulmonary aspergillosis superinfects severe influenza CAP in 19% of ICU patients (32% in immunocompromised and 14% in non-immunocompromised), with 90-day mortality of 51% vs 28% in those without aspergillosis ^[101]^B3b. Empyema and necrotising pneumonia are more common when presentation is delayed >7 days ^[221]^B2b. Macrolide resistance in S. pneumoniae does not worsen outcomes when guideline-compliant therapy is given ^[188]^B2b.

Treatment-related harms include hyperglycaemia with adjunctive corticosteroids; however, corticosteroids reduce mortality in severe CAP (RR 0.58) and early clinical failure (RR 0.32) ^[36]^A1a. Prolonged antibiotic duration beyond 1 week is associated with increased length of stay in a non-linear relationship, with an inflection point at 7.4 days ^[375]^B2b.

Hospital-acquired complications, pressure ulcers, urinary tract infection, and secondary sepsis, are more frequent in patients with longer stays, hypoalbuminaemia, and prior hospitalisation ^[371]^B2b^[375]^B2b. Routine deep-vein thrombosis prophylaxis is warranted given the hypercoagulable state induced by systemic inflammation, although specific CAP trial data are limited ^[384]^B2b.

Functional recovery is often incomplete. In severe pneumonia survivors, 68% reported persistent fatigue, 44% had worsened dyspnoea, and 38% had slow gait speed (<0.8 m/s) at 2 months despite radiographic resolution in 87% ^[224]^B2b. Multi-disciplinary rehabilitation, including early mobilisation, respiratory physiotherapy, and psychological screening, is recommended for patients with prolonged ICU stays or significant functional decline.

Pearl: Cardiovascular complications are the leading driver of mortality in hospitalised CAP; a high index of suspicion and low threshold for ECG, troponin, and echocardiography is warranted, especially in patients with pre-existing heart disease or severe sepsis.

11. Prognosis and Natural History

▸30-day mortality ranges from 6-14% in hospitalized CAP; ICU mortality reaches 37-61%, with higher rates for specific pathogens like Pseudomonas and staphylococcal necrotizing pneumonia.
▸CAP survivors have a 65% relative increase in all-cause mortality over the next decade compared to matched controls (absolute risk difference 30 per 1,000 patient-years); 15.7% are readmitted within 30 days, mostly for pneumonia.
▸Prognostic factors beyond severity scores include age ≥80, poor functional status (ECOG ≥3, OR 5.70), biomarkers (troponin, procalcitonin, glycemic gap), and immune dysregulation phenotypes.

HY High Yield: The Long-term Pneumonia Mortality Index (L-PMI) is a novel tool that predicts 1-year mortality after discharge with an AUC of 0.82, incorporating age, smoking, nursing home residency, Charlson comorbidity index, CURB-65, mechanical ventilation, and in-hospital cardiovascular events [12].

Short-Term Mortality

Among hospitalized patients with CAP, 30-day mortality ranges from 6% to 14% depending on severity and setting ^[387]^B2b^[96]^A1b. In the CAP-START trial, 90-day mortality was 9.0% with beta-lactam monotherapy and similar with alternative regimens ^[96]^A1b. For patients requiring ICU admission, mortality increases substantially: a systematic review of intensive care units in middle-income countries reported a pooled short-term mortality of 37% (95% CI 31-42), rising to 61% among those requiring mechanical ventilation ^[147]^B2a. Severe CAP due to specific pathogens carries even higher risk: definitive P aeruginosa pneumonia had 30-day mortality of 28%, and Panton-Valentine leukocidin-positive staphylococcal pneumonia in older patients reached 47% ^[167]^B2b^[121]^B2b. Corticosteroid therapy alters this trajectory, in the CAPE COD trial, reduced 28-day mortality from 11.9% to 6.2% in severe CAP (absolute difference -5.6 percentage points, NNT = 18) ^[94]^A1b.

Long-Term Outcomes

The mortality risk does not end with discharge. In a landmark Canadian cohort of 6,078 CAP survivors matched to controls, all-cause mortality over a median 9.8 years was significantly higher in the CAP group, with an adjusted hazard ratio of 1.65 (95% CI 1.57-1.73) and an absolute risk difference of 30 per 1,000 patient-years ^[113]^B2b. This excess risk persists across all age strata. Within one year after discharge, mortality was 6.3% in a Spanish derivation cohort, and the Long-term Pneumonia Mortality Index (L-PMI), incorporating age, smoking, nursing home residence, Charlson comorbidity index, score, mechanical ventilation, and in-hospital cardiovascular events, achieved an AUC of 0.82 for predicting 1-year death ^[12]^B2b. Readmission within 30 days occurs in 15.7% of survivors, most commonly for pneumonia itself (39.6%), and readmission for pneumonia carries an in-hospital mortality of 15.9% versus 6.5% for other causes ^[142]^B3b.

Factors That Modify Prognosis

Several host and illness factors independently predict worse outcomes. Age ≥80 years, malignant disease, congestive heart failure, cerebrovascular disease, renal disease, and diabetes mellitus are each independently associated with 30-day mortality in large cohorts ^[387]^B2b. Poor premorbid functional status ( ≥3) is a powerful predictor (adjusted OR 5.70 for 30-day mortality) ^[162]^B2b. Biomarkers add incremental accuracy: elevated troponin T-high sensitivity and procalcitonin improve the CRB-65 score’s AUC from 0.67 to 0.77 for predicting death or ICU admission ^[170]^B2b. The glycemic gap, an elevated admission glucose relative to a patient’s estimated average, is associated with a 2.5- to 2.6-fold increase in 90-day mortality, independent of diabetes status ^[118]^B2b. A three-biomarker immune dysregulation score (procalcitonin, soluble TREM-1, IL-6) identifies patients with CAP who have the most aberrant host response and highest mortality, suggesting that clinical severity alone is an inadequate proxy for immune state ^[5]^B2b.

Recovery and Functional Morbidity

Symptom burden remains substantial weeks after discharge. At 4-6 weeks, fatigue is reported by 45.0%-72.6% of patients, cough by 35.3%-69.7%, and dyspnea by 34.2%-67.1% ^[180]^B2a. Functional impairment at 4 weeks occurs in 18%-51%, and median time to return to normal activities ranges from 15 to 28 days ^[180]^B2a. These PROMs are increasingly recognized as essential trial endpoints.

Pearl: The single most actionable point for clinicians: a CAP episode doubles the long-term risk of death, this is not a self-limited illness, and discharge planning should include vaccination, comorbidity optimization, and functional assessment to bend the curve ^[113]^B2b.

12. Special Populations & Pregnancy

▸Pediatric CAP: early tNGS within 48 hours accelerates recovery; piperacillin-tazobactam superior to ampicillin for severe cases; macrolide resistance in Mycoplasma is high.
▸Elderly CAP: atypical presentation is common; severity scores underperform; screen for dysphagia and PE; high-dose simvastatin shows promise as adjunct.
▸Immunocompromised CAP: broader microbial workup (viruses, fungi, TB) is mandatory; empirical therapy must cover Pseudomonas and MRSA; influenza-associated aspergillosis carries high mortality.

HY High Yield: In elderly patients with CAP, a D-dimer >3.13 mg/L should prompt evaluation for pulmonary embolism, even in the absence of classic symptoms [404].

! Warning: In immunocompromised patients with influenza CAP, consider invasive aspergillosis; 90-day mortality exceeds 50% if untreated [101].

Prognosis after CAP varies substantially across patient subgroups, driven by age, immune status, and physiologic reserve. must therefore be tailored for four key populations.

Pediatrics

Presentation differs by age: infants present with tachypnea and poor feeding; school-aged children with fever and cough. Wheezing is common in viral CAP, particularly human metapneumovirus (HMPV) ^[213]^B2b. Mycoplasma pneumoniae peaks at age 6-12 years, with a nonlinear risk inflection at age 8; macrolide resistance is high (71.4-100% in refractory cases) ^[376]^B2b. Early targeted next-generation sequencing (tNGS) within 48 hours accelerates clinical recovery (cough improvement median 6 vs 9 days) ^[402]^B3b. For severe CAP, reduces early clinical failure (2.11% vs 9.47%) and improves cure rate (88.17% vs 76.74%) compared with ^[403]^B3b. For parapneumonic effusion, chest tube with fibrinolytics shortens length of stay similarly to (mean difference -5.05 days) ^[99]^A1a. Adjunctive oral pentoxifylline improves oxygenation and reduces inflammation ^[301]^A1b. Mortality is very low (0% in one influenza cohort) ^[389]^B2b; risk factors for severe disease include premature birth, wheezing, CRP ≥50 mg/L, and MP co-infection ^[213]^B2b.

Pregnancy

Physiologic changes (increased heart rate, decreased lung volumes) may mask severity; fever and tachypnea remain key signs. Chest radiography with abdominal shielding is safe. Beta-lactams (penicillins, cephalosporins) and macrolides ( ) are first-line. Tetracyclines and fluoroquinolones are contraindicated due to teratogenicity. is safe for influenza. No specific trial data exist; extrapolate from non-pregnant adults. Maternal mortality is low with prompt treatment; risk of warrants close monitoring.

Elderly

Presentation is often atypical: less fever, more confusion, falls, anorexia. is a strong risk factor (OR 11.9) ^[60]^B3b; screen with volume-viscosity swallow test. Long-term air pollution exposure increases risk (OR 2.30 for NO₂) ^[321]^B3b. Severity scores underperform in the very old (≥85 years): AUC 0.69, AUC 0.60 ^[374]^B2b. D-dimer >3.13 mg/L may indicate concurrent pulmonary embolism ^[404]^B2b. Standard antibiotic regimens apply, with attention to renal dosing. High-dose 80 mg for 7 days improved neutrophil function and hospitalization-free survival in a pilot study of CAP with sepsis ^[280]^A1b. Thirty-day mortality is 8.2% in ≥65 years vs 1.7% in younger patients ^[195]^B2b; long-term prognosis is predicted by performance status ≥2, albumin ≤2.5 g/dL, and dementia (score AUC 0.85) ^[258]^B2b. ARDS is less frequent in patients ≥85 years ^[400]^C4.

Immunocompromised Hosts

Includes HIV, transplant, chemotherapy, biologic therapy, chronic steroids. Presentation may be blunted; influenza is an independent risk factor for ^[101]^B3b. Broader workup is essential: respiratory viruses by PCR (rhinovirus most common after S. pneumoniae) ^[235]^B2b; BAL with metagenomic NGS for TB, PJP, fungi ^[268]^C4. Serology for if endemic ^[164]^D5. Empirical therapy should cover Pseudomonas and MRSA if risk factors are present ^[394]^D5. For influenza-associated CAP, consider antifungal coverage. Avoid live vaccines. Drug interactions with immunosuppressants (e.g., macrolides with calcineurin inhibitors) require vigilance. Mortality is high: 90-day mortality 51% in influenza+aspergillosis ^[101]^B3b; severity scores (PSI) have poor specificity ^[391]^B2b.

Pearl: In elderly patients with CAP, screen for dysphagia and consider concurrent pulmonary embolism when D-dimer exceeds 3.13 mg/L; in immunocompromised patients, add respiratory virus PCR and fungal workup early, especially during influenza season.

13. Prevention, Screening & Surveillance

▸Pneumococcal vaccination reduces CAP incidence in COPD (NNT 21) and is cost-effective in older adults; influenza vaccination reduces CAP severity during influenza seasons.
▸Herd protection from childhood PCV programmes substantially reduces adult pneumococcal CAP, but non-vaccine serotypes are emerging.
▸Vaccination should target high-risk groups (COPD, heart disease, diabetes, smoking, HIV, CKD) at the earliest opportunity; surveillance of serotype trends is essential for future vaccine policy.

HY High Yield: Pneumococcal vaccine NNT to prevent one CAP episode in COPD is 21; influenza vaccine reduces symptomatic influenza by 70% (RR 0.30).

Having addressed special populations, the focus now shifts to prevention, the most cost-effective strategy to reduce the burden of community-acquired pneumonia (CAP). Primary prevention targets modifiable risk factors and vaccination; secondary prevention aims to reduce recurrence in high-risk individuals; surveillance tracks serotype shifts and emerging threats.

Primary Prevention: Vaccination

reduces the incidence of CAP. In a meta-analysis of 12 RCTs in , pneumococcal polysaccharide vaccine (PPV23) lowered the odds of CAP by 38% (OR 0.62, 95% CI 0.43-0.89); NNT = 21 to prevent one episode ^[153]^A1a. Efficacy is greatest in patients aged <65 years with severe airflow obstruction (91% efficacy, 95% CI 35-99) ^[288]^A1b. In the elderly, PPV23 effectiveness against hospitalisation for CAP is 23.6% (95% CI 0.9-41.0) ^[410]^B3b. Conjugate vaccines (PCV13, PCV15, PCV20) provide broader serotype coverage; PCV13 was cost-effective in adults aged 65-74 years (ICER €8650 per QALY) in the Netherlands ^[409]^B2c. Among cancer patients, pneumococcal vaccination rates are low (26.9%), yet serotype 7F (covered by all vaccines) remains common ^[416]^B2b.

Influenza vaccination is supported by high-quality evidence: it reduces symptomatic influenza by 70% (RR 0.30, 95% CI 0.22-0.40) ^[92]^B2a. During influenza seasons, prior vaccination is associated with less severe CAP (CURB index ≥1: OR 0.76) and improved 6-month survival (HR 0.63, 95% CI 0.45-0.89) ^[327]^B2b. However, observational studies may overestimate mortality benefits due to confounding by the healthy-user effect ^[406]^B2b. In older adults, adjuvanted and high-dose influenza vaccines are preferentially recommended; a cluster-randomised crossover study found no significant difference in relative vaccine effectiveness against PCR-confirmed influenza between adjuvanted and high-dose formulations (rVE not significant) ^[302]^A1b.

Herd protection from childhood PCV programmes reduces adult pneumococcal CAP. After UK introduction of infant PCV13, adult CAP due to PCV7 serotypes declined by 88% (IRR 0.12, 95% CI 0.08-0.20) and due to additional PCV13 serotypes by 30% (IRR 0.70, 95% CI 0.51-0.96) ^[411]^B2b. Adults with contact with vaccinated children are less likely to have vaccine-type CAP (OR 0.37, 95% CI 0.14-0.99) ^[355]^B2b.

Secondary Prevention and Screening

Who should be vaccinated? Individuals with COPD, asthma, chronic heart disease, diabetes, smoking, and HIV are at increased risk of pneumococcal disease and should receive pneumococcal vaccination at the earliest opportunity ^[138]^D5. In virologically suppressed HIV patients with CD4 >350 cells/µL, pneumococcal vaccination rates are higher (10% vs 1%) and outcomes are similar to non-HIV patients ^[182]^B3b. In people with HIV, CAP incidence is highest with CD4 ≤200 cells/µL (34-107/1000 PYFU); those with CD4 ≥500 cells/µL and ≥1 year on ART have risk comparable to the general population ^[417]^B2b. In CKD not on dialysis, pneumococcal vaccination reduces CAP risk ^[415]^B2a.

Surveillance of serotype trends is essential. The incidence of pneumococcal CAP is increasing in the UK, driven by non-vaccine serotypes and serotype 3 (PCV13 non-7) ^[414]^B2b. After the pandemic, CAP incidence resurged to 95.9/1000 person-years in Shanghai, highlighting the need for continued vaccination efforts ^[420]^B2b. The PNEUMO study Europe will provide updated serotype prevalence data to inform future vaccine policy ^[172]^D5.

Patient education should emphasise smoking cessation (a strong modifiable risk factor ^[407]^B3b), dental hygiene, and avoidance of upper respiratory colonisation. Vaccination uptake should be promoted at every healthcare encounter, especially in autumn before influenza season.

Pearl: Vaccination remains the single most effective intervention to prevent CAP; pneumococcal vaccine NNT to prevent one episode of CAP in COPD is 21 ^[153]^A1a, and influenza vaccine reduces symptomatic influenza by 70% ^[92]^B2a.

Vaccine Efficacy and Effectiveness in CAP Prevention

Vaccine	Population	Outcome	Effect Estimate	NNT	Source
PPV23	COPD	CAP incidence	OR 0.62 (95% CI 0.43-0.89)	21	^[153]^A1a
PPV23	COPD, age <65 yr, severe obstruction	CAP prevention	91% efficacy (95% CI 35-99)	,	^[288]^A1b
PPV23	Elderly ≥65 yr	Hospitalisation for CAP	23.6% effectiveness (95% CI 0.9-41.0)	,	^[410]^B3b
Influenza vaccine	General adult	Symptomatic influenza	RR 0.30 (95% CI 0.22-0.40)	,	^[92]^B2a
Influenza vaccine	CAP patients (influenza season)	6-month survival	HR 0.63 (95% CI 0.45-0.89)	,	^[327]^B2b
PCV13 (infant)	Adults (herd effect)	PCV7-type CAP decline	IRR 0.12 (95% CI 0.08-0.20)	,	^[411]^B2b

References

[1]
Jones BE, Ramirez JA, Oren E et al.. “Diagnosis and Management of Community-acquired Pneumonia: An Official American Thoracic Society Clinical Practice Guideline.” American journal of respiratory and critical care medicine (2026). PMID: 40679934 ↗
L1GUIDELINECited in: 1. Definition, Classification and Nomenclature, 5. Diagnosis and Workup (Pulmonary Function, Bronchoscopy and Imaging Anchored), History and Evolution of Treatment
[2]
Metlay JP, Waterer GW, Long AC et al.. “Diagnosis and Treatment of Adults with Community-acquired Pneumonia. An Official Clinical Practice Guideline of the American Thoracic Society and Infectious Diseases Society of America.” American journal of respiratory and critical care medicine (2019). PMID: 31573350 ↗
L1GUIDELINECited in: 1. Definition, Classification and Nomenclature, 5. Diagnosis and Workup (Pulmonary Function, Bronchoscopy and Imaging Anchored), History and Evolution of Treatment
[3]
Evans SE, Jennerich AL, Azar MM et al.. “Nucleic Acid-based Testing for Noninfluenza Viral Pathogens in Adults with Suspected Community-acquired Pneumonia. An Official American Thoracic Society Clinical Practice Guideline.” American journal of respiratory and critical care medicine (2021). PMID: 33929301 ↗
L1GUIDELINECited in: 1. Definition, Classification and Nomenclature, History and Evolution of Treatment, 11. Prognosis and Natural History
[4]
Claessens YE, Debray MP, Tubach F et al.. “Early Chest Computed Tomography Scan to Assist Diagnosis and Guide Treatment Decision for Suspected Community-acquired Pneumonia.” American journal of respiratory and critical care medicine (2015). PMID: 26168322 ↗
L2TRIAL_NONRANDOMCited in: 1. Definition, Classification and Nomenclature, 5. Diagnosis and Workup (Pulmonary Function, Bronchoscopy and Imaging Anchored), 7. Acute Management and Exacerbation Rescue, History and Evolution of Treatment
[5]
Michels EHA, Dequin PF, Butler JM et al.. “Quantifying immune dysregulation in pneumonia and sepsis with a parsimonious machine-learning model: a multicohort analysis across care settings and reanalysis of a hydrocortisone randomised controlled trial.” The Lancet. Respiratory medicine (2026). PMID: 41856148 ↗
L2RCTCited in: 1. Definition, Classification and Nomenclature, 3. Epidemiology, Etiology and Risk Factors, 4. Clinical Presentation, 6. Severity, Staging and Risk Stratification, 7. Acute Management and Exacerbation Rescue, 11. Prognosis and Natural History
[6]
Harris M, Clark J, Coote N et al.. “British Thoracic Society guidelines for the management of community acquired pneumonia in children: update 2011.” Thorax (2011). PMID: 21903691 ↗
L1GUIDELINECited in: 1. Definition, Classification and Nomenclature, History and Evolution of Treatment
[7]
Thomson A, Harris M. “Community-acquired pneumonia in children: what's new?” Thorax (2011). PMID: 21933948 ↗
L5GUIDELINECited in: 1. Definition, Classification and Nomenclature, 3. Epidemiology, Etiology and Risk Factors, History and Evolution of Treatment
[8]
Davenport EE, Burnham KL, Radhakrishnan J et al.. “Genomic landscape of the individual host response and outcomes in sepsis: a prospective cohort study.” The Lancet. Respiratory medicine (2016). PMID: 26917434 ↗
L2COHORTCited in: 1. Definition, Classification and Nomenclature, 2. Pathophysiology and Mechanism, 3. Epidemiology, Etiology and Risk Factors, 6. Severity, Staging and Risk Stratification, 11. Prognosis and Natural History
[9]
Scicluna BP, van Vught LA, Zwinderman AH et al.. “Classification of patients with sepsis according to blood genomic endotype: a prospective cohort study.” The Lancet. Respiratory medicine (2017). PMID: 28864056 ↗
L2COHORTCited in: 1. Definition, Classification and Nomenclature, 3. Epidemiology, Etiology and Risk Factors, 6. Severity, Staging and Risk Stratification, 11. Prognosis and Natural History
[10]
Vestjens SMT, Spoorenberg SMC, Rijkers GT et al.. “High-sensitivity cardiac troponin T predicts mortality after hospitalization for community-acquired pneumonia.” Respirology (Carlton, Vic.) (2017). PMID: 28221010 ↗
L2RCTCited in: 1. Definition, Classification and Nomenclature, 7. Acute Management and Exacerbation Rescue, 8. Long-term and Definitive Management, History and Evolution of Treatment
[11]
Wunderink RG, Walley KR. “Update in sepsis and pulmonary infections 2013.” American journal of respiratory and critical care medicine (2014). PMID: 24983219 ↗
L5OTHERCited in: 1. Definition, Classification and Nomenclature, 6. Severity, Staging and Risk Stratification
[12]
Méndez R, González-Jiménez P, Latorre A et al.. “The Long-term Pneumonia Mortality Index: an international multicenter derivation and validation study for patients with community-acquired pneumonia.” American journal of respiratory and critical care medicine (2026). PMID: 41738235 ↗
L2OTHERCited in: 1. Definition, Classification and Nomenclature, 3. Epidemiology, Etiology and Risk Factors, 6. Severity, Staging and Risk Stratification, 8. Long-term and Definitive Management, 11. Prognosis and Natural History
[13]
Bedi P, Davidson DJ, McHugh BJ et al.. “Blood Neutrophils Are Reprogrammed in Bronchiectasis.” American journal of respiratory and critical care medicine (2018). PMID: 29733693 ↗
L3OTHERCited in: 1. Definition, Classification and Nomenclature, 2. Pathophysiology and Mechanism, 7. Acute Management and Exacerbation Rescue
[14]
Ranzani OT, Prina E, Menéndez R et al.. “New Sepsis Definition (Sepsis-3) and Community-acquired Pneumonia Mortality. A Validation and Clinical Decision-Making Study.” American journal of respiratory and critical care medicine (2017). PMID: 28613918 ↗
L2OTHERCited in: 1. Definition, Classification and Nomenclature, 7. Acute Management and Exacerbation Rescue
[15]
Komiya K, Ishii H, Umeki K et al.. “Impact of aspiration pneumonia in patients with community-acquired pneumonia and healthcare-associated pneumonia: a multicenter retrospective cohort study.” Respirology (Carlton, Vic.) (2013). PMID: 23231701 ↗
L2COHORTCited in: 1. Definition, Classification and Nomenclature, 5. Diagnosis and Workup (Pulmonary Function, Bronchoscopy and Imaging Anchored)
[16]
Cilloniz C, Ferrer M, Liapikou A et al.. “Acute respiratory distress syndrome in mechanically ventilated patients with community-acquired pneumonia.” The European respiratory journal (2018). PMID: 29545274 ↗
L2OTHERCited in: 1. Definition, Classification and Nomenclature, 7. Acute Management and Exacerbation Rescue
[17]
Gutierrez P, Closa D, Piñer R et al.. “Macrophage activation in exacerbated COPD with and without community-acquired pneumonia.” The European respiratory journal (2009). PMID: 20032016 ↗
L5OTHERCited in: 1. Definition, Classification and Nomenclature, 7. Acute Management and Exacerbation Rescue
[18]
Kolditz M, Ewig S, Höffken G. “Management-based risk prediction in community-acquired pneumonia by scores and biomarkers.” The European respiratory journal (2012). PMID: 23018905 ↗
L5REVIEW_NARRATIVECited in: 1. Definition, Classification and Nomenclature, 3. Epidemiology, Etiology and Risk Factors, 6. Severity, Staging and Risk Stratification, 10. Complications, 11. Prognosis and Natural History
[19]
Ginsburg AS, Klugman KP. “Antibiotics for paediatric community-acquired pneumonia in resource-constrained settings.” The European respiratory journal (2020). PMID: 32943429 ↗
L5OTHERCited in: 1. Definition, Classification and Nomenclature, 3. Epidemiology, Etiology and Risk Factors, 4. Clinical Presentation, 6. Severity, Staging and Risk Stratification, 11. Prognosis and Natural History, 13. Prevention, Screening & Surveillance
[20]
Long B, Gottlieb M. “2025 guideline updates for community-acquired pneumonia diagnosis and management.” The American journal of emergency medicine (2026). PMID: 42127879 ↗
L5GUIDELINECited in: 1. Definition, Classification and Nomenclature, 5. Diagnosis and Workup (Pulmonary Function, Bronchoscopy and Imaging Anchored), 7. Acute Management and Exacerbation Rescue, History and Evolution of Treatment
[21]
Backman K, Helminen M, Kekäläinen E et al.. “Working group summary of the 2023 full update of the Finnish national guidelines for paediatric lower respiratory tract infections.” Acta paediatrica (Oslo, Norway : 1992) (2024). PMID: 39487609 ↗
L1GUIDELINECited in: 1. Definition, Classification and Nomenclature
[22]
Restrepo MI, Mortensen EM, Velez JA et al.. “A comparative study of community-acquired pneumonia patients admitted to the ward and the ICU.” Chest (2007). PMID: 17989157 ↗
L2OTHERCited in: 1. Definition, Classification and Nomenclature, 5. Diagnosis and Workup (Pulmonary Function, Bronchoscopy and Imaging Anchored)
[23]
Dean NC, Bateman KA, Donnelly SM et al.. “Improved clinical outcomes with utilization of a community-acquired pneumonia guideline.” Chest (2006). PMID: 16963677 ↗
L2OTHERCited in: 1. Definition, Classification and Nomenclature
[24]
Kyriacou DN, Yarnold PR, Stein AC et al.. “Discriminating inhalational anthrax from community-acquired pneumonia using chest radiograph findings and a clinical algorithm.” Chest (2007). PMID: 17296652 ↗
L3OTHERCited in: 1. Definition, Classification and Nomenclature
[25]
Restrepo MI, Mortensen EM, Rello J et al.. “Late admission to the ICU in patients with community-acquired pneumonia is associated with higher mortality.” Chest (2009). PMID: 19880910 ↗
L2OTHERCited in: 1. Definition, Classification and Nomenclature
[26]
Akram AR, Singanayagam A, Choudhury G et al.. “Incidence and prognostic implications of acute kidney injury on admission in patients with community-acquired pneumonia.” Chest (2010). PMID: 20435657 ↗
L2OTHERCited in: 1. Definition, Classification and Nomenclature
[27]
Renaud B, Schuetz P, Claessens YE et al.. “Proadrenomedullin improves Risk of Early Admission to ICU score for predicting early severe community-acquired pneumonia.” Chest (2012). PMID: 22661450 ↗
L2OTHERCited in: 1. Definition, Classification and Nomenclature
[28]
Pervaiz F, Chavez MA, Ellington LE et al.. “Building a Prediction Model for Radiographically Confirmed Pneumonia in Peruvian Children: From Symptoms to Imaging.” Chest (2018). PMID: 30291926 ↗
L2OTHERCited in: 1. Definition, Classification and Nomenclature
[29]
Sun HK, Nicolau DP, Kuti JL. “Resource utilization of adults admitted to a large urban hospital with community-acquired pneumonia caused by Streptococcus pneumoniae.” Chest (2006). PMID: 16963679 ↗
L3OTHERCited in: 1. Definition, Classification and Nomenclature
[30]
Principi N, Esposito S. “Management of severe community-acquired pneumonia of children in developing and developed countries.” Thorax (2010). PMID: 20965930 ↗
L5REVIEW_NARRATIVECited in: 1. Definition, Classification and Nomenclature, 3. Epidemiology, Etiology and Risk Factors, 5. Diagnosis and Workup (Pulmonary Function, Bronchoscopy and Imaging Anchored), 6. Severity, Staging and Risk Stratification, 10. Complications, 11. Prognosis and Natural History
[31]
Brown JS, Lipman MC, Zar HJ. “What's new in respiratory infections and tuberculosis 2008-2010.” Thorax (2011). PMID: 21502098 ↗
L5REVIEW_NARRATIVECited in: 1. Definition, Classification and Nomenclature, 13. Prevention, Screening & Surveillance
[32]
Daniel P, Bewick T, Welham S et al.. “Adults miscoded and misdiagnosed as having pneumonia: results from the British Thoracic Society pneumonia audit.” Thorax (2017). PMID: 28108620 ↗
L3OTHERCited in: 1. Definition, Classification and Nomenclature, 4. Clinical Presentation
[33]
Fally M, Hansel J, Robey RC et al.. “Decoding community-acquired pneumonia: a systematic review and analysis of diagnostic criteria and definitions used in clinical trials.” Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases (2024). PMID: 39725075 ↗
L1TRIAL_NONRANDOMCited in: 1. Definition, Classification and Nomenclature
[34]
Almirall J, Boixeda R, de la Torre MC et al.. “Factors driving outcome variability in aspiration and community-acquired pneumonia: a meta-analysis.” European respiratory review : an official journal of the European Respiratory Society (2025). PMID: 41062168 ↗
L2SR_OBSCited in: 1. Definition, Classification and Nomenclature
[35]
Dinh A, Barbier F, Bedos JP et al.. “Update of guidelines for management of Community Acquired pneumonia in adults by the French Infectious Disease Society (SPILF) and the French-Speaking Society of Respiratory Diseases (SPLF): Endorsed by the French intensive care society (SRLF), the French microbiology society (SFM), the French radiology society (SFR) and the French emergency society (SFMU).” Respiratory medicine and research (2025). PMID: 40037948 ↗
L1GUIDELINECited in: 1. Definition, Classification and Nomenclature
[36]
Stern A, Skalsky K, Avni T et al.. “Corticosteroids for pneumonia.” The Cochrane database of systematic reviews (2017). PMID: 29236286 ↗
L1SR_OBSCited in: 1. Definition, Classification and Nomenclature, 3. Epidemiology, Etiology and Risk Factors, 6. Severity, Staging and Risk Stratification, 7. Acute Management and Exacerbation Rescue, 10. Complications, 11. Prognosis and Natural History
[37]
Pakhale S, Mulpuru S, Verheij TJ et al.. “Antibiotics for community-acquired pneumonia in adult outpatients.” The Cochrane database of systematic reviews (2014). PMID: 25300166 ↗
L1SR_OBSCited in: 1. Definition, Classification and Nomenclature, 3. Epidemiology, Etiology and Risk Factors, 5. Diagnosis and Workup (Pulmonary Function, Bronchoscopy and Imaging Anchored), 11. Prognosis and Natural History, 12. Special Populations & Pregnancy
[38]
Bjerre LM, Verheij TJ, Kochen MM. “Antibiotics for community acquired pneumonia in adult outpatients.” The Cochrane database of systematic reviews (2009). PMID: 19821292 ↗
L1SR_OBSCited in: 1. Definition, Classification and Nomenclature, 12. Special Populations & Pregnancy
[39]
Das RR, Singh M, Naik SS. “Vitamin D as an adjunct to antibiotics for the treatment of acute childhood pneumonia.” The Cochrane database of systematic reviews (2023). PMID: 36633175 ↗
L1SR_OBSCited in: 1. Definition, Classification and Nomenclature, 5. Diagnosis and Workup (Pulmonary Function, Bronchoscopy and Imaging Anchored)
[40]
Chen S, Jiang Y, Lv D et al.. “Identification of subtypes and construction of a predictive model for novel subtypes in severe community-acquired pneumonia based on clinical metagenomics: a multicenter, retrospective cohort study.” Frontiers in cellular and infection microbiology (2025). PMID: 41446276 ↗
L3COHORTCited in: 1. Definition, Classification and Nomenclature
[41]
Dobler CC, Waterer G. “Healthcare-associated pneumonia: a US disease or relevant to the Asia Pacific, too?” Respirology (Carlton, Vic.) (2013). PMID: 23714303 ↗
L5REVIEW_NARRATIVECited in: 1. Definition, Classification and Nomenclature, 6. Severity, Staging and Risk Stratification, 11. Prognosis and Natural History
[42]
Ishida T, Miyashita N, Nakahama C. “Clinical differentiation of atypical pneumonia using Japanese guidelines.” Respirology (Carlton, Vic.) (2007). PMID: 17207034 ↗
L3OTHERCited in: 1. Definition, Classification and Nomenclature, 4. Clinical Presentation, 5. Diagnosis and Workup (Pulmonary Function, Bronchoscopy and Imaging Anchored), 12. Special Populations & Pregnancy
[43]
Kelly E, MacRedmond RE, Cullen G et al.. “Community-acquired pneumonia in older patients: does age influence systemic cytokine levels in community-acquired pneumonia?” Respirology (Carlton, Vic.) (2009). PMID: 19272082 ↗
L2OTHERCited in: 1. Definition, Classification and Nomenclature, 7. Acute Management and Exacerbation Rescue, 12. Special Populations & Pregnancy
[44]
Taylor SP, Taylor BT. “Health care-associated pneumonia in haemodialysis patients: clinical outcomes in patients treated with narrow versus broad spectrum antibiotic therapy.” Respirology (Carlton, Vic.) (2013). PMID: 23066809 ↗
L3OTHERCited in: 1. Definition, Classification and Nomenclature
[45]
Henry C, Boethel C, Copeland LA et al.. “Clinical Utility of Testing for Legionella Pneumonia in Central Texas.” Annals of the American Thoracic Society (2017). PMID: 27739904 ↗
L3OTHERCited in: 1. Definition, Classification and Nomenclature, History and Evolution of Treatment
[46]
McCauley LM, Webb BJ, Sorensen J et al.. “Use of Tracheal Aspirate Culture in Newly Intubated Patients with Community-Onset Pneumonia.” Annals of the American Thoracic Society (2016). PMID: 26793950 ↗
L3OTHERCited in: 1. Definition, Classification and Nomenclature, 5. Diagnosis and Workup (Pulmonary Function, Bronchoscopy and Imaging Anchored), 7. Acute Management and Exacerbation Rescue
[47]
Vaidyanathan A, Guiot J, Zerka F et al.. “An externally validated fully automated deep learning algorithm to classify COVID-19 and other pneumonias on chest computed tomography.” ERJ open research (2022). PMID: 35509437 ↗
L3OTHERCited in: 1. Definition, Classification and Nomenclature, 5. Diagnosis and Workup (Pulmonary Function, Bronchoscopy and Imaging Anchored)
[48]
Giamarellos-Bourboulis EJ, Siampanos A, Bolanou A et al.. “Clarithromycin for early anti-inflammatory responses in community-acquired pneumonia in Greece (ACCESS): a randomised, double-blind, placebo-controlled trial.” The Lancet. Respiratory medicine (2024). PMID: 38184008 ↗
L1RCTCited in: 2. Pathophysiology and Mechanism, 6. Severity, Staging and Risk Stratification, 7. Acute Management and Exacerbation Rescue, 8. Long-term and Definitive Management, History and Evolution of Treatment, 11. Prognosis and Natural History
[49]
Brown AO, Millett ER, Quint JK et al.. “Cardiotoxicity during invasive pneumococcal disease.” American journal of respiratory and critical care medicine (2015). PMID: 25629643 ↗
L5REVIEW_NARRATIVECited in: 2. Pathophysiology and Mechanism, 3. Epidemiology, Etiology and Risk Factors
[50]
Michels EHA, Peters-Sengers H, de Brabander J et al.. “The Plasma Proteome in Community-acquired Pneumonia: Pathophysiology, Outcome, and 10-Year Risk.” American journal of respiratory and critical care medicine (2025). PMID: 40600965 ↗
L3OTHERCited in: 2. Pathophysiology and Mechanism, 8. Long-term and Definitive Management, 11. Prognosis and Natural History
[51]
Waterer GW, Rello J, Wunderink RG. “Management of community-acquired pneumonia in adults.” American journal of respiratory and critical care medicine (2010). PMID: 20693379 ↗
L5REVIEW_NARRATIVECited in: 2. Pathophysiology and Mechanism, 3. Epidemiology, Etiology and Risk Factors, 6. Severity, Staging and Risk Stratification, 8. Long-term and Definitive Management, 11. Prognosis and Natural History
[52]
Reyes LF, Restrepo MI, Hinojosa CA et al.. “Severe Pneumococcal Pneumonia Causes Acute Cardiac Toxicity and Subsequent Cardiac Remodeling.” American journal of respiratory and critical care medicine (2017). PMID: 28614669 ↗
L4OTHERCited in: 2. Pathophysiology and Mechanism, 10. Complications
[53]
Burnham KL, Davenport EE, Radhakrishnan J et al.. “Shared and Distinct Aspects of the Sepsis Transcriptomic Response to Fecal Peritonitis and Pneumonia.” American journal of respiratory and critical care medicine (2017). PMID: 28036233 ↗
L2OTHERCited in: 2. Pathophysiology and Mechanism, 4. Clinical Presentation
[54]
Preston JA, Bewley MA, Marriott HM et al.. “Alveolar Macrophage Apoptosis-associated Bacterial Killing Helps Prevent Murine Pneumonia.” American journal of respiratory and critical care medicine (2019). PMID: 30649895 ↗
L5OTHERCited in: 2. Pathophysiology and Mechanism, 7. Acute Management and Exacerbation Rescue
[55]
van Vught LA, Scicluna BP, Wiewel MA et al.. “Comparative Analysis of the Host Response to Community-acquired and Hospital-acquired Pneumonia in Critically Ill Patients.” American journal of respiratory and critical care medicine (2016). PMID: 27267747 ↗
L2OTHERCited in: 2. Pathophysiology and Mechanism
[56]
Park SY, Shrestha S, Youn YJ et al.. “Autophagy Primes Neutrophils for Neutrophil Extracellular Trap Formation during Sepsis.” American journal of respiratory and critical care medicine (2017). PMID: 28358992 ↗
L4OTHERCited in: 2. Pathophysiology and Mechanism
[57]
Marriott HM, Jackson LE, Wilkinson TS et al.. “Reactive oxygen species regulate neutrophil recruitment and survival in pneumococcal pneumonia.” American journal of respiratory and critical care medicine (2008). PMID: 18202350 ↗
L5OTHERCited in: 2. Pathophysiology and Mechanism, 7. Acute Management and Exacerbation Rescue
[58]
Singanayagam A, Singanayagam A, Elder DH et al.. “Is community-acquired pneumonia an independent risk factor for cardiovascular disease?” The European respiratory journal (2011). PMID: 21737556 ↗
L5REVIEW_NARRATIVECited in: 2. Pathophysiology and Mechanism, 3. Epidemiology, Etiology and Risk Factors, 6. Severity, Staging and Risk Stratification, 7. Acute Management and Exacerbation Rescue, 8. Long-term and Definitive Management, 11. Prognosis and Natural History
[59]
Defres S, Marwick C, Nathwani D. “MRSA as a cause of lung infection including airway infection, community-acquired pneumonia and hospital-acquired pneumonia.” The European respiratory journal (2009). PMID: 19948913 ↗
L5REVIEW_NARRATIVECited in: 2. Pathophysiology and Mechanism
[60]
Almirall J, Rofes L, Serra-Prat M et al.. “Oropharyngeal dysphagia is a risk factor for community-acquired pneumonia in the elderly.” The European respiratory journal (2012). PMID: 22835620 ↗
L3OTHERCited in: 2. Pathophysiology and Mechanism, 12. Special Populations & Pregnancy
[61]
Fatykhova D, Fritsch VN, Siebert K et al.. “Microenvironmental acidification by pneumococcal sugar consumption fosters barrier disruption and immune suppression in the human alveolus.” The European respiratory journal (2024). PMID: 39231629 ↗
L5OTHERCited in: 2. Pathophysiology and Mechanism
[62]
Bordon J, Wiemken T, Peyrani P et al.. “Decrease in long-term survival for hospitalized patients with community-acquired pneumonia.” Chest (2010). PMID: 20382718 ↗
L2OTHERCited in: 2. Pathophysiology and Mechanism, 8. Long-term and Definitive Management, 12. Special Populations & Pregnancy
[63]
Feldman C, Anderson R. “Community-Acquired Pneumonia: Pathogenesis of Acute Cardiac Events and Potential Adjunctive Therapies.” Chest (2015). PMID: 25951315 ↗
L5REVIEW_NARRATIVECited in: 2. Pathophysiology and Mechanism, History and Evolution of Treatment, 12. Special Populations & Pregnancy
[64]
Peyrani P, Arnold FW, Bordon J et al.. “Incidence and Mortality of Adults Hospitalized With Community-Acquired Pneumonia According to Clinical Course.” Chest (2019). PMID: 31610158 ↗
L2OTHERCited in: 2. Pathophysiology and Mechanism, 8. Long-term and Definitive Management
[65]
Corrales-Medina VF, deKemp RA, Chirinos JA et al.. “Persistent Lung Inflammation After Clinical Resolution of Community-Acquired Pneumonia as Measured by 18FDG-PET/CT Imaging.” Chest (2021). PMID: 33667494 ↗
L2OTHERCited in: 2. Pathophysiology and Mechanism, History and Evolution of Treatment
[66]
Leung WS, Chu CM, Tsang KY et al.. “Fulminant community-acquired Acinetobacter baumannii pneumonia as a distinct clinical syndrome.” Chest (2006). PMID: 16424419 ↗
L3OTHERCited in: 2. Pathophysiology and Mechanism, 4. Clinical Presentation
[67]
Waterer GW, Kessler LA, Wunderink RG. “Delayed administration of antibiotics and atypical presentation in community-acquired pneumonia.” Chest (2006). PMID: 16840376 ↗
L2OTHERCited in: 2. Pathophysiology and Mechanism
[68]
Aliberti S, Amir A, Peyrani P et al.. “Incidence, etiology, timing, and risk factors for clinical failure in hospitalized patients with community-acquired pneumonia.” Chest (2008). PMID: 18583514 ↗
L2OTHERCited in: 2. Pathophysiology and Mechanism
[69]
Metersky ML, Ma A, Houck PM et al.. “Antibiotics for bacteremic pneumonia: Improved outcomes with macrolides but not fluoroquinolones.” Chest (2007). PMID: 17296649 ↗
L2OTHERCited in: 2. Pathophysiology and Mechanism
[70]
Pereira PC, de Lima CJ, Fernandes AB et al.. “Effects of photobiomodulation by infrared LED-therapy on improving cardiopulmonary functions and hematologic parameters in patients with community-acquired pneumonia (CAP).” Respiratory medicine (2026). PMID: 42009264 ↗
L1RCTCited in: 2. Pathophysiology and Mechanism, 4. Clinical Presentation, 5. Diagnosis and Workup (Pulmonary Function, Bronchoscopy and Imaging Anchored), 7. Acute Management and Exacerbation Rescue, 8. Long-term and Definitive Management, History and Evolution of Treatment
[71]
Zhou Y, Wei Y, Wang J et al.. “Efficacy and metabolomic analysis of the pneumonia compound formulation against community-acquired pneumonia: an observational controlled before-after clinical trial.” BMC infectious diseases (2025). PMID: 40165069 ↗
L1RCTCited in: 2. Pathophysiology and Mechanism
[72]
Grudzinska F, Faniyi AA, Belchamber KBR et al.. “Hospitalised older adults with community-acquired pneumonia and sepsis have dysregulated neutrophil function but preserved glycolysis.” Thorax (2025). PMID: 39689942 ↗
L3OTHERCited in: 2. Pathophysiology and Mechanism
[73]
Herr C, Beisswenger C, Hess C et al.. “Suppression of pulmonary innate host defence in smokers.” Thorax (2008). PMID: 18852155 ↗
L4OTHERCited in: 2. Pathophysiology and Mechanism
[74]
Violi F, Carnevale R, Calvieri C et al.. “Nox2 up-regulation is associated with an enhanced risk of atrial fibrillation in patients with pneumonia.” Thorax (2015). PMID: 26123660 ↗
L2OTHERCited in: 2. Pathophysiology and Mechanism, History and Evolution of Treatment
[75]
Wootton DG, Diggle PJ, Court J et al.. “Recovery from pneumonia requires efferocytosis which is impaired in smokers and those with low body mass index and enhanced by statins.” Thorax (2016). PMID: 27471049 ↗
L2OTHERCited in: 2. Pathophysiology and Mechanism, 5. Diagnosis and Workup (Pulmonary Function, Bronchoscopy and Imaging Anchored), 9. Respiratory Support, Procedures & Interventional Pulmonology (Specialty-Distinctive)
[76]
Yende S, van der Poll T, Lee M et al.. “The influence of pre-existing diabetes mellitus on the host immune response and outcome of pneumonia: analysis of two multicentre cohort studies.” Thorax (2010). PMID: 20861291 ↗
L2OTHERCited in: 2. Pathophysiology and Mechanism
[77]
Liu C, Yang X, Paoli-Bruno J et al.. “Allo-Priming Reverses Immunosenescence and May Restore Broad Respiratory Viral Protection and Vaccine Responsiveness to the Elderly: Results of a Phase I/II Clinical Trial.” Vaccines (2025). PMID: 40432075 ↗
L4TRIAL_NONRANDOMCited in: 2. Pathophysiology and Mechanism
[78]
Cillóniz C, Civljak R, Nicolini A et al.. “Polymicrobial community-acquired pneumonia: An emerging entity.” Respirology (Carlton, Vic.) (2015). PMID: 26494527 ↗
L5REVIEW_NARRATIVECited in: 2. Pathophysiology and Mechanism, 3. Epidemiology, Etiology and Risk Factors
[79]
Chen YH, Yao WZ, Gao JZ et al.. “Serum hydrogen sulfide as a novel marker predicting bacterial involvement in patients with community-acquired lower respiratory tract infections.” Respirology (Carlton, Vic.) (2009). PMID: 19659653 ↗
L3OTHERCited in: 2. Pathophysiology and Mechanism
[80]
Tagami T, Kushimoto S, Tosa R et al.. “Plasma neutrophil elastase correlates with pulmonary vascular permeability: a prospective observational study in patients with pneumonia.” Respirology (Carlton, Vic.) (2011). PMID: 21605276 ↗
L4OTHERCited in: 2. Pathophysiology and Mechanism
[81]
Wu M, Han S, Li H. “Lefamulin versus omadacycline for community acquired bacterial pneumonia: a systematic review and anchored indirect treatment comparison using moxifloxacin as the common comparator.” Journal of comparative effectiveness research (2026). PMID: 41823576 ↗
L1SR_OBSCited in: 2. Pathophysiology and Mechanism
[82]
Georgakopoulou VE, Dodos K, Pitiriga VC. “Role of Lipidomics in Respiratory Tract Infections: A Systematic Review of Emerging Evidence.” Microorganisms (2025). PMID: 41011521 ↗
L5SR_OBSCited in: 2. Pathophysiology and Mechanism
[83]
Pott H, Gaffron S, Martin R et al.. “Self-organising map clustering identifies high-risk clusters of post-acute mortality in a prospective multicentre study of community-acquired pneumonia.” ERJ open research (2026). PMID: 41561102 ↗
L2OTHERCited in: 2. Pathophysiology and Mechanism
[84]
Steven Yi BS, Saurav Sumughan BS, Jessica Cobb MD et al.. “Fluoroquinolone Use and Risk of Pneumothorax in Adults Hospitalized With Community Acquired Pneumonia: A Retrospective Cohort Study.” The clinical respiratory journal (2026). PMID: 42387596 ↗
L2COHORTCited in: 2. Pathophysiology and Mechanism, 10. Complications
[85]
Ke Q, Zhao C, Luo S et al.. “Effect of the maxing huoqiao granule on nonsevere community-acquired pneumonia: A multicenter, double-blind, placebo-controlled randomized trial.” Pharmacological research (2026). PMID: 41966499 ↗
L1RCTCited in: 2. Pathophysiology and Mechanism
[86]
Luo H, Zeng Q, Xie N et al.. “Coordinated Regulation of TLR2 Signaling by Neu1 Sialidase and the Siglec-5/Siglec-14 Receptor Pair During Mycoplasma pneumoniae Infection.” ACS infectious diseases (2026). PMID: 42350323 ↗
L5OTHERCited in: 2. Pathophysiology and Mechanism
[87]
Feldman C, Richards GA. “The Impact of Environmental and Climate Factors on Pneumonia Pathogenesis.” Clinics in chest medicine (2026). PMID: 42203411 ↗
L5REVIEW_NARRATIVECited in: 2. Pathophysiology and Mechanism
[88]
Tu S, Li Y, Zhou Y et al.. “Chlamydia beyond the genital tract: a major contributor to community-acquired pneumonia.” Frontiers in cellular and infection microbiology (2026). PMID: 42180254 ↗
L5REVIEW_NARRATIVECited in: 2. Pathophysiology and Mechanism
[89]
Wunderink RG, Laterre PF, Francois B et al.. “Recombinant tissue factor pathway inhibitor in severe community-acquired pneumonia: a randomized trial.” American journal of respiratory and critical care medicine (2011). PMID: 21297074 ↗
L1RCTCited in: 3. Epidemiology, Etiology and Risk Factors, 7. Acute Management and Exacerbation Rescue, 8. Long-term and Definitive Management, History and Evolution of Treatment
[90]
Wirz SA, Blum CA, Schuetz P et al.. “Pathogen- and antibiotic-specific effects of prednisone in community-acquired pneumonia.” The European respiratory journal (2016). PMID: 27471201 ↗
L1RCTCited in: 3. Epidemiology, Etiology and Risk Factors, 5. Diagnosis and Workup (Pulmonary Function, Bronchoscopy and Imaging Anchored), 7. Acute Management and Exacerbation Rescue, 8. Long-term and Definitive Management, History and Evolution of Treatment, 10. Complications, 11. Prognosis and Natural History
[91]
Heming N, Renault A, Kuperminc E et al.. “Hydrocortisone plus fludrocortisone for community acquired pneumonia-related septic shock: a subgroup analysis of the APROCCHSS phase 3 randomised trial.” The Lancet. Respiratory medicine (2024). PMID: 38310918 ↗
L1RCTCited in: 3. Epidemiology, Etiology and Risk Factors, 5. Diagnosis and Workup (Pulmonary Function, Bronchoscopy and Imaging Anchored), 6. Severity, Staging and Risk Stratification, 7. Acute Management and Exacerbation Rescue, 8. Long-term and Definitive Management, History and Evolution of Treatment, 11. Prognosis and Natural History
[92]
Wilson KC, Schünemann HJ. “An appraisal of the evidence underlying performance measures for community-acquired pneumonia.” American journal of respiratory and critical care medicine (2011). PMID: 21239689 ↗
L2SR_OBSCited in: 3. Epidemiology, Etiology and Risk Factors, 13. Prevention, Screening & Surveillance
[93]
Chalmers JD, Akram AR, Hill AT. “Increasing outpatient treatment of mild community-acquired pneumonia: systematic review and meta-analysis.” The European respiratory journal (2010). PMID: 20729221 ↗
L1SR_OBSCited in: 3. Epidemiology, Etiology and Risk Factors, 6. Severity, Staging and Risk Stratification, 11. Prognosis and Natural History
[94]
Dequin PF, Meziani F, Quenot JP et al.. “Hydrocortisone in Severe Community-Acquired Pneumonia.” The New England journal of medicine (2023). PMID: 36942789 ↗
L1RCTCited in: 3. Epidemiology, Etiology and Risk Factors, 6. Severity, Staging and Risk Stratification, 7. Acute Management and Exacerbation Rescue, 8. Long-term and Definitive Management, History and Evolution of Treatment, 11. Prognosis and Natural History
[95]
Lucinde RK, Gathuri H, Mwaniki P et al.. “A Pragmatic Trial of Glucocorticoids for Community-Acquired Pneumonia.” The New England journal of medicine (2025). PMID: 41159889 ↗
L1RCTCited in: 3. Epidemiology, Etiology and Risk Factors, 5. Diagnosis and Workup (Pulmonary Function, Bronchoscopy and Imaging Anchored), 6. Severity, Staging and Risk Stratification, 7. Acute Management and Exacerbation Rescue, 8. Long-term and Definitive Management, History and Evolution of Treatment, 11. Prognosis and Natural History
[96]
Postma DF, van Werkhoven CH, van Elden LJ et al.. “Antibiotic treatment strategies for community-acquired pneumonia in adults.” The New England journal of medicine (2015). PMID: 25830421 ↗
L1RCTCited in: 3. Epidemiology, Etiology and Risk Factors, 6. Severity, Staging and Risk Stratification, 7. Acute Management and Exacerbation Rescue, 8. Long-term and Definitive Management, History and Evolution of Treatment, 11. Prognosis and Natural History
[97]
Smit JM, Van Der Zee PA, Stoof SCM et al.. “Predicting benefit from adjuvant therapy with corticosteroids in community-acquired pneumonia: a data-driven analysis of randomised trials.” The Lancet. Respiratory medicine (2025). PMID: 39892408 ↗
L1SR_OBSCited in: 3. Epidemiology, Etiology and Risk Factors, 6. Severity, Staging and Risk Stratification, 7. Acute Management and Exacerbation Rescue, 11. Prognosis and Natural History
[98]
Saleem N, Kulkarni A, Snow TAC et al.. “Effect of Corticosteroids on Mortality and Clinical Cure in Community-Acquired Pneumonia: A Systematic Review, Meta-analysis, and Meta-regression of Randomized Control Trials.” Chest (2022). PMID: 36087797 ↗
L1SR_OBSCited in: 3. Epidemiology, Etiology and Risk Factors, 6. Severity, Staging and Risk Stratification, 7. Acute Management and Exacerbation Rescue, 11. Prognosis and Natural History
[99]
Fernandez Elviro C, Longcroft-Harris B, Allin E et al.. “Conservative and Surgical Modalities in the Management of Pediatric Parapneumonic Effusion and Empyema: A Living Systematic Review and Network Meta-Analysis.” Chest (2023). PMID: 37463660 ↗
L1SR_OBSCited in: 3. Epidemiology, Etiology and Risk Factors, 6. Severity, Staging and Risk Stratification, 8. Long-term and Definitive Management, 9. Respiratory Support, Procedures & Interventional Pulmonology (Specialty-Distinctive), 10. Complications, 11. Prognosis and Natural History, 12. Special Populations & Pregnancy
[100]
Wan YD, Sun TW, Liu ZQ et al.. “Efficacy and Safety of Corticosteroids for Community-Acquired Pneumonia: A Systematic Review and Meta-Analysis.” Chest (2016). PMID: 26501852 ↗
L2SR_OBSCited in: 3. Epidemiology, Etiology and Risk Factors, 6. Severity, Staging and Risk Stratification, 7. Acute Management and Exacerbation Rescue, 11. Prognosis and Natural History
[101]
Schauwvlieghe AFAD, Rijnders BJA, Philips N et al.. “Invasive aspergillosis in patients admitted to the intensive care unit with severe influenza: a retrospective cohort study.” The Lancet. Respiratory medicine (2018). PMID: 30076119 ↗
L3COHORTCited in: 3. Epidemiology, Etiology and Risk Factors, 5. Diagnosis and Workup (Pulmonary Function, Bronchoscopy and Imaging Anchored), 6. Severity, Staging and Risk Stratification, 7. Acute Management and Exacerbation Rescue, 10. Complications, 11. Prognosis and Natural History, 12. Special Populations & Pregnancy
[102]
Bai AD, Srivastava S, Digby GC et al.. “Anaerobic Antibiotic Coverage in Aspiration Pneumonia and the Associated Benefits and Harms: A Retrospective Cohort Study.” Chest (2024). PMID: 38387648 ↗
L3COHORTCited in: 3. Epidemiology, Etiology and Risk Factors, 6. Severity, Staging and Risk Stratification, 11. Prognosis and Natural History
[103]
Montes-Andujar L, Tinoco E, Baez-Pravia O et al.. “Empiric antibiotics for community-acquired pneumonia in adult patients: a systematic review and a network meta-analysis.” Thorax (2021). PMID: 33723019 ↗
L1SR_OBSCited in: 3. Epidemiology, Etiology and Risk Factors, 6. Severity, Staging and Risk Stratification, 7. Acute Management and Exacerbation Rescue, 11. Prognosis and Natural History
[104]
Loke YK, Kwok CS, Niruban A et al.. “Value of severity scales in predicting mortality from community-acquired pneumonia: systematic review and meta-analysis.” Thorax (2010). PMID: 20729235 ↗
L2SR_OBSCited in: 3. Epidemiology, Etiology and Risk Factors, 6. Severity, Staging and Risk Stratification, 11. Prognosis and Natural History
[105]
Ruopp M, Chiswell K, Thaden JT et al.. “Respiratory Tract Infection Clinical Trials from 2007 to 2012. A Systematic Review of ClinicalTrials.gov.” Annals of the American Thoracic Society (2015). PMID: 26360527 ↗
L5TRIAL_NONRANDOMCited in: 3. Epidemiology, Etiology and Risk Factors, 6. Severity, Staging and Risk Stratification, 11. Prognosis and Natural History
[106]
Angus DC, Berry S, Lewis RJ et al.. “The REMAP-CAP (Randomized Embedded Multifactorial Adaptive Platform for Community-acquired Pneumonia) Study. Rationale and Design.” Annals of the American Thoracic Society (2020). PMID: 32267771 ↗
L5TRIAL_NONRANDOMCited in: 3. Epidemiology, Etiology and Risk Factors, 6. Severity, Staging and Risk Stratification, 7. Acute Management and Exacerbation Rescue, 11. Prognosis and Natural History
[107]
Liu D, Su LX, Guan W et al.. “Prognostic value of procalcitonin in pneumonia: A systematic review and meta-analysis.” Respirology (Carlton, Vic.) (2015). PMID: 26662169 ↗
L2SR_OBSCited in: 3. Epidemiology, Etiology and Risk Factors, 6. Severity, Staging and Risk Stratification, 11. Prognosis and Natural History
[108]
Wang M, Cai F, Wu X et al.. “Incidence of viral infection detected by PCR and real-time PCR in childhood community-acquired pneumonia: a meta-analysis.” Respirology (Carlton, Vic.) (2015). PMID: 25615588 ↗
L4SR_OBSCited in: 3. Epidemiology, Etiology and Risk Factors
[109]
Jiang HL, Chen HX, Liu W et al.. “Is COPD associated with increased mortality and morbidity in hospitalized pneumonia? A systematic review and meta-analysis.” Respirology (Carlton, Vic.) (2015). PMID: 26177049 ↗
L2SR_OBSCited in: 3. Epidemiology, Etiology and Risk Factors, 6. Severity, Staging and Risk Stratification, 11. Prognosis and Natural History
[110]
Horita N, Otsuka T, Haranaga S et al.. “Beta-lactam plus macrolides or beta-lactam alone for community-acquired pneumonia: A systematic review and meta-analysis.” Respirology (Carlton, Vic.) (2016). PMID: 27338144 ↗
L2SR_OBSCited in: 3. Epidemiology, Etiology and Risk Factors, 6. Severity, Staging and Risk Stratification, 11. Prognosis and Natural History
[111]
Blanc PD, Annesi-Maesano I, Balmes JR et al.. “The Occupational Burden of Nonmalignant Respiratory Diseases. An Official American Thoracic Society and European Respiratory Society Statement.” American journal of respiratory and critical care medicine (2019). PMID: 31149852 ↗
L1REVIEW_NARRATIVECited in: 3. Epidemiology, Etiology and Risk Factors
[112]
Chouchane O, Schuurman AR, Reijnders TDY et al.. “The Plasma Lipidomic Landscape in Patients with Sepsis due to Community-acquired Pneumonia.” American journal of respiratory and critical care medicine (2024). PMID: 38240721 ↗
L3OTHERCited in: 3. Epidemiology, Etiology and Risk Factors, 4. Clinical Presentation, 6. Severity, Staging and Risk Stratification, 10. Complications, 11. Prognosis and Natural History
[113]
Eurich DT, Marrie TJ, Minhas-Sandhu JK et al.. “Ten-Year Mortality after Community-acquired Pneumonia. A Prospective Cohort.” American journal of respiratory and critical care medicine (2015). PMID: 26067221 ↗
L2OTHERCited in: 3. Epidemiology, Etiology and Risk Factors, 6. Severity, Staging and Risk Stratification, 7. Acute Management and Exacerbation Rescue, 8. Long-term and Definitive Management, 11. Prognosis and Natural History
[114]
Gutbier B, Neuhauß AK, Reppe K et al.. “Prognostic and Pathogenic Role of Angiopoietin-1 and -2 in Pneumonia.” American journal of respiratory and critical care medicine (2018). PMID: 29447449 ↗
L2OTHERCited in: 3. Epidemiology, Etiology and Risk Factors, 5. Diagnosis and Workup (Pulmonary Function, Bronchoscopy and Imaging Anchored), 6. Severity, Staging and Risk Stratification, 11. Prognosis and Natural History
[115]
Aston SJ, Ho A, Jary H et al.. “Etiology and Risk Factors for Mortality in an Adult Community-acquired Pneumonia Cohort in Malawi.” American journal of respiratory and critical care medicine (2019). PMID: 30625278 ↗
L2OTHERCited in: 3. Epidemiology, Etiology and Risk Factors, 6. Severity, Staging and Risk Stratification
[116]
Kobe H, Momose M, Miyazaki Y et al.. “A 73-Year-Old Man With Refractory Hemoptysis.” Chest (2022). PMID: 36210108 ↗
L4CASE_REPORTCited in: 3. Epidemiology, Etiology and Risk Factors, 4. Clinical Presentation, 7. Acute Management and Exacerbation Rescue, History and Evolution of Treatment
[117]
Frencken JF, van Baal L, Kappen TH et al.. “Myocardial Injury in Critically Ill Patients with Community-acquired Pneumonia. A Cohort Study.” Annals of the American Thoracic Society (2019). PMID: 30521759 ↗
L3COHORTCited in: 3. Epidemiology, Etiology and Risk Factors, 6. Severity, Staging and Risk Stratification, 7. Acute Management and Exacerbation Rescue
[118]
Jensen AV, Baunbæk Egelund G, Bang Andersen S et al.. “The Glycemic Gap and 90-Day Mortality in Community-acquired Pneumonia. A Prospective Cohort Study.” Annals of the American Thoracic Society (2019). PMID: 31437014 ↗
L2COHORTCited in: 3. Epidemiology, Etiology and Risk Factors, 6. Severity, Staging and Risk Stratification, 11. Prognosis and Natural History
[119]
Martin-Loeches I, Torres A, Nagavci B et al.. “ERS/ESICM/ESCMID/ALAT guidelines for the management of severe community-acquired pneumonia.” The European respiratory journal (2023). PMID: 37012080 ↗
L1OTHERCited in: 3. Epidemiology, Etiology and Risk Factors, 5. Diagnosis and Workup (Pulmonary Function, Bronchoscopy and Imaging Anchored), 6. Severity, Staging and Risk Stratification, 11. Prognosis and Natural History
[120]
de Roux A, Ewig S, García E et al.. “Mixed community-acquired pneumonia in hospitalised patients.” The European respiratory journal (2006). PMID: 16585087 ↗
L4OTHERCited in: 3. Epidemiology, Etiology and Risk Factors
[121]
Gillet Y, Tristan A, Rasigade JP et al.. “Prognostic factors of severe community-acquired staphylococcal pneumonia in France.” The European respiratory journal (2021). PMID: 33833037 ↗
L2OTHERCited in: 3. Epidemiology, Etiology and Risk Factors, 4. Clinical Presentation, 6. Severity, Staging and Risk Stratification, History and Evolution of Treatment, 11. Prognosis and Natural History
[122]
Pereverzeva L, Uhel F, Peters Sengers H et al.. “Blood leukocyte transcriptomes in Gram-positive and Gram-negative community-acquired pneumonia.” The European respiratory journal (2022). PMID: 34446464 ↗
L4OTHERCited in: 3. Epidemiology, Etiology and Risk Factors, 6. Severity, Staging and Risk Stratification, 11. Prognosis and Natural History
[123]
Nouailles G, Bischoff R, Linke K et al.. “Trimodulin supports antibacterial defence and restricts inflammation in preclinical pneumonia models.” The European respiratory journal (2026). PMID: 40935582 ↗
L5OTHERCited in: 3. Epidemiology, Etiology and Risk Factors, 6. Severity, Staging and Risk Stratification
[124]
Jensen AV, Egelund GB, Andersen SB et al.. “The impact of blood glucose on community-acquired pneumonia: a retrospective cohort study.” ERJ open research (2017). PMID: 28656133 ↗
L3COHORTCited in: 3. Epidemiology, Etiology and Risk Factors, 6. Severity, Staging and Risk Stratification, 11. Prognosis and Natural History
[125]
Lac J, Han S, Ahmad M et al.. “Low-dose corticosteroids in severe pulmonary infection: a meta-analysis of randomised controlled trials.” BMJ open respiratory research (2026). PMID: 42425738 ↗
L1SR_MA_RCTCited in: 3. Epidemiology, Etiology and Risk Factors, 6. Severity, Staging and Risk Stratification, 11. Prognosis and Natural History
[126]
Singanayagam A, Chalmers JD. “Severity assessment scores to guide empirical use of antibiotics in community acquired pneumonia.” The Lancet. Respiratory medicine (2013). PMID: 24461668 ↗
L5REVIEW_NARRATIVECited in: 3. Epidemiology, Etiology and Risk Factors, 6. Severity, Staging and Risk Stratification, 10. Complications, 11. Prognosis and Natural History, 12. Special Populations & Pregnancy
[127]
Marik PE. “The role of glucocorticoids as adjunctive treatment for sepsis in the modern era.” The Lancet. Respiratory medicine (2018). PMID: 30006071 ↗
L5OTHERCited in: 3. Epidemiology, Etiology and Risk Factors, 6. Severity, Staging and Risk Stratification, 7. Acute Management and Exacerbation Rescue, 11. Prognosis and Natural History
[128]
Cilloniz C, Ward L, Mogensen ML et al.. “Machine-Learning Model for Mortality Prediction in Patients With Community-Acquired Pneumonia: Development and Validation Study.” Chest (2022). PMID: 35850287 ↗
L2OTHERCited in: 3. Epidemiology, Etiology and Risk Factors, 6. Severity, Staging and Risk Stratification, 11. Prognosis and Natural History
[129]
Marin-Corral J, Pascual-Guardia S, Amati F et al.. “Aspiration Risk Factors, Microbiology, and Empiric Antibiotics for Patients Hospitalized With Community-Acquired Pneumonia.” Chest (2020). PMID: 32687909 ↗
L2OTHERCited in: 3. Epidemiology, Etiology and Risk Factors, History and Evolution of Treatment
[130]
Menendez R, Torres A. “Treatment failure in community-acquired pneumonia.” Chest (2007). PMID: 17934120 ↗
L5REVIEW_NARRATIVECited in: 3. Epidemiology, Etiology and Risk Factors, 5. Diagnosis and Workup (Pulmonary Function, Bronchoscopy and Imaging Anchored), 6. Severity, Staging and Risk Stratification, 9. Respiratory Support, Procedures & Interventional Pulmonology (Specialty-Distinctive), 11. Prognosis and Natural History, 12. Special Populations & Pregnancy
[131]
Cilloniz C, Pericàs JM, Restrepo MI. “Community-Acquired Pneumonia in Nursing-Home Residents in the Post-HCAP Era.” Chest (2026). PMID: 42425406 ↗
L5REVIEW_NARRATIVECited in: 3. Epidemiology, Etiology and Risk Factors, 4. Clinical Presentation, 5. Diagnosis and Workup (Pulmonary Function, Bronchoscopy and Imaging Anchored), 6. Severity, Staging and Risk Stratification, 11. Prognosis and Natural History
[132]
Fujitani S, Sun HY, Yu VL et al.. “Pneumonia due to Pseudomonas aeruginosa: part I: epidemiology, clinical diagnosis, and source.” Chest (2011). PMID: 21467058 ↗
L5REVIEW_NARRATIVECited in: 3. Epidemiology, Etiology and Risk Factors, 5. Diagnosis and Workup (Pulmonary Function, Bronchoscopy and Imaging Anchored)
[133]
Gohil SK, Avery TR, Kleinman K et al.. “Improving Empiric Antibiotic Selection for Patients With Cancer Hospitalized With Infection: Secondary Analysis of the INSPIRE Cluster Randomized Trials.” JAMA network open (2026). PMID: 42268612 ↗
L2RCTCited in: 3. Epidemiology, Etiology and Risk Factors, 5. Diagnosis and Workup (Pulmonary Function, Bronchoscopy and Imaging Anchored), 6. Severity, Staging and Risk Stratification, 7. Acute Management and Exacerbation Rescue, 8. Long-term and Definitive Management, History and Evolution of Treatment, 11. Prognosis and Natural History
[134]
Freiberg JA, Qian ET, Nairon KG et al.. “Swab Testing to Optimize Pneumonia Treatment With Empiric Vancomycin: A Randomized Controlled Trial.” Clinical infectious diseases : an official publication of the Infectious Diseases Society of America (2026). PMID: 42227019 ↗
L1RCTCited in: 3. Epidemiology, Etiology and Risk Factors, 6. Severity, Staging and Risk Stratification, 11. Prognosis and Natural History
[135]
Jain S, Self WH, Wunderink RG et al.. “Community-Acquired Pneumonia Requiring Hospitalization among U.S. Adults.” The New England journal of medicine (2015). PMID: 26172429 ↗
L2OTHERCited in: 3. Epidemiology, Etiology and Risk Factors, 13. Prevention, Screening & Surveillance
[136]
Jain S, Williams DJ, Arnold SR et al.. “Community-acquired pneumonia requiring hospitalization among U.S. children.” The New England journal of medicine (2015). PMID: 25714161 ↗
L2OTHERCited in: 3. Epidemiology, Etiology and Risk Factors, 13. Prevention, Screening & Surveillance
[137]
Martin-Loeches I, Reyes LF, Rodriguez A. “Severe community-acquired pneumonia (sCAP): advances in management and future directions.” Thorax (2025). PMID: 40360263 ↗
L5REVIEW_NARRATIVECited in: 3. Epidemiology, Etiology and Risk Factors, 6. Severity, Staging and Risk Stratification, 7. Acute Management and Exacerbation Rescue, 11. Prognosis and Natural History
[138]
Torres A, Blasi F, Dartois N et al.. “Which individuals are at increased risk of pneumococcal disease and why? Impact of COPD, asthma, smoking, diabetes, and/or chronic heart disease on community-acquired pneumonia and invasive pneumococcal disease.” Thorax (2015). PMID: 26219979 ↗
L5REVIEW_NARRATIVECited in: 3. Epidemiology, Etiology and Risk Factors, 6. Severity, Staging and Risk Stratification, 8. Long-term and Definitive Management, 11. Prognosis and Natural History, 13. Prevention, Screening & Surveillance
[139]
Grudzinska FS, Brodlie M, Scholefield BR et al.. “Neutrophils in community-acquired pneumonia: parallels in dysfunction at the extremes of age.” Thorax (2019). PMID: 31732687 ↗
L5REVIEW_NARRATIVECited in: 3. Epidemiology, Etiology and Risk Factors, 6. Severity, Staging and Risk Stratification, 11. Prognosis and Natural History, 13. Prevention, Screening & Surveillance
[140]
Torres A, Peetermans WE, Viegi G et al.. “Risk factors for community-acquired pneumonia in adults in Europe: a literature review.” Thorax (2013). PMID: 24130229 ↗
L5REVIEW_NARRATIVECited in: 3. Epidemiology, Etiology and Risk Factors, 6. Severity, Staging and Risk Stratification, 11. Prognosis and Natural History, 12. Special Populations & Pregnancy
[141]
Welte T, Torres A, Nathwani D. “Clinical and economic burden of community-acquired pneumonia among adults in Europe.” Thorax (2010). PMID: 20729232 ↗
L5REVIEW_NARRATIVECited in: 3. Epidemiology, Etiology and Risk Factors, 6. Severity, Staging and Risk Stratification, 8. Long-term and Definitive Management, 11. Prognosis and Natural History
[142]
Lawrence H, McKeever TM, Lim WS. “Readmission following hospital admission for community-acquired pneumonia in England.” Thorax (2023). PMID: 37524392 ↗
L3OTHERCited in: 3. Epidemiology, Etiology and Risk Factors, 5. Diagnosis and Workup (Pulmonary Function, Bronchoscopy and Imaging Anchored), 6. Severity, Staging and Risk Stratification, 7. Acute Management and Exacerbation Rescue, 11. Prognosis and Natural History
[143]
Takeda K, Takazono T, Ashizawa N et al.. “Lascufloxacin switch therapy versus ampicillin/sulbactam for older patients with community-acquired pneumonia in Japan (STEP study): a study protocol for a multicentre open-label randomised controlled non-inferiority trial.” BMJ open (2026). PMID: 42379706 ↗
L5TRIAL_NONRANDOMCited in: 3. Epidemiology, Etiology and Risk Factors, 6. Severity, Staging and Risk Stratification, 8. Long-term and Definitive Management, 10. Complications, 11. Prognosis and Natural History
[144]
Choi YY, Kang C, Choe YJ et al.. “Efficacy and safety of Doxycycline versus Macrolides for Mycoplasma pneumoniae INfectiOn in Children (DOMINO): a protocol for a multicentre, randomised, open-label, superiority trial.” BMJ open (2026). PMID: 42191206 ↗
L5TRIAL_NONRANDOMCited in: 3. Epidemiology, Etiology and Risk Factors, 11. Prognosis and Natural History
[145]
Wang H, Dou H, Chen G et al.. “Efficacy and Safety of Lianhua Qingke Tablets in Children With Mycoplasma pneumoniae Pneumonia: A Randomized, Double-Blind, Multicenter, Placebo-Controlled Clinical Trial.” The clinical respiratory journal (2026). PMID: 42357817 ↗
L1RCTCited in: 3. Epidemiology, Etiology and Risk Factors, 4. Clinical Presentation, 8. Long-term and Definitive Management, History and Evolution of Treatment, 11. Prognosis and Natural History, 12. Special Populations & Pregnancy
[146]
Ouyang Y, Lai J, Wang P et al.. “Efficacy of higher-dose versus lower-dose corticosteroids in community-acquired pneumonia: a systematic review and network meta-analysis.” Critical care (London, England) (2026). PMID: 42402602 ↗
L1SR_OBSCited in: 3. Epidemiology, Etiology and Risk Factors, 6. Severity, Staging and Risk Stratification, 11. Prognosis and Natural History
[147]
Pitrowsky M, Pacheco MB, Ranzani O et al.. “Outcomes of Pneumonia in ICUs in Low- and Middle-Income Countries - A Systematic Review.” NEJM evidence (2026). PMID: 42189048 ↗
L2SR_OBSCited in: 3. Epidemiology, Etiology and Risk Factors, 6. Severity, Staging and Risk Stratification, 11. Prognosis and Natural History
[148]
Korang SK, Nava C, Mohana SP et al.. “Antibiotics for hospital-acquired pneumonia in neonates and children.” The Cochrane database of systematic reviews (2021). PMID: 34727368 ↗
L1SR_OBSCited in: 3. Epidemiology, Etiology and Risk Factors, 6. Severity, Staging and Risk Stratification, 11. Prognosis and Natural History
[149]
Lodha R, Kabra SK, Pandey RM. “Antibiotics for community-acquired pneumonia in children.” The Cochrane database of systematic reviews (2013). PMID: 23733365 ↗
L1SR_OBSCited in: 3. Epidemiology, Etiology and Risk Factors, 6. Severity, Staging and Risk Stratification, 11. Prognosis and Natural History
[150]
Kabra SK, Lodha R, Pandey RM. “Antibiotics for community-acquired pneumonia in children.” The Cochrane database of systematic reviews (2010). PMID: 20238334 ↗
L1SR_OBSCited in: 3. Epidemiology, Etiology and Risk Factors, 6. Severity, Staging and Risk Stratification, 11. Prognosis and Natural History
[151]
Kabra SK, Lodha R, Pandey RM. “Antibiotics for community acquired pneumonia in children.” The Cochrane database of systematic reviews (2006). PMID: 16856067 ↗
L1SR_OBSCited in: 3. Epidemiology, Etiology and Risk Factors, 6. Severity, Staging and Risk Stratification, 11. Prognosis and Natural History
[152]
Martí-Carvajal AJ, Conterno LO. “Antibiotics for treating community-acquired pneumonia in people with sickle cell disease.” The Cochrane database of systematic reviews (2016). PMID: 27841444 ↗
L2SR_OBSCited in: 3. Epidemiology, Etiology and Risk Factors, 5. Diagnosis and Workup (Pulmonary Function, Bronchoscopy and Imaging Anchored), 6. Severity, Staging and Risk Stratification, 10. Complications, 11. Prognosis and Natural History
[153]
Walters JA, Tang JN, Poole P et al.. “Pneumococcal vaccines for preventing pneumonia in chronic obstructive pulmonary disease.” The Cochrane database of systematic reviews (2017). PMID: 28116747 ↗
L1SR_OBSCited in: 3. Epidemiology, Etiology and Risk Factors, 6. Severity, Staging and Risk Stratification, 7. Acute Management and Exacerbation Rescue, 11. Prognosis and Natural History, 13. Prevention, Screening & Surveillance
[154]
Zhang Y, Fang C, Dong BR et al.. “Oxygen therapy for pneumonia in adults.” The Cochrane database of systematic reviews (2012). PMID: 22419316 ↗
L1SR_OBSCited in: 3. Epidemiology, Etiology and Risk Factors, 6. Severity, Staging and Risk Stratification, 7. Acute Management and Exacerbation Rescue, 10. Complications, 11. Prognosis and Natural History
[155]
Martí-Carvajal AJ, Conterno LO. “Antibiotics for treating community acquired pneumonia in people with sickle cell disease.” The Cochrane database of systematic reviews (2012). PMID: 23076916 ↗
L2SR_OBSCited in: 3. Epidemiology, Etiology and Risk Factors, 5. Diagnosis and Workup (Pulmonary Function, Bronchoscopy and Imaging Anchored), 6. Severity, Staging and Risk Stratification, 10. Complications
[156]
Santoso P, Muliandini GR, Izzati SD et al.. “Antimicrobial Resistance and Clinical Outcome Among Hospitalized Bacterial Pneumonia: A Retrospective Cohort Study in Indonesian Tertiary Hospital.” Antibiotics (Basel, Switzerland) (2026). PMID: 42353706 ↗
L2COHORTCited in: 3. Epidemiology, Etiology and Risk Factors, 6. Severity, Staging and Risk Stratification, 11. Prognosis and Natural History, 13. Prevention, Screening & Surveillance
[157]
Nasr R, Rahal EA, Haddad C et al.. “Assessment of Compliance with National and International Guidelines in the Empirical Management of Community-Acquired Pneumonia (CAP) in Lebanese Hospitals: A Multicenter Retrospective Cohort Study.” Antibiotics (Basel, Switzerland) (2026). PMID: 42353675 ↗
L2COHORTCited in: 3. Epidemiology, Etiology and Risk Factors, 6. Severity, Staging and Risk Stratification
[158]
Cilloniz C, Ewig S, Gabarrus A et al.. “Seasonality of pathogens causing community-acquired pneumonia.” Respirology (Carlton, Vic.) (2017). PMID: 28093834 ↗
L2OTHERCited in: 3. Epidemiology, Etiology and Risk Factors
[159]
Hadfield J, Bennett L. “Determining best outcomes from community-acquired pneumonia and how to achieve them.” Respirology (Carlton, Vic.) (2017). PMID: 29150897 ↗
L5REVIEW_NARRATIVECited in: 3. Epidemiology, Etiology and Risk Factors, 6. Severity, Staging and Risk Stratification, 11. Prognosis and Natural History
[160]
Mecham ID, Vines C, Dean NC. “Community-acquired pneumonia management and outcomes in the era of health information technology.” Respirology (Carlton, Vic.) (2017). PMID: 28758325 ↗
L5REVIEW_NARRATIVECited in: 3. Epidemiology, Etiology and Risk Factors, 5. Diagnosis and Workup (Pulmonary Function, Bronchoscopy and Imaging Anchored), 6. Severity, Staging and Risk Stratification, 11. Prognosis and Natural History
[161]
Niederman MS. “Making sense of scoring systems in community acquired pneumonia.” Respirology (Carlton, Vic.) (2009). PMID: 19353770 ↗
L5REVIEW_NARRATIVECited in: 3. Epidemiology, Etiology and Risk Factors, 6. Severity, Staging and Risk Stratification, 11. Prognosis and Natural History, 12. Special Populations & Pregnancy
[162]
Jeon K, Yoo H, Jeong BH et al.. “Functional status and mortality prediction in community-acquired pneumonia.” Respirology (Carlton, Vic.) (2017). PMID: 28513919 ↗
L2OTHERCited in: 3. Epidemiology, Etiology and Risk Factors, 6. Severity, Staging and Risk Stratification, 11. Prognosis and Natural History, 12. Special Populations & Pregnancy
[163]
Mattila JT, Fine MJ, Limper AH et al.. “Pneumonia. Treatment and diagnosis.” Annals of the American Thoracic Society (2014). PMID: 25148424 ↗
L5REVIEW_NARRATIVECited in: 3. Epidemiology, Etiology and Risk Factors, 5. Diagnosis and Workup (Pulmonary Function, Bronchoscopy and Imaging Anchored), 6. Severity, Staging and Risk Stratification, 11. Prognosis and Natural History
[164]
Malo J, Luraschi-Monjagatta C, Wolk DM et al.. “Update on the diagnosis of pulmonary coccidioidomycosis.” Annals of the American Thoracic Society (2014). PMID: 24575994 ↗
L5REVIEW_NARRATIVECited in: 3. Epidemiology, Etiology and Risk Factors, 5. Diagnosis and Workup (Pulmonary Function, Bronchoscopy and Imaging Anchored), 8. Long-term and Definitive Management, 10. Complications, 12. Special Populations & Pregnancy
[165]
Jones BE, Ying J, Nevers M et al.. “Computerized Mortality Prediction for Community-acquired Pneumonia at 117 Veterans Affairs Medical Centers.” Annals of the American Thoracic Society (2021). PMID: 33635750 ↗
L2OTHERCited in: 3. Epidemiology, Etiology and Risk Factors, 6. Severity, Staging and Risk Stratification, 7. Acute Management and Exacerbation Rescue, 11. Prognosis and Natural History
[166]
Prina E, Ranzani OT, Polverino E et al.. “Risk factors associated with potentially antibiotic-resistant pathogens in community-acquired pneumonia.” Annals of the American Thoracic Society (2015). PMID: 25521229 ↗
L2OTHERCited in: 3. Epidemiology, Etiology and Risk Factors, 5. Diagnosis and Workup (Pulmonary Function, Bronchoscopy and Imaging Anchored), 6. Severity, Staging and Risk Stratification, 11. Prognosis and Natural History
[167]
Sando E, Suzuki M, Ishida M et al.. “Definitive and Indeterminate Pseudomonas aeruginosa Infection in Adults with Community-acquired Pneumonia: A Prospective Observational Study.” Annals of the American Thoracic Society (2021). PMID: 33565942 ↗
L2OTHERCited in: 3. Epidemiology, Etiology and Risk Factors, 4. Clinical Presentation, 5. Diagnosis and Workup (Pulmonary Function, Bronchoscopy and Imaging Anchored), 6. Severity, Staging and Risk Stratification, History and Evolution of Treatment, 11. Prognosis and Natural History
[168]
Cangemi R, Falcone M, Taliani G et al.. “Corticosteroid Use and Incident Myocardial Infarction in Adults Hospitalized for Community-acquired Pneumonia.” Annals of the American Thoracic Society (2019). PMID: 30188173 ↗
L2OTHERCited in: 3. Epidemiology, Etiology and Risk Factors, 6. Severity, Staging and Risk Stratification, 7. Acute Management and Exacerbation Rescue, 11. Prognosis and Natural History
[169]
Chouchane O, Léopold V, Michels EHA et al.. “Differential platelet protein release profiles in community-acquired pneumonia and COVID-19.” ERJ open research (2025). PMID: 40551807 ↗
L3OTHERCited in: 3. Epidemiology, Etiology and Risk Factors, 6. Severity, Staging and Risk Stratification, 11. Prognosis and Natural History
[170]
Farhat I, Rosolowski M, Ahrens K et al.. “Biomarkers troponin and procalcitonin in addition to CRB-65 enhance risk stratification in patients with community-acquired pneumonia.” ERJ open research (2024). PMID: 39624382 ↗
L2OTHERCited in: 3. Epidemiology, Etiology and Risk Factors, 6. Severity, Staging and Risk Stratification, 11. Prognosis and Natural History
[171]
Richter T, Tesch F, Schmitt J et al.. “Validation of the qSOFA and CRB-65 in SARS-CoV-2-infected community-acquired pneumonia.” ERJ open research (2023). PMID: 37337510 ↗
L2OTHERCited in: 3. Epidemiology, Etiology and Risk Factors, 6. Severity, Staging and Risk Stratification, 11. Prognosis and Natural History
[172]
Prat-Aymerich C, Hessels L, Karssen D et al.. “Rationale and design of the Pneumococcal Pneumonia Epidemiology, Urine Serotyping and Mental Outcomes (PNEUMO) study Europe.” ERJ open research (2025). PMID: 41367668 ↗
L5OTHERCited in: 3. Epidemiology, Etiology and Risk Factors, 6. Severity, Staging and Risk Stratification, 11. Prognosis and Natural History, 13. Prevention, Screening & Surveillance
[173]
Cilloniz C, Mogensen ML, Ward L. “Transforming post-acute pneumonia management: risk stratification using machine learning.” ERJ open research (2026). PMID: 41561110 ↗
L5OTHERCited in: 3. Epidemiology, Etiology and Risk Factors, 6. Severity, Staging and Risk Stratification, 11. Prognosis and Natural History
[174]
Wittermans E, van der Zee PA, Qi H et al.. “Community-acquired pneumonia subgroups and differential response to corticosteroids: a secondary analysis of controlled studies.” ERJ open research (2022). PMID: 35036417 ↗
L2OTHERCited in: 3. Epidemiology, Etiology and Risk Factors, 4. Clinical Presentation, 6. Severity, Staging and Risk Stratification, 7. Acute Management and Exacerbation Rescue, 11. Prognosis and Natural History
[175]
Rademacher J, von Eynern L, Dettmer S et al.. “Performance of risk prediction scores for severe pneumonia in patients with community-acquired pneumonia after organ transplantation.” ERJ open research (2025). PMID: 41122418 ↗
L2OTHERCited in: 3. Epidemiology, Etiology and Risk Factors, 6. Severity, Staging and Risk Stratification, 8. Long-term and Definitive Management, 11. Prognosis and Natural History
[176]
Kaal AG, Op de Hoek L, Hochheimer DT et al.. “Outcomes of community-acquired pneumonia using the Pneumonia Severity Index versus the CURB-65 in routine practice of emergency departments.” ERJ open research (2023). PMID: 37143846 ↗
L2OTHERCited in: 3. Epidemiology, Etiology and Risk Factors, 6. Severity, Staging and Risk Stratification, 7. Acute Management and Exacerbation Rescue, 11. Prognosis and Natural History
[177]
Nemoto M, Nakashima K, Noma S et al.. “Prognostic value of chest computed tomography in community-acquired pneumonia patients.” ERJ open research (2020). PMID: 33263023 ↗
L2OTHERCited in: 3. Epidemiology, Etiology and Risk Factors, 6. Severity, Staging and Risk Stratification
[178]
Fitzgerald DB, Waterer GW, Budgeon C et al.. “Steroid Therapy and Outcome of Parapneumonic Pleural Effusions (STOPPE): A Pilot Randomized Clinical Trial.” American journal of respiratory and critical care medicine (2022). PMID: 35081010 ↗
L1RCTCited in: 4. Clinical Presentation, 7. Acute Management and Exacerbation Rescue, 8. Long-term and Definitive Management, History and Evolution of Treatment, 11. Prognosis and Natural History
[179]
Paul M, Nielsen AD, Gafter-Gvili A et al.. “The need for macrolides in hospitalised community-acquired pneumonia: propensity analysis.” The European respiratory journal (2007). PMID: 17537772 ↗
L2RCTCited in: 4. Clinical Presentation, 8. Long-term and Definitive Management, History and Evolution of Treatment
[180]
Pick HJ, Bolton CE, Lim WS et al.. “Patient-reported outcome measures in the recovery of adults hospitalised with community-acquired pneumonia: a systematic review.” The European respiratory journal (2019). PMID: 30635298 ↗
L2SR_OBSCited in: 4. Clinical Presentation, 11. Prognosis and Natural History
[181]
Atkinson M, Lakhanpaul M, Smyth A et al.. “Comparison of oral amoxicillin and intravenous benzyl penicillin for community acquired pneumonia in children (PIVOT trial): a multicentre pragmatic randomised controlled equivalence trial.” Thorax (2007). PMID: 17567657 ↗
L1RCTCited in: 4. Clinical Presentation, 7. Acute Management and Exacerbation Rescue, 8. Long-term and Definitive Management, History and Evolution of Treatment, 10. Complications
[182]
Cillóniz C, Torres A, Manzardo C et al.. “Community-Acquired Pneumococcal Pneumonia in Virologically Suppressed HIV-Infected Adult Patients: A Matched Case-Control Study.” Chest (2017). PMID: 28302496 ↗
L3CASE_CONTROLCited in: 4. Clinical Presentation, 5. Diagnosis and Workup (Pulmonary Function, Bronchoscopy and Imaging Anchored), 13. Prevention, Screening & Surveillance
[183]
Polverino E, Torres A, Menendez R et al.. “Microbial aetiology of healthcare associated pneumonia in Spain: a prospective, multicentre, case-control study.” Thorax (2013). PMID: 24130227 ↗
L3CASE_CONTROLCited in: 4. Clinical Presentation
[184]
Méndez R, Menéndez R, Cillóniz C et al.. “Initial Inflammatory Profile in Community-acquired Pneumonia Depends on Time since Onset of Symptoms.” American journal of respiratory and critical care medicine (2018). PMID: 29509439 ↗
L2OTHERCited in: 4. Clinical Presentation, 5. Diagnosis and Workup (Pulmonary Function, Bronchoscopy and Imaging Anchored)
[185]
Shindo Y, Ito R, Kobayashi D et al.. “Risk factors for drug-resistant pathogens in community-acquired and healthcare-associated pneumonia.” American journal of respiratory and critical care medicine (2013). PMID: 23855620 ↗
L2OTHERCited in: 4. Clinical Presentation, 5. Diagnosis and Workup (Pulmonary Function, Bronchoscopy and Imaging Anchored)
[186]
España PP, Capelastegui A, Gorordo I et al.. “Development and validation of a clinical prediction rule for severe community-acquired pneumonia.” American journal of respiratory and critical care medicine (2006). PMID: 16973986 ↗
L2OTHERCited in: 4. Clinical Presentation, 5. Diagnosis and Workup (Pulmonary Function, Bronchoscopy and Imaging Anchored)
[187]
Christ-Crain M, Stolz D, Jutla S et al.. “Free and total cortisol levels as predictors of severity and outcome in community-acquired pneumonia.” American journal of respiratory and critical care medicine (2007). PMID: 17702966 ↗
L2OTHERCited in: 4. Clinical Presentation
[188]
Cilloniz C, Albert RK, Liapikou A et al.. “The Effect of Macrolide Resistance on the Presentation and Outcome of Patients Hospitalized for Streptococcus pneumoniae Pneumonia.” American journal of respiratory and critical care medicine (2015). PMID: 25807239 ↗
L2OTHERCited in: 4. Clinical Presentation, 10. Complications
[189]
Yende S, D'Angelo G, Kellum JA et al.. “Inflammatory markers at hospital discharge predict subsequent mortality after pneumonia and sepsis.” American journal of respiratory and critical care medicine (2008). PMID: 18369199 ↗
L2OTHERCited in: 4. Clinical Presentation
[190]
Quigley N, Couture C, Gervais P et al.. “A 37-Year-Old Man With Right Lung Consolidation.” Chest (2023). PMID: 36894264 ↗
L4CASE_REPORTCited in: 4. Clinical Presentation, 7. Acute Management and Exacerbation Rescue, History and Evolution of Treatment, 10. Complications
[191]
Wang H, Tang Y, Shen Y. “Late-Onset Diffuse Lung Disease in an 8-Year-Old Girl.” Chest (2024). PMID: 38461021 ↗
L4CASE_REPORTCited in: 4. Clinical Presentation, History and Evolution of Treatment
[192]
Ko MY, Guzner A, Saini I. “A 19-Year-Old With Hemoptysis and Shortness of Breath.” Chest (2023). PMID: 37945196 ↗
L4CASE_REPORTCited in: 4. Clinical Presentation, History and Evolution of Treatment
[193]
Cilloniz C, Torres A, Polverino E et al.. “Community-acquired lung respiratory infections in HIV-infected patients: microbial aetiology and outcome.” The European respiratory journal (2014). PMID: 24525448 ↗
L2OTHERCited in: 4. Clinical Presentation
[194]
Liapikou A, Polverino E, Ewig S et al.. “Severity and outcomes of hospitalised community-acquired pneumonia in COPD patients.” The European respiratory journal (2011). PMID: 21920895 ↗
L2OTHERCited in: 4. Clinical Presentation, 5. Diagnosis and Workup (Pulmonary Function, Bronchoscopy and Imaging Anchored), 7. Acute Management and Exacerbation Rescue, 10. Complications
[195]
Klapdor B, Ewig S, Pletz MW et al.. “Community-acquired pneumonia in younger patients is an entity on its own.” The European respiratory journal (2011). PMID: 22088967 ↗
L2OTHERCited in: 4. Clinical Presentation, 8. Long-term and Definitive Management, 12. Special Populations & Pregnancy
[196]
von Baum H, Welte T, Marre R et al.. “Community-acquired pneumonia through Enterobacteriaceae and Pseudomonas aeruginosa: Diagnosis, incidence and predictors.” The European respiratory journal (2009). PMID: 19679601 ↗
L2OTHERCited in: 4. Clinical Presentation, 5. Diagnosis and Workup (Pulmonary Function, Bronchoscopy and Imaging Anchored)
[197]
Garcia-Vidal C, Fernández-Sabé N, Carratalà J et al.. “Early mortality in patients with community-acquired pneumonia: causes and risk factors.” The European respiratory journal (2008). PMID: 18508820 ↗
L2OTHERCited in: 4. Clinical Presentation, 10. Complications, 12. Special Populations & Pregnancy
[198]
Ho PL, Cheng VC, Chu CM. “Antibiotic resistance in community-acquired pneumonia caused by Streptococcus pneumoniae, methicillin-resistant Staphylococcus aureus, and Acinetobacter baumannii.” Chest (2009). PMID: 19809053 ↗
L5REVIEW_NARRATIVECited in: 4. Clinical Presentation, 10. Complications
[199]
Upchurch CP, Grijalva CG, Wunderink RG et al.. “Community-Acquired Pneumonia Visualized on CT Scans but Not Chest Radiographs: Pathogens, Severity, and Clinical Outcomes.” Chest (2017). PMID: 28802696 ↗
L2OTHERCited in: 4. Clinical Presentation, 13. Prevention, Screening & Surveillance
[200]
Malhotra A. “Low-tidal-volume ventilation in the acute respiratory distress syndrome.” The New England journal of medicine (2007). PMID: 17855672 ↗
L4REVIEW_NARRATIVECited in: 4. Clinical Presentation, 5. Diagnosis and Workup (Pulmonary Function, Bronchoscopy and Imaging Anchored), 7. Acute Management and Exacerbation Rescue
[201]
Kolditz M, Ewig S, Klapdor B et al.. “Community-acquired pneumonia as medical emergency: predictors of early deterioration.” Thorax (2015). PMID: 25782758 ↗
L2OTHERCited in: 4. Clinical Presentation, 7. Acute Management and Exacerbation Rescue
[202]
Ewig S, Klapdor B, Pletz MW et al.. “Nursing-home-acquired pneumonia in Germany: an 8-year prospective multicentre study.” Thorax (2011). PMID: 22058186 ↗
L2OTHERCited in: 4. Clinical Presentation, 8. Long-term and Definitive Management
[203]
Chalmers JD, Singanayagam A, Murray MP et al.. “Risk factors for complicated parapneumonic effusion and empyema on presentation to hospital with community-acquired pneumonia.” Thorax (2009). PMID: 19131449 ↗
L2OTHERCited in: 4. Clinical Presentation, History and Evolution of Treatment
[204]
Buising KL, Thursky KA, Black JF et al.. “A prospective comparison of severity scores for identifying patients with severe community acquired pneumonia: reconsidering what is meant by severe pneumonia.” Thorax (2006). PMID: 16449258 ↗
L2OTHERCited in: 4. Clinical Presentation, 5. Diagnosis and Workup (Pulmonary Function, Bronchoscopy and Imaging Anchored)
[205]
Ong CW, Lye DC, Khoo KL et al.. “Severe community-acquired Acinetobacter baumannii pneumonia: an emerging highly lethal infectious disease in the Asia-Pacific.” Respirology (Carlton, Vic.) (2009). PMID: 19909464 ↗
L4CASE_REPORTCited in: 4. Clinical Presentation, 10. Complications
[206]
Wang C, Gao H, Zhu C et al.. “Safety of proton pump inhibitors: an overview of systematic reviews and meta-analyses.” BMJ evidence-based medicine (2026). PMID: 42303374 ↗
L5SR_OBSCited in: 4. Clinical Presentation, 11. Prognosis and Natural History
[207]
Lassi ZS, Imdad A, Bhutta ZA. “Short-course versus long-course intravenous therapy with the same antibiotic for severe community-acquired pneumonia in children aged two months to 59 months.” The Cochrane database of systematic reviews (2017). PMID: 29020436 ↗
L1SR_OBSCited in: 4. Clinical Presentation, 5. Diagnosis and Workup (Pulmonary Function, Bronchoscopy and Imaging Anchored)
[208]
Lassi ZS, Imdad A, Bhutta ZA. “Short-course versus long-course intravenous therapy with the same antibiotic for severe community-acquired pneumonia in children aged two months to 59 months.” The Cochrane database of systematic reviews (2015). PMID: 26077639 ↗
L1SR_OBSCited in: 4. Clinical Presentation, 5. Diagnosis and Workup (Pulmonary Function, Bronchoscopy and Imaging Anchored)
[209]
Wang K, Gill P, Perera R et al.. “Clinical symptoms and signs for the diagnosis of Mycoplasma pneumoniae in children and adolescents with community-acquired pneumonia.” The Cochrane database of systematic reviews (2012). PMID: 23076954 ↗
L1SR_OBSCited in: 4. Clinical Presentation, 5. Diagnosis and Workup (Pulmonary Function, Bronchoscopy and Imaging Anchored), 6. Severity, Staging and Risk Stratification, 11. Prognosis and Natural History
[210]
Huang Y, Lin Q. “A novel risk stratification model based on creatine kinase and direct bilirubin for identifying severe Chlamydia psittaci pneumonia: a double-center, hypothesis-generating retrospective cohort study.” BMC infectious diseases (2026). PMID: 42249297 ↗
L2COHORTCited in: 4. Clinical Presentation, 6. Severity, Staging and Risk Stratification
[211]
Wang F, Han A, Hong W et al.. “Comparison of targeted next-generation sequencing and conventional tests for pathogen detection in community-acquired and severe community-acquired pneumonia: a retrospective cohort study.” Frontiers in microbiology (2026). PMID: 42199547 ↗
L2COHORTCited in: 4. Clinical Presentation, 5. Diagnosis and Workup (Pulmonary Function, Bronchoscopy and Imaging Anchored)
[212]
Cochand L, Bürgisser N, Buclin CP et al.. “Frank's Sign and Risk of Cardiovascular Events in Patients Hospitalized for Pneumonia: A Prospective Single-Center Cohort Study.” Journal of clinical medicine (2026). PMID: 42194618 ↗
L2COHORTCited in: 4. Clinical Presentation, 10. Complications
[213]
Liu L, Wang J, Jiang W et al.. “Clinical characteristics and risk factors for severe community-acquired pneumonia in hospitalized children with human metapneumovirus infection in Shanghai: a retrospective cohort study.” Frontiers in medicine (2026). PMID: 42145772 ↗
L2COHORTCited in: 4. Clinical Presentation, 5. Diagnosis and Workup (Pulmonary Function, Bronchoscopy and Imaging Anchored), 12. Special Populations & Pregnancy
[214]
Li Y, Zhu H, Zhan Z et al.. “Clinical features and prognostic factors of Chlamydia psittaci pneumonia: a retrospective study.” Frontiers in medicine (2026). PMID: 42006869 ↗
L2COHORTCited in: 4. Clinical Presentation
[215]
Thomas R, Ferguson J, Coombs G et al.. “Community-acquired methicillin-resistant Staphylococcus aureus pneumonia: a clinical audit.” Respirology (Carlton, Vic.) (2011). PMID: 21382130 ↗
L4OTHERCited in: 4. Clinical Presentation, 10. Complications
[216]
Seo H, Cha SI, Shin KM et al.. “Clinical relevance of necrotizing change in patients with community-acquired pneumonia.” Respirology (Carlton, Vic.) (2016). PMID: 27862706 ↗
L2OTHERCited in: 4. Clinical Presentation
[217]
Liam CK, Pang YK, Poosparajah S. “Pulmonary tuberculosis presenting as community-acquired pneumonia.” Respirology (Carlton, Vic.) (2006). PMID: 17052309 ↗
L2OTHERCited in: 4. Clinical Presentation, History and Evolution of Treatment, 12. Special Populations & Pregnancy
[218]
Sibila O, Laserna E, Maselli DJ et al.. “Risk factors and antibiotic therapy in P. aeruginosa community-acquired pneumonia.” Respirology (Carlton, Vic.) (2015). PMID: 25776134 ↗
L2OTHERCited in: 4. Clinical Presentation, 5. Diagnosis and Workup (Pulmonary Function, Bronchoscopy and Imaging Anchored), 6. Severity, Staging and Risk Stratification
[219]
Falguera M, Carratalà J, Ruiz-Gonzalez A et al.. “Risk factors and outcome of community-acquired pneumonia due to Gram-negative bacilli.” Respirology (Carlton, Vic.) (2009). PMID: 18699803 ↗
L2OTHERCited in: 4. Clinical Presentation
[220]
Polverino E, Cillóniz C, Dambrava P et al.. “Systemic corticosteroids for community-acquired pneumonia: reasons for use and lack of benefit on outcome.” Respirology (Carlton, Vic.) (2013). PMID: 23134361 ↗
L2OTHERCited in: 4. Clinical Presentation, 7. Acute Management and Exacerbation Rescue
[221]
Sanz F, Restrepo MI, Fernández-Fabrellas E et al.. “Does prolonged onset of symptoms have a prognostic significance in community-acquired pneumonia?” Respirology (Carlton, Vic.) (2014). PMID: 24995803 ↗
L2OTHERCited in: 4. Clinical Presentation, 5. Diagnosis and Workup (Pulmonary Function, Bronchoscopy and Imaging Anchored), 7. Acute Management and Exacerbation Rescue, 10. Complications
[222]
D'Agostino S, Granberg V, Valentini G et al.. “Mucositis Associated with Mycoplasma pneumoniae: Systematic Review and Case Series.” Children (Basel, Switzerland) (2026). PMID: 42194164 ↗
L2SR_OBSCited in: 4. Clinical Presentation, 10. Complications
[223]
Wetzke M, Schütz K, Kopp MV et al.. “Pathogen spectra in hospitalised and nonhospitalised children with community-acquired pneumonia.” ERJ open research (2023). PMID: 36923566 ↗
L2OTHERCited in: 4. Clinical Presentation
[224]
D'Cruz RF, Waller MD, Perrin F et al.. “Chest radiography is a poor predictor of respiratory symptoms and functional impairment in survivors of severe COVID-19 pneumonia.” ERJ open research (2021). PMID: 33575312 ↗
L2OTHERCited in: 4. Clinical Presentation, 7. Acute Management and Exacerbation Rescue, 8. Long-term and Definitive Management, 10. Complications
[225]
Migliori GB, Langendam MW, D'Ambrosio L et al.. “Protecting the tuberculosis drug pipeline: stating the case for the rational use of fluoroquinolones.” The European respiratory journal (2012). PMID: 22653774 ↗
L1SR_OBSCited in: 5. Diagnosis and Workup (Pulmonary Function, Bronchoscopy and Imaging Anchored)
[226]
Konstantinidis I, Jones BE, Ramirez J et al.. “Summary for Clinicians: Clinical Practice Guideline for the Diagnosis and Management of Community-acquired Pneumonia.” Annals of the American Thoracic Society (2026). PMID: 41902840 ↗
L1GUIDELINECited in: 5. Diagnosis and Workup (Pulmonary Function, Bronchoscopy and Imaging Anchored)
[227]
Chalmers JD, Singanayagam A, Akram AR et al.. “Severity assessment tools for predicting mortality in hospitalised patients with community-acquired pneumonia. Systematic review and meta-analysis.” Thorax (2010). PMID: 20729231 ↗
L2SR_OBSCited in: 5. Diagnosis and Workup (Pulmonary Function, Bronchoscopy and Imaging Anchored), 11. Prognosis and Natural History
[228]
Horita N, Miyazawa N, Kojima R et al.. “Sensitivity and specificity of the Streptococcus pneumoniae urinary antigen test for unconcentrated urine from adult patients with pneumonia: a meta-analysis.” Respirology (Carlton, Vic.) (2013). PMID: 23910720 ↗
L2SR_OBSCited in: 5. Diagnosis and Workup (Pulmonary Function, Bronchoscopy and Imaging Anchored)
[229]
Bhuiyan MU, Snelling TL, West R et al.. “The contribution of viruses and bacteria to community-acquired pneumonia in vaccinated children: a case-control study.” Thorax (2018). PMID: 30337417 ↗
L3CASE_CONTROLCited in: 5. Diagnosis and Workup (Pulmonary Function, Bronchoscopy and Imaging Anchored)
[230]
Obiora E, Hubbard R, Sanders RD et al.. “The impact of benzodiazepines on occurrence of pneumonia and mortality from pneumonia: a nested case-control and survival analysis in a population-based cohort.” Thorax (2012). PMID: 23220867 ↗
L3CASE_CONTROLCited in: 5. Diagnosis and Workup (Pulmonary Function, Bronchoscopy and Imaging Anchored), 8. Long-term and Definitive Management
[231]
Scicluna BP, Klein Klouwenberg PM, van Vught LA et al.. “A molecular biomarker to diagnose community-acquired pneumonia on intensive care unit admission.” American journal of respiratory and critical care medicine (2015). PMID: 26121490 ↗
L2OTHERCited in: 5. Diagnosis and Workup (Pulmonary Function, Bronchoscopy and Imaging Anchored), 10. Complications
[232]
Sellares J, López-Giraldo A, Lucena C et al.. “Influence of previous use of inhaled corticoids on the development of pleural effusion in community-acquired pneumonia.” American journal of respiratory and critical care medicine (2013). PMID: 23590264 ↗
L2OTHERCited in: 5. Diagnosis and Workup (Pulmonary Function, Bronchoscopy and Imaging Anchored), 10. Complications
[233]
Ambrosino N, Guarracino F. “Unusual applications of noninvasive ventilation.” The European respiratory journal (2011). PMID: 21349915 ↗
L5REVIEW_NARRATIVECited in: 5. Diagnosis and Workup (Pulmonary Function, Bronchoscopy and Imaging Anchored), 7. Acute Management and Exacerbation Rescue, 9. Respiratory Support, Procedures & Interventional Pulmonology (Specialty-Distinctive), 10. Complications, 11. Prognosis and Natural History, 12. Special Populations & Pregnancy
[234]
Singanayagam A, Chalmers JD, Akram AR et al.. “Impact of inhaled corticosteroid use on outcome in COPD patients admitted with pneumonia.” The European respiratory journal (2011). PMID: 21429980 ↗
L2OTHERCited in: 5. Diagnosis and Workup (Pulmonary Function, Bronchoscopy and Imaging Anchored)
[235]
Camps Serra M, Cervera C, Pumarola T et al.. “Virological diagnosis in community-acquired pneumonia in immunocompromised patients.” The European respiratory journal (2007). PMID: 17959637 ↗
L2OTHERCited in: 5. Diagnosis and Workup (Pulmonary Function, Bronchoscopy and Imaging Anchored), 12. Special Populations & Pregnancy
[236]
Torres A, Cillóniz C, Ferrer M et al.. “Bacteraemia and antibiotic-resistant pathogens in community acquired pneumonia: risk and prognosis.” The European respiratory journal (2015). PMID: 25614173 ↗
L2OTHERCited in: 5. Diagnosis and Workup (Pulmonary Function, Bronchoscopy and Imaging Anchored), 7. Acute Management and Exacerbation Rescue
[237]
Capelastegui A, España PP, Quintana JM et al.. “Validation of a predictive rule for the management of community-acquired pneumonia.” The European respiratory journal (2006). PMID: 16387948 ↗
L2OTHERCited in: 5. Diagnosis and Workup (Pulmonary Function, Bronchoscopy and Imaging Anchored)
[238]
Huijts SM, Pride MW, Vos JM et al.. “Diagnostic accuracy of a serotype-specific antigen test in community-acquired pneumonia.” The European respiratory journal (2013). PMID: 23397295 ↗
L2OTHERCited in: 5. Diagnosis and Workup (Pulmonary Function, Bronchoscopy and Imaging Anchored)
[239]
Teepe J, Grigoryan L, Verheij TJ. “Determinants of community-acquired pneumonia in children and young adults in primary care.” The European respiratory journal (2010). PMID: 20436174 ↗
L3OTHERCited in: 5. Diagnosis and Workup (Pulmonary Function, Bronchoscopy and Imaging Anchored), 12. Special Populations & Pregnancy
[240]
Mongodi S, Via G, Girard M et al.. “Lung Ultrasound for Early Diagnosis of Ventilator-Associated Pneumonia.” Chest (2015). PMID: 26836896 ↗
L2OTHERCited in: 5. Diagnosis and Workup (Pulmonary Function, Bronchoscopy and Imaging Anchored)
[241]
Ceccato A, Torres A, Cilloniz C et al.. “Invasive Disease vs Urinary Antigen-Confirmed Pneumococcal Community-Acquired Pneumonia.” Chest (2017). PMID: 28093269 ↗
L2OTHERCited in: 5. Diagnosis and Workup (Pulmonary Function, Bronchoscopy and Imaging Anchored), 10. Complications
[242]
Donovan FM, Thompson GR, Blair JE et al.. “Managing Cavitary Coccidioidomycosis Expert Opinions for Improving Patient Outcomes.” Chest (2024). PMID: 39675520 ↗
L5REVIEW_NARRATIVECited in: 5. Diagnosis and Workup (Pulmonary Function, Bronchoscopy and Imaging Anchored), 8. Long-term and Definitive Management, 10. Complications
[243]
Joean O, von Eynern LP, Welte T et al.. “Clinical Features, Diagnostics, Etiology, and Outcomes of Hospitalized Solid Organ Recipients With Community-Acquired Pneumonia: A Retrospective Cohort Analysis.” Chest (2024). PMID: 38823578 ↗
L2OTHERCited in: 5. Diagnosis and Workup (Pulmonary Function, Bronchoscopy and Imaging Anchored), 7. Acute Management and Exacerbation Rescue, 8. Long-term and Definitive Management, 9. Respiratory Support, Procedures & Interventional Pulmonology (Specialty-Distinctive)
[244]
Thomas CP, Ryan M, Chapman JD et al.. “Incidence and cost of pneumonia in medicare beneficiaries.” Chest (2012). PMID: 22406959 ↗
L2OTHERCited in: 5. Diagnosis and Workup (Pulmonary Function, Bronchoscopy and Imaging Anchored), 8. Long-term and Definitive Management, 12. Special Populations & Pregnancy
[245]
Huang DT, Angus DC, Kellum JA et al.. “Midregional proadrenomedullin as a prognostic tool in community-acquired pneumonia.” Chest (2009). PMID: 19363212 ↗
L2OTHERCited in: 5. Diagnosis and Workup (Pulmonary Function, Bronchoscopy and Imaging Anchored)
[246]
Menéndez R, Sahuquillo-Arce JM, Reyes S et al.. “Cytokine activation patterns and biomarkers are influenced by microorganisms in community-acquired pneumonia.” Chest (2011). PMID: 22194589 ↗
L2OTHERCited in: 5. Diagnosis and Workup (Pulmonary Function, Bronchoscopy and Imaging Anchored)
[247]
Jennings LC, Anderson TP, Beynon KA et al.. “Incidence and characteristics of viral community-acquired pneumonia in adults.” Thorax (2007). PMID: 17573440 ↗
L2OTHERCited in: 5. Diagnosis and Workup (Pulmonary Function, Bronchoscopy and Imaging Anchored)
[248]
Lahti E, Peltola V, Waris M et al.. “Induced sputum in the diagnosis of childhood community-acquired pneumonia.” Thorax (2008). PMID: 19052043 ↗
L2OTHERCited in: 5. Diagnosis and Workup (Pulmonary Function, Bronchoscopy and Imaging Anchored)
[249]
Lim WS, Smith DL, Wise MP et al.. “British Thoracic Society community acquired pneumonia guideline and the NICE pneumonia guideline: how they fit together.” Thorax (2015). PMID: 25977290 ↗
L5OTHERCited in: 5. Diagnosis and Workup (Pulmonary Function, Bronchoscopy and Imaging Anchored)
[250]
Bewick T, Cooper VJ, Lim WS. “Does early review by a respiratory physician lead to a shorter length of stay for patients with non-severe community-acquired pneumonia?” Thorax (2009). PMID: 19386582 ↗
L2REVIEW_NARRATIVECited in: 5. Diagnosis and Workup (Pulmonary Function, Bronchoscopy and Imaging Anchored), 7. Acute Management and Exacerbation Rescue
[251]
Miyashita N, Akaike H, Teranishi H et al.. “Chest computed tomography for the diagnosis of Mycoplasma pneumoniae infection.” Respirology (Carlton, Vic.) (2013). PMID: 25219424 ↗
L4CASE_REPORTCited in: 5. Diagnosis and Workup (Pulmonary Function, Bronchoscopy and Imaging Anchored)
[252]
Das RR, Singh M, Naik SS. “Vitamin D as an adjunct to antibiotics for the treatment of acute childhood pneumonia.” The Cochrane database of systematic reviews (2018). PMID: 30024634 ↗
L1SR_OBSCited in: 5. Diagnosis and Workup (Pulmonary Function, Bronchoscopy and Imaging Anchored)
[253]
Samara KA, Barqawi HJ, Adra S et al.. “PneumoMLPred: Innovating pneumonia management with guideline adherence review and explainable machine learning-based mortality prediction - A single-centre retrospective study.” Respiratory medicine (2026). PMID: 42162923 ↗
L4COHORTCited in: 5. Diagnosis and Workup (Pulmonary Function, Bronchoscopy and Imaging Anchored)
[254]
. “Aspiration pneumonia.” Respirology (Carlton, Vic.) (2009). PMID: 19857224 ↗
L5OTHERCited in: 5. Diagnosis and Workup (Pulmonary Function, Bronchoscopy and Imaging Anchored)
[255]
Aston SJ. “Pneumonia in the developing world: Characteristic features and approach to management.” Respirology (Carlton, Vic.) (2017). PMID: 28681972 ↗
L5REVIEW_NARRATIVECited in: 5. Diagnosis and Workup (Pulmonary Function, Bronchoscopy and Imaging Anchored), 6. Severity, Staging and Risk Stratification, 11. Prognosis and Natural History, 12. Special Populations & Pregnancy
[256]
Ferrer M, Torres A, Martínez R et al.. “Inhaled corticosteroids and systemic inflammatory response in community-acquired pneumonia: a prospective clinical study.” Respirology (Carlton, Vic.) (2014). PMID: 24909304 ↗
L2OTHERCited in: 5. Diagnosis and Workup (Pulmonary Function, Bronchoscopy and Imaging Anchored), 7. Acute Management and Exacerbation Rescue, 8. Long-term and Definitive Management
[257]
Lui G, Ip M, Lee N et al.. “Role of 'atypical pathogens' among adult hospitalized patients with community-acquired pneumonia.” Respirology (Carlton, Vic.) (2009). PMID: 19818051 ↗
L2OTHERCited in: 5. Diagnosis and Workup (Pulmonary Function, Bronchoscopy and Imaging Anchored), 7. Acute Management and Exacerbation Rescue, 12. Special Populations & Pregnancy
[258]
Takazono T, Namie H, Nagayoshi Y et al.. “Development of a score model to predict long-term prognosis after community-onset pneumonia in older patients.” Respirology (Carlton, Vic.) (2024). PMID: 38769707 ↗
L2OTHERCited in: 5. Diagnosis and Workup (Pulmonary Function, Bronchoscopy and Imaging Anchored), 8. Long-term and Definitive Management, 12. Special Populations & Pregnancy
[259]
Molinos L, Zalacain R, Menéndez R et al.. “Sensitivity, Specificity, and Positivity Predictors of the Pneumococcal Urinary Antigen Test in Community-Acquired Pneumonia.” Annals of the American Thoracic Society (2015). PMID: 26288389 ↗
L2OTHERCited in: 5. Diagnosis and Workup (Pulmonary Function, Bronchoscopy and Imaging Anchored)
[260]
Prins HJ, Duijkers R, Kramer G et al.. “Relationship between biomarkers and findings on low-dose computed tomography in hospitalised patients with acute exacerbation of COPD.” ERJ open research (2022). PMID: 35747233 ↗
L2OTHERCited in: 5. Diagnosis and Workup (Pulmonary Function, Bronchoscopy and Imaging Anchored), 7. Acute Management and Exacerbation Rescue
[261]
Dobler CC, Hakim M, Singh S et al.. “Ability of the LACE index to predict 30-day hospital readmissions in patients with community-acquired pneumonia.” ERJ open research (2020). PMID: 32714954 ↗
L4OTHERCited in: 5. Diagnosis and Workup (Pulmonary Function, Bronchoscopy and Imaging Anchored), 7. Acute Management and Exacerbation Rescue
[262]
Daniel P, Rodrigo C, Bewick T et al.. “Increased incidence of adult pneumococcal pneumonia during school holiday periods.” ERJ open research (2017). PMID: 28326311 ↗
L2OTHERCited in: 5. Diagnosis and Workup (Pulmonary Function, Bronchoscopy and Imaging Anchored)
[263]
Yurt R, Agca M, Turkar A et al.. “Impact of emphysema on biomarkers in hospitalized COPD patients with community-acquired pneumonia: a retrospective study.” BMC pulmonary medicine (2026). PMID: 42177477 ↗
L4COHORTCited in: 5. Diagnosis and Workup (Pulmonary Function, Bronchoscopy and Imaging Anchored)
[264]
Zha Q, Li H, Li Y et al.. “Clinical characteristics of Mycoplasma pneumoniae pneumonia in children and construction of a severe case prediction model: a retrospective study from Yan'an, China.” Frontiers in pediatrics (2026). PMID: 41960034 ↗
L4COHORTCited in: 5. Diagnosis and Workup (Pulmonary Function, Bronchoscopy and Imaging Anchored)
[265]
Li G, Li X, Feng Q et al.. “A case report of spherical pneumonia caused by Chlamydia psittaci infection.” Frontiers in medicine (2026). PMID: 42338934 ↗
L4CASE_REPORTCited in: 5. Diagnosis and Workup (Pulmonary Function, Bronchoscopy and Imaging Anchored)
[266]
Zamfir AS, Mihailovici AS, Mihai F et al.. “Case Report: Chronic eosinophilic pneumonia with acute-like presentation and diagnostic challenges.” Frontiers in medicine (2026). PMID: 42318416 ↗
L4CASE_REPORTCited in: 5. Diagnosis and Workup (Pulmonary Function, Bronchoscopy and Imaging Anchored), 9. Respiratory Support, Procedures & Interventional Pulmonology (Specialty-Distinctive)
[267]
Li Q, Su G, Yu R et al.. “Application of BALF combined with tNGS for detecting Chlamydia psittaci in resource-limited areas: lessons learned from the 2025 temporally associated case series investigation.” BMC infectious diseases (2026). PMID: 42288822 ↗
L4CASE_REPORTCited in: 5. Diagnosis and Workup (Pulmonary Function, Bronchoscopy and Imaging Anchored)
[268]
Pan J, Kong H, Liang M et al.. “Pneumonia caused by co-infection with Mycobacterium tuberculosis and Pneumocystis jirovecii leading to acute respiratory distress syndrome in an HIV-negative immunocompromised patient: a case report and literature review.” BMC infectious diseases (2026). PMID: 42026490 ↗
L4CASE_REPORTCited in: 5. Diagnosis and Workup (Pulmonary Function, Bronchoscopy and Imaging Anchored), 12. Special Populations & Pregnancy
[269]
Snijders D, Daniels JM, de Graaff CS et al.. “Efficacy of corticosteroids in community-acquired pneumonia: a randomized double-blinded clinical trial.” American journal of respiratory and critical care medicine (2010). PMID: 20133929 ↗
L1RCTCited in: 6. Severity, Staging and Risk Stratification, 7. Acute Management and Exacerbation Rescue, 8. Long-term and Definitive Management, History and Evolution of Treatment, 11. Prognosis and Natural History
[270]
Christ-Crain M, Stolz D, Bingisser R et al.. “Procalcitonin guidance of antibiotic therapy in community-acquired pneumonia: a randomized trial.” American journal of respiratory and critical care medicine (2006). PMID: 16603606 ↗
L1RCTCited in: 6. Severity, Staging and Risk Stratification, 7. Acute Management and Exacerbation Rescue, 8. Long-term and Definitive Management, History and Evolution of Treatment
[271]
Arnold FW, Summersgill JT, Lajoie AS et al.. “A worldwide perspective of atypical pathogens in community-acquired pneumonia.” American journal of respiratory and critical care medicine (2007). PMID: 17332485 ↗
L5OTHERCited in: 6. Severity, Staging and Risk Stratification
[272]
Chouchane O, Michels EHA, Leite GGF et al.. “The proteomic landscape of blood monocytes in community-acquired pneumonia.” The European respiratory journal (2025). PMID: 41151990 ↗
L3OTHERCited in: 6. Severity, Staging and Risk Stratification, History and Evolution of Treatment
[273]
Bastrup Israelsen S, Fally M, Brok Nielsen P et al.. “Reassessing Halm's clinical stability criteria in community-acquired pneumonia management.” The European respiratory journal (2024). PMID: 39174283 ↗
L4OTHERCited in: 6. Severity, Staging and Risk Stratification, 10. Complications, 12. Special Populations & Pregnancy
[274]
Niederman MS. “Recent advances in community-acquired pneumonia: inpatient and outpatient.” Chest (2007). PMID: 17426229 ↗
L5REVIEW_NARRATIVECited in: 6. Severity, Staging and Risk Stratification, History and Evolution of Treatment, 11. Prognosis and Natural History
[275]
Deshpande A, Klompas M, Yu PC et al.. “Influenza Testing and Treatment Among Patients Hospitalized With Community-Acquired Pneumonia.” Chest (2022). PMID: 35134384 ↗
L4OTHERCited in: 6. Severity, Staging and Risk Stratification, 11. Prognosis and Natural History
[276]
Waterer GW, Self WH, Courtney DM et al.. “In-Hospital Deaths Among Adults With Community-Acquired Pneumonia.” Chest (2018). PMID: 29859184 ↗
L4OTHERCited in: 6. Severity, Staging and Risk Stratification
[277]
Lim WS. “Severity assessment in community-acquired pneumonia: moving on.” Thorax (2007). PMID: 17387212 ↗
L5OTHERCited in: 6. Severity, Staging and Risk Stratification
[278]
Li Y, Zhu H, Li G et al.. “Computed tomography findings and severity scores in Chlamydia psittaci pneumonia: a retrospective study of 69 cases with clinical correlation.” BMC infectious diseases (2026). PMID: 42365231 ↗
L2COHORTCited in: 6. Severity, Staging and Risk Stratification
[279]
Ceccato A, Mendez R, Ewig S et al.. “Validation of a Prediction Score for Drug-Resistant Microorganisms in Community-acquired Pneumonia.” Annals of the American Thoracic Society (2021). PMID: 32915057 ↗
L2OTHERCited in: 6. Severity, Staging and Risk Stratification
[280]
Sapey E, Patel JM, Greenwood H et al.. “Simvastatin Improves Neutrophil Function and Clinical Outcomes in Pneumonia. A Pilot Randomized Controlled Clinical Trial.” American journal of respiratory and critical care medicine (2019). PMID: 31206313 ↗
L1RCTCited in: 7. Acute Management and Exacerbation Rescue, 8. Long-term and Definitive Management, History and Evolution of Treatment, 11. Prognosis and Natural History, 12. Special Populations & Pregnancy
[281]
Sapey E, Patel JM, Greenwood HL et al.. “Pulmonary Infections in the Elderly Lead to Impaired Neutrophil Targeting, Which Is Improved by Simvastatin.” American journal of respiratory and critical care medicine (2017). PMID: 28657793 ↗
L4RCTCited in: 7. Acute Management and Exacerbation Rescue, 8. Long-term and Definitive Management, History and Evolution of Treatment, 12. Special Populations & Pregnancy
[282]
Lorgelly PK, Atkinson M, Lakhanpaul M et al.. “Oral versus i.v. antibiotics for community-acquired pneumonia in children: a cost-minimisation analysis.” The European respiratory journal (2009). PMID: 19717479 ↗
L1RCTCited in: 7. Acute Management and Exacerbation Rescue, 8. Long-term and Definitive Management, History and Evolution of Treatment
[283]
Wu X, Sun T, He H et al.. “Effect of Metagenomic Next-Generation Sequencing on Clinical Outcomes of Patients With Severe Community-Acquired Pneumonia in the ICU: A Multicenter, Randomized Controlled Trial.” Chest (2024). PMID: 39067508 ↗
L1RCTCited in: 7. Acute Management and Exacerbation Rescue, 8. Long-term and Definitive Management, History and Evolution of Treatment, 11. Prognosis and Natural History
[284]
El Moussaoui R, Opmeer BC, de Borgie CA et al.. “Long-term symptom recovery and health-related quality of life in patients with mild-to-moderate-severe community-acquired pneumonia.” Chest (2006). PMID: 17035452 ↗
L2RCTCited in: 7. Acute Management and Exacerbation Rescue, 8. Long-term and Definitive Management
[285]
Cosentini R, Brambilla AM, Aliberti S et al.. “Helmet continuous positive airway pressure vs oxygen therapy to improve oxygenation in community-acquired pneumonia: a randomized, controlled trial.” Chest (2010). PMID: 20154071 ↗
L1RCTCited in: 7. Acute Management and Exacerbation Rescue, 8. Long-term and Definitive Management
[286]
Bonten MJ, Huijts SM, Bolkenbaas M et al.. “Polysaccharide conjugate vaccine against pneumococcal pneumonia in adults.” The New England journal of medicine (2015). PMID: 25785969 ↗
L1RCTCited in: 7. Acute Management and Exacerbation Rescue, 8. Long-term and Definitive Management, History and Evolution of Treatment
[287]
Reijnders TDY, Laterre PF, François B et al.. “Effect of mesenchymal stem cells on the host response in severe community-acquired pneumonia.” Thorax (2024). PMID: 39322407 ↗
L1RCTCited in: 7. Acute Management and Exacerbation Rescue, 8. Long-term and Definitive Management, History and Evolution of Treatment
[288]
Alfageme I, Vazquez R, Reyes N et al.. “Clinical efficacy of anti-pneumococcal vaccination in patients with COPD.” Thorax (2005). PMID: 16227328 ↗
L1RCTCited in: 7. Acute Management and Exacerbation Rescue, 8. Long-term and Definitive Management, History and Evolution of Treatment, 13. Prevention, Screening & Surveillance
[289]
Falguera M, Ruiz-González A, Schoenenberger JA et al.. “Prospective, randomised study to compare empirical treatment versus targeted treatment on the basis of the urine antigen results in hospitalised patients with community-acquired pneumonia.” Thorax (2009). PMID: 19703825 ↗
L1RCTCited in: 7. Acute Management and Exacerbation Rescue, 8. Long-term and Definitive Management, History and Evolution of Treatment
[290]
Müller F, Christ-Crain M, Bregenzer T et al.. “Procalcitonin levels predict bacteremia in patients with community-acquired pneumonia: a prospective cohort trial.” Chest (2010). PMID: 20299634 ↗
L2TRIAL_NONRANDOMCited in: 7. Acute Management and Exacerbation Rescue
[291]
Long W, Deng X, Zhang Y et al.. “Procalcitonin guidance for reduction of antibiotic use in low-risk outpatients with community-acquired pneumonia.” Respirology (Carlton, Vic.) (2011). PMID: 21507143 ↗
L1RCTCited in: 7. Acute Management and Exacerbation Rescue, 8. Long-term and Definitive Management, History and Evolution of Treatment
[292]
Fox SC, Trivedi AP. “A 47-Year Old Woman With Rapidly Progressive Hypoxemic Respiratory Failure.” Chest (2021). PMID: 33563457 ↗
L4CASE_REPORTCited in: 7. Acute Management and Exacerbation Rescue, 9. Respiratory Support, Procedures & Interventional Pulmonology (Specialty-Distinctive), 10. Complications
[293]
Adamuz J, Viasus D, Campreciós-Rodríguez P et al.. “A prospective cohort study of healthcare visits and rehospitalizations after discharge of patients with community-acquired pneumonia.” Respirology (Carlton, Vic.) (2011). PMID: 21736665 ↗
L2COHORTCited in: 7. Acute Management and Exacerbation Rescue
[294]
Cillóniz C, Ewig S, Polverino E et al.. “Community-acquired pneumonia in outpatients: aetiology and outcomes.” The European respiratory journal (2012). PMID: 22267760 ↗
L2OTHERCited in: 7. Acute Management and Exacerbation Rescue, 10. Complications
[295]
Tagami T, Matsui H, Horiguchi H et al.. “Low-dose corticosteroid use and mortality in severe community-acquired pneumonia patients.” The European respiratory journal (2014). PMID: 25323232 ↗
L2OTHERCited in: 7. Acute Management and Exacerbation Rescue
[296]
Endeman H, Meijvis SC, Rijkers GT et al.. “Systemic cytokine response in patients with community-acquired pneumonia.” The European respiratory journal (2010). PMID: 20884746 ↗
L4OTHERCited in: 7. Acute Management and Exacerbation Rescue
[297]
Ewig S, Torres A. “Community-acquired pneumonia as an emergency: time for an aggressive intervention to lower mortality.” The European respiratory journal (2011). PMID: 21349916 ↗
L5OTHERCited in: 7. Acute Management and Exacerbation Rescue, 8. Long-term and Definitive Management
[298]
Cao B, Huang GH, Pu ZH et al.. “Emergence of community-acquired adenovirus type 55 as a cause of community-onset pneumonia.” Chest (2014). PMID: 24551881 ↗
L2OTHERCited in: 7. Acute Management and Exacerbation Rescue, 13. Prevention, Screening & Surveillance
[299]
Crisafulli E, Menéndez R, Huerta A et al.. “Systemic inflammatory pattern of patients with community-acquired pneumonia with and without COPD.” Chest (2013). PMID: 23187314 ↗
L2OTHERCited in: 7. Acute Management and Exacerbation Rescue
[300]
Hashmi M, Haniffa R, Jayakumar D et al.. “Ivermectin for Critically and Noncritically Ill Hospitalized Patients With COVID-19: Randomized, Embedded, Multifactorial Adaptive Platform Trial for Community-Acquired Pneumonia (REMAP-CAP).” Critical care medicine (2026). PMID: 42101205 ↗
L1RCTCited in: 7. Acute Management and Exacerbation Rescue, 8. Long-term and Definitive Management, History and Evolution of Treatment
[301]
Elmeazawy R, AbdElsamea MZ, Barakat A et al.. “Oral pentoxifylline as a novel adjunct to standard therapy in pediatric community-acquired pneumonia: a randomized controlled trial.” Pediatric research (2026). PMID: 42086944 ↗
L1RCTCited in: 7. Acute Management and Exacerbation Rescue, 12. Special Populations & Pregnancy
[302]
Hsiao A, Leong T, Fireman B et al.. “Adjuvanted vs High-Dose Influenza Vaccines in Older US Adults: A Cluster Randomized Crossover Study.” JAMA network open (2026). PMID: 42081247 ↗
L1RCTCited in: 7. Acute Management and Exacerbation Rescue, 8. Long-term and Definitive Management, History and Evolution of Treatment, 13. Prevention, Screening & Surveillance
[303]
Stylianakis E, Kakavoulis N, Foutadakis S et al.. “Molecular pathways driving clarithromycin benefit in community-acquired pneumonia: analysis of the ACCESS randomised trial.” EBioMedicine (2026). PMID: 41934919 ↗
L1RCTCited in: 7. Acute Management and Exacerbation Rescue, 8. Long-term and Definitive Management, History and Evolution of Treatment, 10. Complications
[304]
Bradbury CA, McVerry BJ, Lawler PR et al.. “Intermediate dose heparin thromboprophylaxis among critically ill patients with COVID-19: a randomized clinical trial.” Journal of thrombosis and haemostasis : JTH (2026). PMID: 41895526 ↗
L1RCTCited in: 7. Acute Management and Exacerbation Rescue, 8. Long-term and Definitive Management, History and Evolution of Treatment
[305]
Pinot J, Delory T, Pétrier M et al.. “Clinical data, chest X-ray or C-reactive protein to initiate antibiotic therapy in outpatients with suspected community-acquired pneumonia: a prospective, randomized, controlled, digital case vignette study.” Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases (2026). PMID: 41839418 ↗
L4RCTCited in: 7. Acute Management and Exacerbation Rescue, 8. Long-term and Definitive Management, History and Evolution of Treatment
[306]
Baghdadi JD, Harris AD, Pineles L et al.. “Using Probability of Community-Acquired Pneumonia to Tailor Antimicrobials Among Inpatients: A Pragmatic, Randomized Trial.” Clinical infectious diseases : an official publication of the Infectious Diseases Society of America (2026). PMID: 41823187 ↗
L1RCTCited in: 7. Acute Management and Exacerbation Rescue, 8. Long-term and Definitive Management, History and Evolution of Treatment
[307]
Menéndez R, Martinez R, Reyes S et al.. “Stability in community-acquired pneumonia: one step forward with markers?” Thorax (2009). PMID: 19762338 ↗
L2OTHERCited in: 7. Acute Management and Exacerbation Rescue, 10. Complications
[308]
Phua J, See KC, Chan YH et al.. “Validation and clinical implications of the IDSA/ATS minor criteria for severe community-acquired pneumonia.” Thorax (2009). PMID: 19386583 ↗
L3OTHERCited in: 7. Acute Management and Exacerbation Rescue
[309]
Man SY, Lee N, Ip M et al.. “Prospective comparison of three predictive rules for assessing severity of community-acquired pneumonia in Hong Kong.” Thorax (2006). PMID: 17121867 ↗
L2OTHERCited in: 7. Acute Management and Exacerbation Rescue
[310]
Stotts C, Corrales-Medina VF, deKemp RA et al.. “Targeting Vascular Inflammation In Patients with Community-Acquired Pneumonia (TIN-CAP): protocol for a multicentre, randomised, double-blind, placebo-controlled trial.” BMJ open (2026). PMID: 41781043 ↗
L5TRIAL_NONRANDOMCited in: 7. Acute Management and Exacerbation Rescue, 10. Complications
[311]
Lansbury L, Rodrigo C, Leonardi-Bee J et al.. “Corticosteroids as adjunctive therapy in the treatment of influenza.” The Cochrane database of systematic reviews (2019). PMID: 30798570 ↗
L1SR_OBSCited in: 7. Acute Management and Exacerbation Rescue
[312]
Serisier DJ, Williams S, Bowler SD. “Australasian respiratory and emergency physicians do not use the pneumonia severity index in community-acquired pneumonia.” Respirology (Carlton, Vic.) (2013). PMID: 23036136 ↗
L4OTHERCited in: 7. Acute Management and Exacerbation Rescue
[313]
Tseng JS, Chan MC, Hsu JY et al.. “Procalcitonin is a valuable prognostic marker in ARDS caused by community-acquired pneumonia.” Respirology (Carlton, Vic.) (2008). PMID: 18422867 ↗
L2OTHERCited in: 7. Acute Management and Exacerbation Rescue, 10. Complications
[314]
Serisier DJ, Bowler SD. “Effect of a simple educational intervention on the hospital management of community-acquired pneumonia.” Respirology (Carlton, Vic.) (2007). PMID: 17539843 ↗
L4OTHERCited in: 7. Acute Management and Exacerbation Rescue
[315]
Chang CL, Sullivan GD, Karalus NC et al.. “Predicting early mortality in acute exacerbation of chronic obstructive pulmonary disease using the CURB65 score.” Respirology (Carlton, Vic.) (2011). PMID: 20920140 ↗
L2OTHERCited in: 7. Acute Management and Exacerbation Rescue
[316]
Kim RY, Glick C, Furmanek S et al.. “Association between body mass index and mortality in hospitalised patients with community-acquired pneumonia.” ERJ open research (2021). PMID: 33778059 ↗
L2OTHERCited in: 7. Acute Management and Exacerbation Rescue
[317]
Venkitakrishnan R, Vijay A, Augustine J et al.. “Hospitalisation outcomes in pneumococcal-vaccinated versus -unvaccinated patients with exacerbation of COPD: results from the HOPE COPD Study.” ERJ open research (2023). PMID: 37143841 ↗
L2OTHERCited in: 7. Acute Management and Exacerbation Rescue, 13. Prevention, Screening & Surveillance
[318]
Wittermans E, Vestjens SMT, Spoorenberg SMC et al.. “Adjunctive treatment with oral dexamethasone in non-ICU patients hospitalised with community-acquired pneumonia: a randomised clinical trial.” The European respiratory journal (2021). PMID: 33446608 ↗
L1RCTCited in: 8. Long-term and Definitive Management
[319]
Ebrahimi F, Wolffenbuttel C, Blum CA et al.. “Fibroblast growth factor 21 predicts outcome in community-acquired pneumonia: secondary analysis of two randomised controlled trials.” The European respiratory journal (2019). PMID: 30578395 ↗
L2RCTCited in: 8. Long-term and Definitive Management, History and Evolution of Treatment
[320]
Ebrahimi F, Giaglis S, Hahn S et al.. “Markers of neutrophil extracellular traps predict adverse outcome in community-acquired pneumonia: secondary analysis of a randomised controlled trial.” The European respiratory journal (2018). PMID: 29519921 ↗
L2RCTCited in: 8. Long-term and Definitive Management
[321]
Neupane B, Jerrett M, Burnett RT et al.. “Long-term exposure to ambient air pollution and risk of hospitalization with community-acquired pneumonia in older adults.” American journal of respiratory and critical care medicine (2009). PMID: 19797763 ↗
L3OTHERCited in: 8. Long-term and Definitive Management, 12. Special Populations & Pregnancy
[322]
Krüger S, Ewig S, Giersdorf S et al.. “Cardiovascular and inflammatory biomarkers to predict short- and long-term survival in community-acquired pneumonia: Results from the German Competence Network, CAPNETZ.” American journal of respiratory and critical care medicine (2010). PMID: 20639437 ↗
L2OTHERCited in: 8. Long-term and Definitive Management
[323]
van der Sande LJTM, Jöbsis Q, Bannier MAGE et al.. “The risk of community-acquired pneumonia in children using gastric acid suppressants.” The European respiratory journal (2021). PMID: 33737412 ↗
L3OTHERCited in: 8. Long-term and Definitive Management, 10. Complications
[324]
Almirall J, Bolíbar I, Serra-Prat M et al.. “Inhaled drugs as risk factors for community-acquired pneumonia.” The European respiratory journal (2010). PMID: 20525710 ↗
L3OTHERCited in: 8. Long-term and Definitive Management
[325]
Guertler C, Wirz B, Christ-Crain M et al.. “Inflammatory responses predict long-term mortality risk in community-acquired pneumonia.” The European respiratory journal (2010). PMID: 21071473 ↗
L2OTHERCited in: 8. Long-term and Definitive Management
[326]
Bello S, Lasierra AB, Mincholé E et al.. “Prognostic power of proadrenomedullin in community-acquired pneumonia is independent of aetiology.” The European respiratory journal (2011). PMID: 22075489 ↗
L2OTHERCited in: 8. Long-term and Definitive Management
[327]
Tessmer A, Welte T, Schmidt-Ott R et al.. “Influenza vaccination is associated with reduced severity of community-acquired pneumonia.” The European respiratory journal (2010). PMID: 21148226 ↗
L2OTHERCited in: 8. Long-term and Definitive Management, 13. Prevention, Screening & Surveillance
[328]
Siljan WW, Holter JC, Michelsen AE et al.. “Inflammatory biomarkers are associated with aetiology and predict outcomes in community-acquired pneumonia: results of a 5-year follow-up cohort study.” ERJ open research (2019). PMID: 30863773 ↗
L2COHORTCited in: 8. Long-term and Definitive Management
[329]
Menéndez R, Méndez R, Aldás I et al.. “Community-Acquired Pneumonia Patients at Risk for Early and Long-term Cardiovascular Events Are Identified by Cardiac Biomarkers.” Chest (2019). PMID: 31381883 ↗
L2OTHERCited in: 8. Long-term and Definitive Management
[330]
Corrales-Medina VF, van Walraven C. “Guideline-Concordant Antibiotic Therapy for the Hospital Treatment of Community-Acquired Pneumonia and 1-Year All-Cause and Cardiovascular Mortality in Older Adult Patients Surviving to Discharge.” Chest (2023). PMID: 36621760 ↗
L2OTHERCited in: 8. Long-term and Definitive Management
[331]
Suissa S, Dell'Aniello S, Ernst P. “Long-Acting Bronchodilator Initiation in COPD and the Risk of Adverse Cardiopulmonary Events: A Population-Based Comparative Safety Study.” Chest (2016). PMID: 27554300 ↗
L2OTHERCited in: 8. Long-term and Definitive Management
[332]
Voiriot G, Dury S, Parrot A et al.. “Nonsteroidal antiinflammatory drugs may affect the presentation and course of community-acquired pneumonia.” Chest (2010). PMID: 20724739 ↗
L2OTHERCited in: 8. Long-term and Definitive Management
[333]
Nowak A, Breidthardt T, Christ-Crain M et al.. “Direct comparison of three natriuretic peptides for prediction of short- and long-term mortality in patients with community-acquired pneumonia.” Chest (2011). PMID: 22135381 ↗
L2OTHERCited in: 8. Long-term and Definitive Management
[334]
Saghaug CS, Markussen DL, Knoop ST et al.. “Diagnostic accuracy of a host response test in suspected community-Acquired pneumonia during the COVID-19 era.” International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases (2025). PMID: 40907740 ↗
L2RCTCited in: 8. Long-term and Definitive Management
[335]
Cheon K, Buchwald UK, Hammitt LL et al.. “The impact of pneumococcal vaccination and nasopharyngeal colonization on the performance of a serotype-specific urine antigen detection (SSUAD) assay.” Vaccine (2025). PMID: 40886427 ↗
L1RCTCited in: 8. Long-term and Definitive Management
[336]
Krüger S, Ewig S, Kunde J et al.. “Pro-atrial natriuretic peptide and pro-vasopressin for predicting short-term and long-term survival in community-acquired pneumonia: results from the German Competence Network CAPNETZ.” Thorax (2010). PMID: 20335288 ↗
L2OTHERCited in: 8. Long-term and Definitive Management
[337]
Yu M, Wang X, Wu S et al.. “Comparison of Efficacy and Safety Profiles Between Omadacycline and Moxifloxacin in Elderly Patients with Community-Acquired Pneumonia: A Randomized, Controlled Trial.” Clinical pharmacology in drug development (2025). PMID: 41267642 ↗
L1RCTCited in: 8. Long-term and Definitive Management, History and Evolution of Treatment
[338]
Spoorenberg SM, Vestjens SM, Rijkers GT et al.. “YKL-40, CCL18 and SP-D predict mortality in patients hospitalized with community-acquired pneumonia.” Respirology (Carlton, Vic.) (2016). PMID: 27782361 ↗
L2OTHERCited in: 8. Long-term and Definitive Management
[339]
Bernstein JM. “Treatment of community-acquired pneumonia--IDSA guidelines. Infectious Diseases Society of America.” Chest (1999). PMID: 10084453 ↗
L1GUIDELINECited in: History and Evolution of Treatment
[340]
Ramsdell J, Narsavage GL, Fink JB. “Management of community-acquired pneumonia in the home: an American College of Chest Physicians clinical position statement.” Chest (2005). PMID: 15888856 ↗
L1GUIDELINECited in: History and Evolution of Treatment
[341]
Confalonieri M, Urbino R, Potena A et al.. “Hydrocortisone infusion for severe community-acquired pneumonia: a preliminary randomized study.” American journal of respiratory and critical care medicine (2004). PMID: 15557131 ↗
L1RCTCited in: History and Evolution of Treatment
[342]
Confalonieri M, Potena A, Carbone G et al.. “Acute respiratory failure in patients with severe community-acquired pneumonia. A prospective randomized evaluation of noninvasive ventilation.” American journal of respiratory and critical care medicine (1999). PMID: 10556125 ↗
L1RCTCited in: History and Evolution of Treatment
[343]
Lode H, Garau J, Grassi C et al.. “Treatment of community-acquired pneumonia: a randomized comparison of sparfloxacin, amoxycillin-clavulanic acid and erythromycin.” The European respiratory journal (1995). PMID: 8666093 ↗
L1RCTCited in: History and Evolution of Treatment
[344]
Wasserfallen JB, Erard V, Cometta A et al.. “Cost-effectiveness of full-course oral levofloxacin in severe community-acquired pneumonia.” The European respiratory journal (2004). PMID: 15459145 ↗
L1RCTCited in: History and Evolution of Treatment
[345]
Torres A, Muir JF, Corris P et al.. “Effectiveness of oral moxifloxacin in standard first-line therapy in community-acquired pneumonia.” The European respiratory journal (2003). PMID: 12570122 ↗
L1RCTCited in: History and Evolution of Treatment
[346]
Mundy LM, Leet TL, Darst K et al.. “Early mobilization of patients hospitalized with community-acquired pneumonia.” Chest (2003). PMID: 12970012 ↗
L1RCTCited in: History and Evolution of Treatment
[347]
El Moussaoui R, Opmeer BC, Bossuyt PM et al.. “Development and validation of a short questionnaire in community acquired pneumonia.” Thorax (2004). PMID: 15223867 ↗
L4RCTCited in: History and Evolution of Treatment
[348]
Blasi F. “Atypical pathogens and respiratory tract infections.” The European respiratory journal (2004). PMID: 15293621 ↗
L5REVIEW_NARRATIVECited in: History and Evolution of Treatment
[349]
Almirall J, Bolíbar I, Balanzó X et al.. “Risk factors for community-acquired pneumonia in adults: a population-based case-control study.” The European respiratory journal (1999). PMID: 10065680 ↗
L3CASE_CONTROLCited in: History and Evolution of Treatment
[350]
Soepandi P, Mangunnegoro H, Yunus F et al.. “The pattern of micro-organisms and the efficacy of new macrolide in acute lower respiratory tract infections.” Respirology (Carlton, Vic.) (1998). PMID: 9692520 ↗
L4RCTCited in: History and Evolution of Treatment
[351]
Zalacain R, Torres A, Celis R et al.. “Community-acquired pneumonia in the elderly: Spanish multicentre study.” The European respiratory journal (2003). PMID: 12608444 ↗
L2OTHERCited in: History and Evolution of Treatment
[352]
Lynn LA. “Flawed design and selection bias in critical care randomized controlled trials (RCTs): the patient safety risk of the "RCT mimic".” Patient safety in surgery (2025). PMID: 41402862 ↗
L5RCTCited in: History and Evolution of Treatment
[353]
Sperandeo M, Rea G, Grimaldi MA et al.. “Contrast-enhanced ultrasound does not discriminate between community acquired pneumonia and lung cancer.” Thorax (2016). PMID: 27742872 ↗
L3OTHERCited in: History and Evolution of Treatment
[354]
Neill AM, Martin IR, Weir R et al.. “Community acquired pneumonia: aetiology and usefulness of severity criteria on admission.” Thorax (1996). PMID: 8977602 ↗
L2OTHERCited in: History and Evolution of Treatment
[355]
Rodrigo C, Bewick T, Sheppard C et al.. “Pneumococcal serotypes in adult non-invasive and invasive pneumonia in relation to child contact and child vaccination status.” Thorax (2013). PMID: 24048505 ↗
L2OTHERCited in: History and Evolution of Treatment, 13. Prevention, Screening & Surveillance
[356]
Okimoto N, Asaoka N, Osaki K et al.. “Clinical features of Q fever pneumonia.” Respirology (Carlton, Vic.) (2004). PMID: 15182283 ↗
L4CASE_REPORTCited in: History and Evolution of Treatment
[357]
Isenman HL, Chambers ST, Pithie AD et al.. “Legionnaires' disease caused by Legionella longbeachae: Clinical features and outcomes of 107 cases from an endemic area.” Respirology (Carlton, Vic.) (2016). PMID: 27199169 ↗
L4OTHERCited in: History and Evolution of Treatment
[358]
St Peter SD, Ampofo K, Brogan T et al.. “2026 Clinical Practice Guideline Update by the Infectious Diseases Society of America and the Pediatric Infectious Diseases Society on The Management of Community-acquired Pneumonia in Infants and Children Older than 3 Months of Age: The Choice of Chest Tube Size.” Clinical infectious diseases : an official publication of the Infectious Diseases Society of America (2026). PMID: 41840880 ↗
L1GUIDELINECited in: 9. Respiratory Support, Procedures & Interventional Pulmonology (Specialty-Distinctive)
[359]
St Peter SD, Ampofo K, Brogan T et al.. “2026 Clinical Practice Guideline Update by the Infectious Diseases Society of America and the Pediatric Infectious Diseases Society on The Management of Community-Acquired Pneumonia in Infants and Children Older than 3 Months of Age: The Use of Pleural fluid drainage compared to Surgical Debridement.” Clinical infectious diseases : an official publication of the Infectious Diseases Society of America (2026). PMID: 41834669 ↗
L1GUIDELINECited in: 9. Respiratory Support, Procedures & Interventional Pulmonology (Specialty-Distinctive)
[360]
Azar MM, Schlaberg R, Malinis MF et al.. “Added Diagnostic Utility of Clinical Metagenomics for the Diagnosis of Pneumonia in Immunocompromised Adults.” Chest (2020). PMID: 33217418 ↗
L2OTHERCited in: 9. Respiratory Support, Procedures & Interventional Pulmonology (Specialty-Distinctive)
[361]
Schwartz B, Dupont V, Dury S et al.. “Aetiology, clinical features, diagnostic studies, and outcomes of community-acquired pneumonia in kidney transplant recipients admitted to hospital: a multicentre retrospective French cohort study.” Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases (2022). PMID: 36574948 ↗
L2COHORTCited in: 9. Respiratory Support, Procedures & Interventional Pulmonology (Specialty-Distinctive)
[362]
Kim J, Park JS, Cho YJ et al.. “Predictors of prolonged stay in patients with community-acquired pneumonia and complicated parapneumonic effusion.” Respirology (Carlton, Vic.) (2015). PMID: 26510382 ↗
L2OTHERCited in: 9. Respiratory Support, Procedures & Interventional Pulmonology (Specialty-Distinctive)
[363]
Hong Y, Wang Q, Song Y et al.. “Factors Associated with Severe Adenovirus Pneumonia in Children: A Retrospective Study from Guangzhou, China (2017-2019).” Medical science monitor : international medical journal of experimental and clinical research (2023). PMID: 37496263 ↗
L2COHORTCited in: 9. Respiratory Support, Procedures & Interventional Pulmonology (Specialty-Distinctive)
[364]
Luo H, Jiang L, Chen J et al.. “Chlamydia psittaci Pneumonia in a patient with motor neuron disease: a case report.” BMC infectious diseases (2023). PMID: 38053032 ↗
L4CASE_REPORTCited in: 9. Respiratory Support, Procedures & Interventional Pulmonology (Specialty-Distinctive)
[365]
Li Y, Lei J, Ren Z et al.. “Case Report: Metagenomic next-generation sequencing assists in dynamic pathogen monitoring: powerful tool for progressing severe pneumonia.” Frontiers in cellular and infection microbiology (2023). PMID: 37743869 ↗
L4CASE_REPORTCited in: 9. Respiratory Support, Procedures & Interventional Pulmonology (Specialty-Distinctive)
[366]
Luo Y, Zhu L, Xu H et al.. “Landscape of the upper and lower airway microbiota in children with community-acquired pneumonia.” Virulence (2026). PMID: 42388029 ↗
L2OTHERCited in: 9. Respiratory Support, Procedures & Interventional Pulmonology (Specialty-Distinctive)
[367]
Qian J, Liu M, Zhu C et al.. “Epidemiological shifts and clinical characteristics of childhood Chlamydia pneumoniae pneumonia in Beijing before, during, and after public health interventions (2017-2025).” BMC infectious diseases (2026). PMID: 42298460 ↗
L2OTHERCited in: 9. Respiratory Support, Procedures & Interventional Pulmonology (Specialty-Distinctive)
[368]
Feng X, Du M, Feng S et al.. “Targeted next-generation sequencing for microbial and clinical diagnosis: a prospective controlled comparison between sputum and bronchoalveolar lavage fluid in patients with community-acquired pneumonia.” BMC infectious diseases (2026). PMID: 42177424 ↗
L2OTHERCited in: 9. Respiratory Support, Procedures & Interventional Pulmonology (Specialty-Distinctive)
[369]
Qian Q, Jinghua S, Jiani W et al.. “A retrospective analysis of 266 cases: clinical features of Chlamydia pneumoniae pneumonia in children.” BMC infectious diseases (2026). PMID: 41933307 ↗
L4OTHERCited in: 9. Respiratory Support, Procedures & Interventional Pulmonology (Specialty-Distinctive)
[370]
Hountras P, Cajigas H. “A 62-Year-Old Woman With Wheezing, Respiratory Failure, and an Abnormal CT Scan.” Chest (2017). PMID: 28889900 ↗
L4CASE_REPORTCited in: 10. Complications
[371]
Reyes S, Martinez R, Vallés JM et al.. “Determinants of hospital costs in community-acquired pneumonia.” The European respiratory journal (2008). PMID: 18448502 ↗
L2OTHERCited in: 10. Complications
[372]
de Wit M, Jones DG, Sessler CN et al.. “Alcohol-use disorders in the critically ill patient.” Chest (2010). PMID: 20923804 ↗
L5REVIEW_NARRATIVECited in: 10. Complications
[373]
Ali AS, Sheikh D, Chandler TR et al.. “Cardiovascular Complications Are the Primary Drivers of Mortality in Hospitalized Patients With SARS-CoV-2 Community-Acquired Pneumonia.” Chest (2022). PMID: 36410493 ↗
L2OTHERCited in: 10. Complications
[374]
Chen JH, Chang SS, Liu JJ et al.. “Comparison of clinical characteristics and performance of pneumonia severity score and CURB-65 among younger adults, elderly and very old subjects.” Thorax (2010). PMID: 20965934 ↗
L2OTHERCited in: 10. Complications, 12. Special Populations & Pregnancy
[375]
Zeng H, Yang C, Jiang M et al.. “Predicting length of hospital stay in community-acquired pneumonia using clinical and treatment factors: a retrospective study with restricted cubic spline and piecewise regression analysis.” Frontiers in public health (2026). PMID: 42100535 ↗
L2COHORTCited in: 10. Complications
[376]
Chen H, Fan Y, Zhang X et al.. “Nonlinear age-season dynamics and macrolide resistance of Mycoplasma pneumoniae: a large pediatric cohort study during the post-pandemic resurgence.” BMC infectious diseases (2026). PMID: 42021202 ↗
L2COHORTCited in: 10. Complications, 12. Special Populations & Pregnancy
[377]
Restrepo MI, Reyes LF. “Pneumonia as a cardiovascular disease.” Respirology (Carlton, Vic.) (2018). PMID: 29325222 ↗
L5REVIEW_NARRATIVECited in: 10. Complications
[378]
Shindo Y, Sato S, Maruyama E et al.. “Comparison of severity scoring systems A-DROP and CURB-65 for community-acquired pneumonia.” Respirology (Carlton, Vic.) (2008). PMID: 18713094 ↗
L4OTHERCited in: 10. Complications
[379]
Chien JY, Hsueh PR, Cheng WC et al.. “Temporal changes in cytokine/chemokine profiles and pulmonary involvement in severe acute respiratory syndrome.” Respirology (Carlton, Vic.) (2006). PMID: 17052299 ↗
L3OTHERCited in: 10. Complications
[380]
Chiang WC, Teoh OH, Chong CY et al.. “Epidemiology, clinical characteristics and antimicrobial resistance patterns of community-acquired pneumonia in 1702 hospitalized children in Singapore.” Respirology (Carlton, Vic.) (2007). PMID: 17298459 ↗
L4OTHERCited in: 10. Complications
[381]
Kasamatsu Y, Yamaguchi T, Kawaguchi T et al.. “Usefulness of a semi-quantitative procalcitonin test and the A-DROP Japanese prognostic scale for predicting mortality among adults hospitalized with community-acquired pneumonia.” Respirology (Carlton, Vic.) (2012). PMID: 22059525 ↗
L2OTHERCited in: 10. Complications
[382]
Torén K, Blanc PD, Qvarfordt I et al.. “Inhaled Corticosteroids Use and Risk of Invasive Pneumococcal Disease in a Population-based Study.” Annals of the American Thoracic Society (2020). PMID: 32649216 ↗
L3OTHERCited in: 10. Complications
[383]
Abdoli E, Eini P, Farashi S et al.. “Optimizing Intubation Prediction in Pneumonia Patients: A Systematic Review and Meta-Analysis of Machine Learning Algorithms.” Pulmonary medicine (2026). PMID: 41848079 ↗
L1SR_OBSCited in: 10. Complications
[384]
Jutant EM, Voiriot G, Labbé V et al.. “Endothelial dysfunction and hypercoagulability in severe sickle-cell acute chest syndrome.” ERJ open research (2021). PMID: 34912886 ↗
L2OTHERCited in: 10. Complications
[385]
Aliberti S, Ramirez J, Cosentini R et al.. “Acute myocardial infarction versus other cardiovascular events in community-acquired pneumonia.” ERJ open research (2015). PMID: 27730139 ↗
L2OTHERCited in: 10. Complications
[386]
Ito A, Ishida T, Tachibana H et al.. “Serial procalcitonin levels for predicting prognosis in community-acquired pneumonia.” Respirology (Carlton, Vic.) (2016). PMID: 27398948 ↗
L2OTHERCited in: 11. Prognosis and Natural History
[387]
Luna CM, Palma I, Niederman MS et al.. “The Impact of Age and Comorbidities on the Mortality of Patients of Different Age Groups Admitted with Community-acquired Pneumonia.” Annals of the American Thoracic Society (2016). PMID: 27398827 ↗
L2OTHERCited in: 11. Prognosis and Natural History
[388]
Long MB, Abo-Leyah H, Giam YH et al.. “SFX-01 in hospitalised patients with community-acquired pneumonia during the COVID-19 pandemic: a double-blind, randomised, placebo-controlled trial.” ERJ open research (2024). PMID: 38469377 ↗
L1OTHERCited in: 11. Prognosis and Natural History
[389]
Maruyama T, Fujisawa T, Suga S et al.. “Outcomes and Prognostic Features of Patients With Influenza Requiring Hospitalization and Receiving Early Antiviral Therapy: A Prospective Multicenter Cohort Study.” Chest (2016). PMID: 26203671 ↗
L2COHORTCited in: 12. Special Populations & Pregnancy
[390]
Yende S, Angus DC, Ding J et al.. “4G/5G plasminogen activator inhibitor-1 polymorphisms and haplotypes are associated with pneumonia.” American journal of respiratory and critical care medicine (2007). PMID: 17761618 ↗
L2OTHERCited in: 12. Special Populations & Pregnancy
[391]
Carrabba M, Zarantonello M, Bonara P et al.. “Severity assessment of healthcare-associated pneumonia and pneumonia in immunosuppression.” The European respiratory journal (2012). PMID: 22408203 ↗
L2OTHERCited in: 12. Special Populations & Pregnancy
[392]
Kothe H, Bauer T, Marre R et al.. “Outcome of community-acquired pneumonia: influence of age, residence status and antimicrobial treatment.” The European respiratory journal (2008). PMID: 18287129 ↗
L2OTHERCited in: 12. Special Populations & Pregnancy
[393]
Zhou F, Wang Y, Liu Y et al.. “Disease severity and clinical outcomes of community-acquired pneumonia caused by non-influenza respiratory viruses in adults: a multicentre prospective registry study from the CAP-China Network.” The European respiratory journal (2019). PMID: 31164430 ↗
L2OTHERCited in: 12. Special Populations & Pregnancy
[394]
Ramirez JA, Musher DM, Evans SE et al.. “Treatment of Community-Acquired Pneumonia in Immunocompromised Adults: A Consensus Statement Regarding Initial Strategies.” Chest (2020). PMID: 32561442 ↗
L5REVIEW_NARRATIVECited in: 12. Special Populations & Pregnancy
[395]
Cillóniz C, Polverino E, Ewig S et al.. “Impact of age and comorbidity on cause and outcome in community-acquired pneumonia.” Chest (2013). PMID: 23670047 ↗
L2OTHERCited in: 12. Special Populations & Pregnancy
[396]
Díaz A, Barria P, Niederman M et al.. “Etiology of community-acquired pneumonia in hospitalized patients in chile: the increasing prevalence of respiratory viruses among classic pathogens.” Chest (2007). PMID: 17356093 ↗
L2OTHERCited in: 12. Special Populations & Pregnancy
[397]
Arancibia F, Cortes CP, Valdés M et al.. “Importance of Legionella pneumophila in the etiology of severe community-acquired pneumonia in Santiago, Chile.” Chest (2014). PMID: 23764871 ↗
L2OTHERCited in: 12. Special Populations & Pregnancy
[398]
Ewig S, Birkner N, Strauss R et al.. “New perspectives on community-acquired pneumonia in 388 406 patients. Results from a nationwide mandatory performance measurement programme in healthcare quality.” Thorax (2009). PMID: 19454409 ↗
L2OTHERCited in: 12. Special Populations & Pregnancy
[399]
Hemilä H, Louhiala P. “Vitamin C for preventing and treating pneumonia.” The Cochrane database of systematic reviews (2013). PMID: 23925826 ↗
L1SR_OBSCited in: 12. Special Populations & Pregnancy
[400]
Toba A, Yamazaki M, Mochizuki H et al.. “Lower incidence of acute respiratory distress syndrome in community-acquired pneumonia patients aged 85 years or older.” Respirology (Carlton, Vic.) (2010). PMID: 20070586 ↗
L4OTHERCited in: 12. Special Populations & Pregnancy
[401]
Lv Q, Li L, Wang R et al.. “Antiviral Efficacy of the Traditional Chinese Medicine Mixture Yuanzhixingrenheji Against Human Adenovirus-7 In Vitro, In Vivo, and in a Clinical Retrospective Study.” Pathogens (Basel, Switzerland) (2026). PMID: 42198590 ↗
L4COHORTCited in: 12. Special Populations & Pregnancy
[402]
Lian D, Wang D, Lin C et al.. “Early targeted next-generation sequencing accelerates clinical recovery in children with community-acquired pneumonia: A retrospective study.” Pakistan journal of medical sciences (2026). PMID: 42369922 ↗
L3COHORTCited in: 12. Special Populations & Pregnancy
[403]
Wang J, Cao J, Zhang L. “Comparative study of piperacillin-tazobactam versus ampicillin in the treatment of severe pneumonia in children: A retrospective study.” Medicine (2026). PMID: 42260869 ↗
L3COHORTCited in: 12. Special Populations & Pregnancy
[404]
Sun L, Lin H, Lin H et al.. “Characteristics and prognostic factors of patients with community-acquired pneumonia combined with pulmonary embolism: A prospective cohort study.” Medicine (2026). PMID: 42071802 ↗
L2COHORTCited in: 12. Special Populations & Pregnancy
[405]
Khreis D, Khdoud MB, El Tawil E et al.. “Outbreak of Mycoplasma pneumoniae infection in Lebanon during 2023-2024.” Journal of infection and public health (2026). PMID: 42407227 ↗
L4OTHERCited in: 12. Special Populations & Pregnancy
[406]
Eurich DT, Marrie TJ, Johnstone J et al.. “Mortality reduction with influenza vaccine in patients with pneumonia outside "flu" season: pleiotropic benefits or residual confounding?” American journal of respiratory and critical care medicine (2008). PMID: 18556629 ↗
L2OTHERCited in: 13. Prevention, Screening & Surveillance
[407]
Almirall J, Bolíbar I, Serra-Prat M et al.. “New evidence of risk factors for community-acquired pneumonia: a population-based study.” The European respiratory journal (2008). PMID: 18216057 ↗
L3OTHERCited in: 13. Prevention, Screening & Surveillance
[408]
Martínez R, Menéndez R, Reyes S et al.. “Factors associated with inflammatory cytokine patterns in community-acquired pneumonia.” The European respiratory journal (2010). PMID: 20595152 ↗
L2OTHERCited in: 13. Prevention, Screening & Surveillance
[409]
Mangen MJ, Rozenbaum MH, Huijts SM et al.. “Cost-effectiveness of adult pneumococcal conjugate vaccination in the Netherlands.” The European respiratory journal (2015). PMID: 26160871 ↗
L2OTHERCited in: 13. Prevention, Screening & Surveillance
[410]
Domínguez A, Izquierdo C, Salleras L et al.. “Effectiveness of the pneumococcal polysaccharide vaccine in preventing pneumonia in the elderly.” The European respiratory journal (2010). PMID: 20075048 ↗
L3OTHERCited in: 13. Prevention, Screening & Surveillance
[411]
Rodrigo C, Bewick T, Sheppard C et al.. “Impact of infant 13-valent pneumococcal conjugate vaccine on serotypes in adult pneumonia.” The European respiratory journal (2015). PMID: 25792633 ↗
L2OTHERCited in: 13. Prevention, Screening & Surveillance
[412]
Elemraid MA, Sails AD, Eltringham GJ et al.. “Aetiology of paediatric pneumonia after the introduction of pneumococcal conjugate vaccine.” The European respiratory journal (2013). PMID: 23598951 ↗
L2OTHERCited in: 13. Prevention, Screening & Surveillance
[413]
Kim DJ, Lee JG, Lee CY et al.. “Long-term survival following pneumonectomy for non-small cell lung cancer: clinical implications for follow-up care.” Chest (2007). PMID: 17505031 ↗
L3OTHERCited in: 13. Prevention, Screening & Surveillance
[414]
Pick H, Daniel P, Rodrigo C et al.. “Pneumococcal serotype trends, surveillance and risk factors in UK adult pneumonia, 2013-18.” Thorax (2019). PMID: 31594801 ↗
L2OTHERCited in: 13. Prevention, Screening & Surveillance
[415]
Lertussavavivat T, Isaranuwatchai S, Eiam-Ong S et al.. “Vaccine efficacy in CKD patients not on dialysis: a systematic review and meta-analysis.” Clinical kidney journal (2026). PMID: 42079457 ↗
L2SR_OBSCited in: 13. Prevention, Screening & Surveillance
[416]
Cintrón M, Gali V, Li Y et al.. “Pneumococcal serotype distribution and outcomes in cancer patients with community-acquired pneumonia: A prospective study using the 15-valent pneumococcal conjugate vaccine serotype specific urinary antigen detection assay.” International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases (2025). PMID: 41468971 ↗
L2COHORTCited in: 13. Prevention, Screening & Surveillance
[417]
Te Linde E, Wit FWNM, van Welzen BJ et al.. “Incidence of Community-acquired Pneumonia and Herpes Zoster in People With HIV Based on CD4 Count and Age in the Current Antiretroviral Therapy Era: A Longitudinal Cohort Study.” Clinical infectious diseases : an official publication of the Infectious Diseases Society of America (2026). PMID: 41406983 ↗
L2COHORTCited in: 13. Prevention, Screening & Surveillance
[418]
Sarsenov R, Solomadin M, Lavrinenko A et al.. “Microbial Etiology and Antimicrobial Resistance in Pneumonia Among Hospitalized Patients in Kazakhstan: A Systematic Review and Single-Arm Meta-Analysis of Prevalence Data.” Health science reports (2026). PMID: 42005672 ↗
L4SR_OBSCited in: 13. Prevention, Screening & Surveillance
[419]
Ankert J, Hagel S, Schwarz C et al.. “Streptococcus pneumoniae re-emerges as a cause of community-acquired pneumonia, including frequent co-infection with SARS-CoV-2, in Germany, 2021.” ERJ open research (2023). PMID: 37260459 ↗
L4OTHERCited in: 13. Prevention, Screening & Surveillance
[420]
Wang B, Zhang T, Yi L et al.. “Incidence of community-acquired pneumonia among adults between 2016 and 2023: an observational cohort study.” Epidemiology and infection (2026). PMID: 41491926 ↗
L2COHORTCited in: 13. Prevention, Screening & Surveillance
[421]
Põder A, Ong-Lim AL, Rivera Medina DM et al.. “Efficacy, immunogenicity, and safety of a cell culture-derived quadrivalent influenza vaccine compared with a non-influenza vaccine in infants and children across five influenza seasons: a phase 3, multinational, observer-blind, randomised controlled trial.” The Lancet. Child & adolescent health (2026). PMID: 41962984 ↗
L1RCTCited in: 13. Prevention, Screening & Surveillance
[422]
Tang J, Yang B, Bai Y. “Diagnostic challenges and management strategies of pulmonary mucosa-associated lymphoid tissue lymphoma: a case report and literature review.” Frontiers in medicine (2025). PMID: 41488067 ↗
L4CASE_REPORTCited in: 13. Prevention, Screening & Surveillance
[423]
Zhang J, Zhang Y, Duan C et al.. “Pediatric necrotizing pneumonia case report: clinical features, treatment experience, and prospects.” Frontiers in medicine (2025). PMID: 41041448 ↗
L4CASE_REPORTCited in: 13. Prevention, Screening & Surveillance

Quick Reference

Overview and Recommendations

Background

Evaluation

Management

Board Review — High Yield

Deep Dive — Evidence Details

1. Definition, Classification and Nomenclature

Classification

Controversies and Guideline Disagreement

2. Pathophysiology and Mechanism

Microbial Invasion and Innate Immune Recognition

Alveolar-Capillary Barrier Disruption and Gas Exchange Derangement

The Systemic Inflammatory Response and Sepsis Signatures

Cardiac Complications and Long-term Injury

Resolution and Host Factors Modulating Outcome

3. Epidemiology, Etiology and Risk Factors

Incidence and Prevalence

Temporal Trends

Risk Factors

Seasonal Variation

Special Considerations

4. Clinical Presentation

Presenting Symptoms

Physical Examination Findings

Phenotypic Variants

Red Flags

Atypical Presentations

5. Diagnosis and Workup (Pulmonary Function, Bronchoscopy and Imaging Anchored)

Imaging - The Initial Anchor

Laboratory Biomarkers

Microbiologic Testing

Diagnostic Bronchoscopy

Arterial Blood Gas

Pulmonary Function Tests

Diagnostic Algorithm

Controversies and Guideline Disagreement

6. Severity, Staging and Risk Stratification

Clinical Severity Scores: PSI and CURB-65

Augmenting Scores with Biomarkers

Identifying Severe CAP and Drug-Resistant Pathogens

Emerging Tools: Machine Learning, Immune Endotypes, and Long-Term Risk

7. Acute Management and Exacerbation Rescue

Step 1: Disposition and Antibiotic Initiation

Step 2: Adjunctive Corticosteroids

Step 3: Oxygen and Ventilatory Support

Step 4: Monitoring and De-escalation

Step 5: Treatment Failure and Rescue

Controversies and Guideline Disagreement

8. Long-term and Definitive Management

Step 1: Defining the Antibiotic Course and Duration

Step 2: Discharge Planning and Long-Term Risk Assessment

Step 3: Cardiovascular Risk Modification

What NOT to Do

Controversies and Guideline Disagreement

History and Evolution of Treatment

The Antibiotic Era: From Empirical Coverage to Precision

The Corticosteroid Controversy: Three Decades of Evidence

Duration, De‑escalation, and Biomarker‑Guided Care

Adjunctive and Supportive Therapies

9. Respiratory Support, Procedures & Interventional Pulmonology (Specialty-Distinctive)

Bronchoscopy: Diagnostic and Therapeutic Roles

Pleural Drainage for Parapneumonic Effusion and Empyema

Long-Term Oxygen and Ventilatory Support

Pulmonary Rehabilitation

10. Complications

11. Prognosis and Natural History

Short-Term Mortality

Long-Term Outcomes

Factors That Modify Prognosis

Recovery and Functional Morbidity

12. Special Populations & Pregnancy

Pediatrics

Pregnancy

Elderly

Immunocompromised Hosts

13. Prevention, Screening & Surveillance

Primary Prevention: Vaccination

Secondary Prevention and Screening

Clinical Severity Scores: and